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Background and aims. Improved outcomes for children on peritoneal dialysis (PD) 
have been evident in recent years due to advances in medical care. However, the 
youngest patients, infants and small children, continue to demonstrate inferior growth, 
more frequent infections, and higher mortality compared to older children. Moreover, 
maintaining normal intravascular volume status, especially in young anuric patients, 
has proven difficult. There are relatively many children needing dialysis in infancy in 
Finland compared to other countries due to the high prevalence of congenital nephrotic 
syndrome of the Finnish type (NPHS1, CNF). While the youngest patients form the 
greatest challenges in PD treatment, the risk for neurological sequelae is higher than 
in older children. However, the neurodevelopment of infants and small children on 
PD is a rarely reported topic. This study was designed to treat and monitor these 
youngest PD patients with a strict protocol, to critically evaluate the results, and 
finally to improve metabolic balance, growth and development in infants and small 
children during PD.
Methods. A retrospective analysis of 23 children under two years of age at onset 
of PD (mean 0.4 years), treated between 1995 and 2000, was performed in the first 
study to obtain a control population for our prospective study. Data about diagnoses, 
dialysis period, medication, laboratory parameters, complications, and growth was 
collected from patient records.
For the second and third studies, 21 patients less than two years of age at the beginning 
of PD (mean 0.6 years) were enrolled in our prospective protocol between 2001 and 2005. 
In the second study, medication for uremia and nutrition were carefully adjusted during 
PD. Laboratory parameters and metabolic controls were regularly analyzed. To evaluate 
the intravascular volume status, blood pressure measurements, echocardiography, and 
analysis of N-terminal atrial natriuretic peptide (ANP-N) were performed. Growth 
before and during PD was analyzed and compared with midparental height. In the 
third study, the risk factors for development and the neurological development of these 
patients was determined. A neurologist, a physiotherapist and an occupational therapist 
evaluated all patients regularly during PD. The brain images taken before PD, during 
PD, and two years after renal transplantation (Tx) were surveyed. Hearing was tested 
during PD; in children at least three years old at the end of the study the hearing was 
tested also after renal Tx. Neuropsychological tests in children at least five years of 
age before the end of this study were collected and assessed.
In the fourth study, the data of six NPHS1 patients with a congruent neurological 
syndrome was analyzed. All these patients, born between 1984 and 2003, had a serious 
dyskinetic cerebral palsy-like syndrome with muscular dystonia and athetosis (MDA). 
They also had a hearing defect. The brain MRI showed increased signal intensity in 
T2-weighted images in the globus pallidus area and their neurological symptoms were 
detected before the age of one year. The analysis of mitochondrial DNA (mtDNA) in 
these NPHS1 patients with MDA was performed in order to find a possible genetic 
defect as an explanation for their neurological syndrome.
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Results. Hospitalization time was clearly shorter in the prospective PD patient group 
(65 days per patient-year) compared to the retrospectively analyzed patient group (124 
days per patient-year). Metabolic control was mainly good in both patient groups. 
However, the control of plasma intact parathyroid hormone level (iPTH) was very 
demanding. Furthermore, in the prospective patient group, although a mean weekly 
urea Kt/V of over 3.0 was achieved, the target of a mean creatinine clearance (Crcl) 
of over 65 L/week per 1.73 m2 was very difficult, even impossible to achieve. It 
seems that a Crcl level of 40 L/week per 1.73 m2 is acceptable in this age group. 
The peritonitis rate diminished, it was 1 per 17.8 patient-months in the prospective 
patient group versus 1 per 14.5 in retrospectively analyzed patients, although this 
difference was not statistically significant. Hypertension was common in retrospectively 
analyzed patients; 70% had antihypertensive medication while in the prospective 
patient group only 33% had antihypertensive medication at some point during PD. 
Thus, prospective patients received antihypertensive medication less frequently, but 
long-term hypertension was still seen in 43% during PD. Left ventricular hypertrophy 
decreased during the prospective study period. None of the patients in either group had 
pulmonary edema or dialysis-related seizures. Growth was good in most patients in 
both patient groups. Catch-up growth was documented in 64% of the retrospectively 
analyzed patients and in 57% of the prospective patients during dialysis. However, 
the prospective PD patients clearly lagged behind their midparental height at the 
end of PD. Mortality was 5% in the prospective PD patient group, and 9% in the 
retrospective PD patient group.
In the prospective PD patient group 11 patients (52%) had some risk factor for their 
neurodevelopment originating from the predialysis period. The neurological problems, 
detected before PD, did not worsen during PD and none of the patients developed new 
neurological complications during PD. Brain infarcts were detected in four patients 
(19%) and other ischemic lesions or periventricular leukomalasia (PVL) in three patients 
(14%). At the end of this study, 29% of the prospectively followed patients had a major 
impairment of their neurodevelopment and 43% only some minor impairment. 
In the NPHS1-patients with MDA, neither mtDNA mutations nor external 
neurological complications could be found that could explain the symptoms. Thus, the 
reason for the neurological syndrome remains a mystery. Kernicterus was contemplated 
to be causative in the hypoproteinemic newborns but it could not be proven. Mortality 
was as high as 67% in this patient group during the whole follow-up period.
Conclusions. Our results for young PD patients were promising. Metabolic control 
was acceptable, growth was good, and mortality was low, however control of their 
calcium-phosphorus status proved demanding. Their peritonitis rate was about the same 
as for older children, whilst the high incidence of blood pressure proved problematic 
and several instruments were needed for examining and managing their intravascular 
volume status. Even if growth was good during PD, the children were significantly 
smaller compared to their midparental height. Although many patients were found 
to have neurological impairment at the end of our follow-up period, PD was a safe 
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treatment for end-stage renal failure (ESRF) in infants and small children whereby 
their neurodevelopment did not worsen.
Key words: peritoneal dialysis, congenital nephrotic syndrome of the Finnish type, 
NPHS1, neurodevelopment, risk factors, blood pressure, motor development, brain 
imaging, intravascular volume status, hypervolemia, neurological development, infants, 
adequacy of dialysis, metabolic control, growth, midparental height.
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abbreviations
AIMS Alberta Infant Motor Scale
ANP-N N-terminal atrial natriuretic peptide
APD Automated peritoneal dialysis
AV Arteriovenous
BERA Brainstem evoked response auditory
BIA Bioelectrical impedance analysis
BOA Behavioral observation audiometry
BP Blood pressure
BSA Body surface area
BUN Blood urea nitrogen
CAPD Continuous ambulatory peritoneal dialysis
CaCO3 Calcium carbonate
CCPD Continuous cycling peritoneal dialysis
CKD Chronic kidney disease
CNF Congenital nephrotic syndrome of the Finnish type (NPHS1)
CNS Central nervous system








ERA-EDTA European Renal Association – European Dialysis and  
 Transplantation Association
ESI Exit-site infection
ESRF End-stage renal failure
FAO Food and Agriculture Organization of the United Nations
FGF23 Fibroblast growth factor 23 
FRKD Finnish Registry for Kidney Diseases
hcfSDS Head circumference standard deviation score
HD Hemodialysis
HDL High-density lipoprotein
hSDS Height standard deviation score
ICW Intra-cellular water
IPP Intraperitoneal pressure
iPTH  Intact parathyroid hormone
KDOQI Kidney Disease Outcomes Quality Initiative
K Dialyzer clearance of the measured molecule in Kt/V
Kt/V  Dialysis clearance measure
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LDL Low-density lipoprotein
LVEDD Left ventricular end-diastolic dimension
LVESD Left ventricular end-systolic dimension 
LVH Left ventricular hypertrophy
LVM Left ventricular mass
LVMI Left ventricular mass index
LVPWD Left ventricular posterior wall thickness at end-diastole 
MDA Muscular dystonia and athetosis
MFED Munich Functional Developmental Diagnostic test
MRI Magnetic resonance imaging
MtDNA Mitochondrial DNA
NAPRTCS North American Pediatric Renal Transplant Cooperative Study
NEPSY Developmental Neuropsychological Assessment
NKF National Kidney Foundation
NNR Nordic Nutrition Recommendation 
NPHS1 Congenital nephrotic syndrome of the Finnish type (CNF)




pmarp per million of age related population
PTH Parathyroid hormone
PVL Periventricular leukomalacia
PET Peritoneal equilibration test
PD Peritoneal dialysis
RDA Recommended dietary allowance
rhGH Recombinant human growth hormone
RI Resistance index
RRF Residual renal function
RRT Renal replacement therapy
SeptD Interventricular septal dimension at end-diastole 
SGA Small for gestational age
SNHL Sensorineural hearing loss
t Time in Kt/V
TBW Total body water
TEOAE Transient evoked otoacoustic emission
TG Triglycerides
TI Tunnel infection
TPD Tidal peritoneal dialysis
Tx Transplantation
UF Ultrafiltration
ULN Upper limit of normal
UNU United Nations University
US Ultrasound
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V Volume of distribution in Kt/V
vs. Versus
WHO The World Health Organization
WISC Wechsler Intelligence Scale for Children




The first successful kidney transplantation (Tx) in an adult was performed in 1954 in 
Boston, USA (Merril et al. 1956) and ten years later, the first adult patient received a 
renal transplant in Finland (Flatmark 1989). Progress in surgical techniques, treatment 
of complications, as well as better immunosuppressive medication, have nowadays 
made kidney Tx a valid therapy for end-stage renal failure (ESRF).
The active treatment of childhood uremia was started in the late 1960’s in Finland 
whereby some older pediatric patients even received kidney transplants in the adult 
unit. In 1971, the first small pediatric patient had a transplant operation at the Children’s 
Hospital, Helsinki University Central Hospital, without success due to inadequate 
immunosuppression. The patient was hemodialyzed before transplantation. Thus, in 
the beginning only a few older children with ESRF were actively treated in Finland 
(Hölttä 2000c). Renal Tx in the youngest patients remained a controversial matter 
globally (Chantler 1979). However, much progress has subsequently been made and 
infants are today also included in Tx programs. Extra peritoneal placement of the 
kidney is used for all pediatric patients in Finland. Their body weight must be over 9 
kg, which is usually reached at about one year of age, before an adult size kidney can 
be successfully transplanted. Infants with ESRF typically require dialysis before Tx 
as an intermediate phase, always aiming at renal Tx.
Continuous ambulatory peritoneal dialysis (CAPD) was commenced in children 
in the 1970’s (Oreopoulos et al. 1979). In Finland, the first pediatric ESRF patients 
were treated with hemodialysis (HD) in units for adults. Peritoneal dialysis (PD) was 
introduced in pediatric patients in the early 1980’s and for infants in the late 1980’s 
(Hölttä 2000c). The latter group has been an especially challenging one because of the 
patients’ small size and problems with growth and development. Today, most pediatric 
ESRF patients in Finland are treated with PD, especially the youngest ones.
Because of a high incidence of congenital nephrotic syndrome of the Finnish type 
(NPHS1, CNF), more Finnish infants need renal replacement therapy (RRT) when 
compared to other countries (van der Heijden et al. 2004). Infections, poor growth 
and higher mortality in infants compared to older children and adults have been the 
major problems encountered during their PD (Warady et al. 1997, Verrina et al. 2004, 
Bunchman 1995, Neu et al. 2002, Shroff et al. 2006). The PD period has also been 
shown to be the most crucial time for complications in small children with ESRF. For 
instance, hemodynamic crises may lead to serious complications (Qvist et al. 2002).
Neurological development of infants and small children on PD has not been 
extensively reported but developmental delay is documented in 11 to 84% during ESRF 
and PD (Polinsky et al. 1987, Geary, Haka-Ikse 1989, Honda et al. 1995, Warady et al. 
1999), although improvement was seen after Tx in one study (Polinsky et al. 1987).
The present study was developed to critically evaluate the nutrition, medication, PD 
treatment, metabolic balance, intravascular volume status, growth, and neurological 
development, in order to improve the overall treatment of infants and small children 
during PD.
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2 review of the literature
2.1 End-stage renal failure in children
End-stage renal failure (ESRF) is the stage of renal disease where the patients’ renal 
insufficiency has progressed so far that they cannot maintain their homeostasis and 
survive with their own renal function. At this point, renal replacement therapy (RRT), 
either dialysis or renal Tx, is needed (Harmon 1999).
2.1.1 Incidence
The incidence of ESRF in children under 5 years of age has increased significantly 
with time in Europe; in 1980―1984 the incidence was 2.4 per million of age related 
population (pmarp), in 1985―1990, was 6.2 pmarp, and in 1995―2000, was 8 pmarp. 
However, in Finland the incidence of ESRF in children under 5 years was as high as 
15.5 pmarp in 1995―2000 (van der Heijden et al. 2004) due to congenital nephrotic 
syndrome of the Finnish type (NPHS1, CNF). The incidence of NPHS1 is 1 in about 
8200 live births in Finland (Huttunen 1976) which makes for a high proportion of 
small children in our ESRF population. 
2.1.2 Etiology
The most prevalent diseases leading to ESRF in young children in Finland (Finnish 
Registry for Kidney Diseases 2009), compared to 29 European countries (van der 
Heijden et al. 2004), are presented in Table 1. Malformations of the kidney and urinary 
tract, such as urethral valves, are not specified in the European Registry, but in Finland 
they constitute 9% and 10% of diagnoses in patients under 2 and under 5 years of age.
table 1. Percentual proportions of renal diseases leading to ESRF in small children in 
Finland and Europe.
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2.1.2.1 Congenital nephrotic syndrome of the Finnish type
NPHS1 is the most comon diagnosis leading to ESRF in Finnish infants (Qvist et al. 
2002, Hölttä et al. 1997). It is an autosomal recessive hereditary nephropathy with 
mutations in the nephrin gene NPHS1 (Holmberg et al. 2004). There are two main 
NPHS1 mutations (Fin-major and Fin-minor) in Finland which both cause a complete 
absence of nephrin in the glomerulus and a severe defect in the slit diaphragm, the 
important filter in the glomerulus, between the podocytes (Kestilä et al. 1998, Patrakka 
et al. 2000, Putaala et al. 2001). This leads to severe proteinuria already in utero and is 
lethal without active treatment in early childhood. The patients are nowadays mostly 
nephrectomized during their first year of life to avoid the massive proteinuria and its 
consequences (Holmberg et al. 1995).
2.1.3 Consequences of end-stage renal failure
ESRF and nephrectomy have several consequences for the patients’ health. The 
urinary excretion of phosphate decreases leading to hyperphosphatemia, active vitamin 
D diminishes, plasma calcium levels decrease, and all of these lead to increased 
parathyroid hormone (PTH) levels causing secondary hyperparathyroidism (see Fig. 
3). These effects on bone cause high bone turnover and, with time, a bone growth 
disorder (Sanchez et al. 1999).
Fibroblast growth factor 23 (FGF23), a phosphatonin secreted by osteocytes and 
osteblasts when serum phosphate increases, has been actively studied recently. FGF23 
appears to be one of the key molecules in the regulation of phosphate homeostasis. It 
increases the secretion of phosphate into urine and thus decreases serum phosphate 
levels. FGF23 expression is also regulated by vitamin D; administration of 1,25(OH)2D, 
the active form of vitamin D, leads to increased levels of FGF23. Increasing FGF23 
reduces 1α-hydroxylase activity leading to a decrease in 1,25(OH)2D formation. This 
in turn increases PTH secretion (see Fig.3) (Silver, Naveh-Many 2010, Wesseling-Perry 
2010, Yu et al. 2005, Isakova, Wolf 2010, Jüppner 2011).
Renal failure leads to metabolic acidosis due to reduced excretion of hydrogen 
ions. Acidosis induces hyperventilation, disturbs the normal metabolism of bones 
(causing growth retardation), and impairs the function of several hormones such as 
glucocorticoids, PTH, thyroid hormone and vitamin D (Mitch 2006). ESRF leads to 
high levels of waste products, such as urea nitrogen (BUN) and creatinine, cause many 
symptoms including nausea, fatigue, headache, and itching. Chronic uremia can also 
lead to more severe effects like pericarditis (Comty et al. 1971). Diminished production 
of erythropoietin in the kidneys leads to anemia (Wassner, Baum 1999). Anemia causes 
fatigue, dyspnea, deterioration of cognition, and stresses the heart among many other 
consequences. Edema and hypertension are also common findings in ESRF (Wassner, 
Baum 1999, Feld, Waz 1999, Haycock 1999).
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2.2 Treatment of end-stage renal failure
figure 1  Treatment of end-stage renal failure (ESRF).
2.2.1 Supportive treatment
2.2.1.1 Nutrition
Individualized nutritional counseling, frequent re-evaluations and modifications of the 
diet should be given to the PD patient and his/her family by a pediatric renal dietitian. 
The age, development, and the family situation should be taken into account when 
planning the nutrition of each child (KDOQI Work Group 2009).
Energy requirements
Children with ESRF should get 100% of the estimated energy requirement for their 
age, adapted to the body size and physical activity level (KDOQI Work Group 2009). 
In infants the daily energy intake should be roughly 80–90 kcal/kg. Additionally 
PD patients receive about 10 to 20 kcal/kg per day from dialysis fluids (Rönnholm, 
Holmberg 2006, Hölttä et al. 2000b). If energy intake is lower than recommended, 
tube feeding or a gastrostomy should be considered. The macronutrient distribution of 
the diet is directed to be as follows: carbohydrate 45–65%, fat 30–40%, and protein 
5–20% in children between one and three years. In children under one year these 
ranges should be as in basic baby formulas: carbohydrate 36–56%, fat 40–54%, and 
7–12% protein (KDOQI Work Group 2009). 
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Protein supply
A report by a joint Food and Agriculture Organization, the United Nations (FAO)/ 
the World Health Organization (WHO)/ United Nations University (UNU) expert 
consultation, has defined the safe levels of protein supply (minimum) for each age-
group (safe levels 1.09−1.86 g/kg per day) (World Health Organization 1985). The 
recommendation of the Kidney Disease Outcomes Quality Initiative (KDOQI) Work 
Group for dietary protein intake in small children is the daily recommended supply 
for a healthy child plus roughly 0.3 g/kg per day extra to replace losses due to dialysis 
(KDOQI Work Group 2009, Quan, Baum 1996). For children under seven months this 
is 1.8 g/kg per day, for children under 12 months 1.5 g/kg per day, and for children 
under four years of age 1.3 g/kg per day (KDOQI Work Group 2009). In infants, 
supplemental nutrients are needed to avoid fluid overload and to maintain a sufficient 
amount of energy and protein (Rönnholm, Holmberg 2006).
Fats
Suitable macronutrient distributions are given above. While cardiovascular diseases 
are the major cause of mortality and morbidity in children with ESRF the diet should 
be planned as to prevent increased plasma levels of triglycerides (TG) and cholesterol. 
If fat supplementation to formula is needed, it should consist of unsaturated fats 
such as in canola, olive, soybean, or rape-seed oils. High amounts of cholesterol, 
saturated fat, or trans fatty acids in the diet may raise total cholesterol and low-
density lipoprotein (LDL) cholesterol levels in blood. On the contrary, high dietary 
intake of polyunsaturated fatty acids such as eicosapentanoic acid (EPA), omega-3 
fatty acids, and docosahexanoic acid (DHA) decrease TG levels in plasma. In case of 
hyperlipidemia (high LDL), the proportion of fat should be lower than usual (<30% 
of calories), trans fatty acids should be avoided and saturated fatty acids should 
not exceed 7% of the calorie amount of the daily diet. In patients with high TG, in 
addition to low dietary fat and emphasis on polyunsaturated fatty acids, only a low 
quantity of simple carbohydrates should be served and complex carbohydrates favored 
(KDOQI Work Group 2009).
Micronutrients and vitamins
Very little is known about the vitamin and micronutrient requirements of children with 
chronic renal failure and during PD (KDOQI Work Group 2009, Rees, Shaw 2007). 
In adult patients on PD, it has been shown that substitution with some water-soluble 
vitamins (C, B vitamins) is necessary to avoid vitamin deficiencies (Kopple et al. 
1981, Ross et al. 1989, Blumberg et al. 1983). Dialysate losses are partly responsible 
for the increased need of these vitamins (Blumberg et al. 1983, Mydlik et al. 1985). 
In children on PD, the blood concentrations of water-soluble vitamins have been 
shown to meet or exceed normal values with combined dietary and substitution intake 
(Kriley, Warady 1991, Warady et al. 1994). It has been suggested that children with 
chronic kidney disease should be given the same amount of vitamins as well as 
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micronutrients and minerals as is recommended for healthy children (Rees, Shaw 
2007). The KDOQI Work Group recommends offering 100% of the daily recommended 
intake for children with ESRF. If the dietary intake is below this goal, supplementary 
water-soluble vitamins should be given. Fat-soluble vitamins are normally not needed 
in addition to food intake if the patient stays on the planned diet (KDOQI Work Group 
2009). In children on PD, low serum levels of copper, selenium, and zinc have been 
documented (Warady et al. 1994, Tamura et al. 1989, Zachara et al. 2006). KDOQI 
recommends that the levels of copper should be monitored every 4 to 6 months, 
and the recommended daily intake of copper, selenium and zinc should be provided 
(KDOQI Work Group 2009).
2.2.1.2 Medication
Treatment of secondary hyperparathyroidism
Secondary hyperparathyroidism is developed as a sum of many factors in chronic kidney 
disease (CKD) (see Figure 3). Treatment of hyperphosphatemia and hypocalcemia 
as well as supplementation with vitamin D in children with ESRF, are discussed in 
the next chapters.
figure 2 A) Pathogenesis of secondary hyperparathyroidism in chronic kidney disease. 
Phosphate (Pi), calcium (Ca), serum vitamin 1,25(OH)2D, serum parathyroid hormone 
(PTH), fibroblast growth factor 23 (FGF23), FGF23 receptor (FGFR), calcium receptor 
(CaR), vitamin D receptor (VDR). The pathways that are disrupted in ESRF are marked 
with broken line arrows. B) In advanced chronic kidney disease such as ESRF, the 
Klotho-FGFR complex is down regulated. Remodeled after Isakova and Wolf (2010) and 
Silver and Naveh-Many (2010).
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Hyperphosphatemia
Hyperphosphatemia caused by diminished excretion of phosphate in the kidneys 
is first treated with dietary phosphate restriction. Traditional medications for 
hyperphosphatemia are calcium carbonate (CaCO3) products, which bind to phosphate 
and reduce absorption of food phosphate in the intestine. At the same time, the patients 
receive calcium for their hypocalcemia. However, vascular calcification and higher 
incidence of cardiovascular disease compared to the general population have been 
reported in adults, as well as in childhood-onset ESRF (Querfeld 2004, Oh et al. 
2002, Groothoff et al. 2005) Cardiovascular diseases are also a much more common 
cause of death compared to malignancies in patients transplanted during childhood 
(Offner et al. 1999). Sevelamer hydrochloride is used as a calcium free phosphate 
binder in grown-up patients, however in children, and especially in infants, sevelamer 
hydrochloride is scarcely used (Rees, Shroff 2010). Sevelamer hydrochloride often 
produces metabolic acidosis, which can be avoided by using sevelamer carbonate 
(Gonzalez et al. 2009). Nonetheless, today there are no calcium-free phosphate binders 
licensed for children (Rees, Shroff 2010) and the Kidney Disease Outcomes Quality 
Initiative (KDOQI) recommends that if sevelamer is used as the only phosphate binder 
in children, calcium should be supplemented with a calcium-including phosphate 
binder or/and a higher calcium concentration in the dialysate should be used (National 
Kidney Foundation (KDOQI) 2005). 
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figure 3 Vitamin D and parathyroid hormone metabolism. Modeled after Deeb et al. 
(2007). Negative feedback is indicated with a dashed line and diamond.
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Vitamin D substitution
The effects and metabolism of vitamin D in a healthy person are shown above in 
Figure 3. Vitamin D deficiency in ESRF originates from reduced or absent renal 
1α-hydroxylation of vitamin 25-OH-D (calcidiol), which in healthy people is already 
25-hydroxylated in the liver. Because of the 1α-hydroxylation defect, ESRF patients need 
vitamin D substitution as 1α-hydroxylated, 1α-hydroxycholecalsiferol (alphacalcidol) 
which is then hydroxylated in the liver to its active form 1,25(OH)2D (calcitriol), 
which may also be used as vitamin D substitute. Calcitriol increases the absorption 
of calcium and phosphate in the gut, increases bone mineralization and adjusts the 
level of serum calcium. Calcitriol provides negative feedback to PTH excretion thereby 
inhibiting the high bone turnover caused by high PTH. Providing an accurate dosage 
of alphacalcidol is challenging, because too high doses reduce PTH secretion, and 
over-suppression of PTH leads to adynamic bone disease, in which bone turnover is 
too low (Wesseling et al. 2008). Thus, to ensure good growth, the European Paediatric 
Dialysis Working Group recommends that in ESRF patients, the aimed level of plasma 
PTH should be two to three times the upper normal limit (Klaus et al. 2006).
Treatment of anemia
Erythropoietin (EPO) deficiency or relative deficiency, alterations in the activity of 
EPO caused by uremic toxins, and inhibition of erythroid progenitor cell formation in 
bone marrow are the most important factors causing anemia in children with ESRF 
(McGonigle et al. 1984, McGonigle et al. 1985). Regular erythropoietin injections 
and supplemental oral iron form the basis of anemia management in children with 
ESRF. In HD patients, the use of intravenous iron is preferred (KDOQI, National 
Kidney Foundation 2006). Infants require higher doses of EPO, from 275 to 350 U/
kg per week, compared to older children and adults. PD patients need less EPO than 
HD patients (NAPRTCS 2004 Annual Report 2005). Early EPO therapy has been 
associated with improved growth in children with chronic kidney disease (Boehm 
et al. 2007).
Treatment of hypertension
Hypertension has been observed in 55% of children during dialysis in Poland. The 
mean age of these patients was 10 ± 5 years and the hypertension incidence rate was 
similar in boys and girls (53 vs. 60%) as well as in PD and HP patients (54 vs. 56%). 
Monotherapy was used in 33% and 36% received two antihypertensive drugs (Tkaczyk 
et al. 2006). In comparison, systolic hypertension was seen in 52% of Finnish children 
on PD and diastolic hypertension in 43%. Furthermore, 73% of children below five 
years of age had systolic hypertension. The antihypertensive medicines used in Finnish 
patients were mostly calcium channel blockers and β-blockers (Hölttä et al. 2001).
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2.2.2 Active treatment - dialysis
When renal function is severely reduced or absent, the tasks typically performed by 
the kidneys must be substituted. Their purification function and removal of excess 
water from the body are both managed by dialysis. Peritoneal dialysis (PD) and 
hemodialysis (HD) are common treatment possibilities, although hemodiafiltration 
may also be used in mainly acute situations. 
In European ESRF patients under 5 years of age the first treatment modality has 
been PD in 70%, HD in 26% and pre-emptive renal transplantation in 4% according to 
the European Renal Association – European Dialysis and Transplantation Association 
(ERA-EDTA) report of 2004 (van der Heijden et al. 2004). In Finland, the percentages 
for the same age group between 1990 and 2008 were 97% for PD, 1% for HD and 2% 
for pre-emptive transplantation (Finnish Registry for Kidney Diseases 2009).
The emphasis of this study is on PD treatment, and HD is discussed only briefly. 
2.2.2.1 Peritoneal dialysis
Peritoneal dialysis has been used in children since the late 1970’s, starting in Canada 
(Oreopoulos et al. 1979). In Europe PD was later introduced and became an established 
treatment modality in children in the 1980’s (Alexander, Honda 1993). During PD, a 
dialysis solution (dialysate) is infused into the patient’s peritoneal cavity through a PD 
catheter and left there for a prescribed dwell time. The peritoneal membrane works 
as a semi-permeable filter through which water as well as urea, potassium, phosphate 
and other waste products diffuse from blood in the capillaries of the peritoneum into 
the dialysate to a lower concentration. Waste material is removed from the body by 
changing the dialysis solution several times per day to maintain the concentration 
gradient. The dialysate contains glucose, which creates an osmotic gradient between 
blood and dialysate. With this gradient, excess water is removed from the body. Small 
molecules such as urea move faster through the peritoneal membrane compared to 
larger molecules such as creatinine and phosphate (Gao et al. 2004). 
The dialysate can be exchanged manually or with the help of a dialysis machine. 
There are different kinds of PD machines with modern techniques, programs, and 
tubing suitable also for small children. At this moment Sleep●safe™ (Fresenius Medical 
Care, Bad Homburg, Germany), HomeChoice Pro (Baxter Healthcare Corp., Deerfield, 
IL, USA) and Serena® (Gambro AB, Stockholm, Sweden) are suitable machines for 
infants.
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figure 4 A) Principle of peritoneal dialysis. Adapted from Picsicio (http://picsicio.us/
image). B) X-ray image showing the right position of a PD catheter in the peritoneal 
cavity.
Access of PD
The access for PD, the catheter, is set into the peritoneal cavity through the abdominal 
wall. The implantation is recommended to be performed approximately two weeks prior 
to starting dialysis treatment, especially in children, to avoid leaks (Rönnholm, Holmberg 
2006). Implantation should be carried out by experienced surgeons (Watson et al. 
2001). According to the North American Pediatric Renal Transplant Cooperative Study 
(NAPRTCS) report 2007, most PD catheters used were the Tenckhoff curled (62%) or 
Tenckhoff straight (27%). Single-cuffs were present in about half of the catheters (53%), 
whilst 65% had a straight tunnel, and 40% of the exit-sites had a lateral orientation. There 
was no difference in the incidence of peritonitis between different catheter properties 
(NAPRTCS 2007 Annual Report 2008). Furth et al. also found no clear difference 
between single and double-cuff catheters concerning exit-site or tunnel infection 
frequency. Nor was there any difference in exit-site and tunnel infection incidence 
between coiled and straight catheters or between different exit-site orientations (up/
down/lateral) (Furth et al. 2000).
Modalities of PD
The first modality of PD was continuous ambulatory peritoneal dialysis (CAPD), which 
was replaced over time by continuous cycling peritoneal dialysis (CCPD); this first 
automated peritoneal dialysis form was developed to reduce the frequency of peritonitis 
(Price, Suki 1981). Tidal peritoneal dialysis (TPD) was introduced some years later; 
in TPD, after the initial fill volume is instilled, a fraction of the volume is exchanged 
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frequently using a cycler machine (Flanigan et al. 1991). It may provide advantages 
for children with outflow problems or outflow pain, and allows better purification for 
patients with high peritoneal membrane permeability (Hölttä et al. 2000a).
Automated peritoneal dialysis (APD) is performed overnight, the treatment time 
varying from 8 to 12 hours with 8 to 14 exchanges per night in CCPD. The fill volume 
in infants is usually 800―1000 ml/m2 of BSA per exchange (Rönnholm, Holmberg 
2006) and in older children larger volumes, from 1000 to 1200 or even up till 1400 
ml/m2 of BSA, are recommended (Fischbach, Warady 2009). The last fill left in the 
peritoneal cavity in the morning is usually half of the nightly fill volume on order to 
avoid discomfort, vomiting, and development of hernias. In addition to automated 
peritoneal dialysis (APD), anuric infants also need extra daytime exchanges to avoid 
hypervolemia (Rönnholm, Holmberg 2006).
Adequacy of PD
The adequacy of peritoneal dialysis is usually measured with a dialysate and urine 
collection test, from which Kt/V for urea and creatinine clearance (Crcl) are calculated 
(II. NKF-K/DOQI 2001). Kt/V urea was initially developed to illustrate the adequacy 
of hemodialysis but was later embraced for PD purification evaluations (Bargman 
2006). In Kt/V, K represents clearance, t stands for observed time period (here 24 
hours) and V for the volume of distribution (total body water). Thus, the clearance of 
urea is compared to total body water (TBW), in contrast to creatinine clearance which 
is compared to body surface area (BSA). Crcl describes the amount of creatinine that 
is removed from the blood over a time interval. According to the National Kidney 
Foundation (NKF) Work Group, based on the available evidence, the minimum target 
of weekly urea Kt/V should be 2.0 and of Crcl, 60 L/week per 1.73 m2. If there 
are difficulties in achieving these targets, the Kt/V for urea should be the principle 
measure of adequacy. Urea Kt/V directly reflects protein metabolism and is also 
less influenced by alternations in residual renal function (II. NKF-K/DOQI 2001). 
These measures characterize small and middle size molecule purification. Moreover, 
blood urea nitrogen, blood creatinine and phosphate are measures of purification; the 
lower these measures are, the better the purification is thought to be. The peritoneal 
equilibration test (PET) expresses peritoneal membrane function (Twardowski et al. 
1987) and together with it and dialysate and urine collection tests it is possible to 
predict urea and creatinine clearances also in pediatric patients (Verrina et al. 1998, 
Warady et al. 2001).
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2.2.2.2 Complications of peritoneal dialysis
figure 5 Complications of PD.
2.2.2.2.1 Catheter-related complications
Catheter-related mechanical problems and infections are noteworthy causes of morbidity 
and treatment failure in children on PD, despite the advanced catheter models and 
PD techniques (Furth et al. 2000, Macchini et al. 2006). In 1995, the NAPRTCS 
reported the revision of 20% of the catheters in children of all ages (Neu et al. 1995), 
and in 2007 the revision of 19% (NAPRTCS 2007 Annual Report 2008). In a recent 
Italian study in children, where the patients’ mean age was six years, the catheter 
survival rate was 80% at one year, and 62% at two years on PD, and the incidence of 
catheter-related complications was one episode per 6.4 months on PD when peritonitis 
was included. Catheter survival was longer in children over five years compared to 
children less than two years of age. Single-cuff catheters had lower infection rates 
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compared to double-cuff catheters (Macchini et al. 2006). Aksu et al. (2007) have 
reported a very low catheter complication rate of 1 episode per 24.7 patient-months 
and a high catheter survival rate of 92% at one year and 83% at 2 years in children 
between three months and 16 years (mean age eight years).
Mechanical problems
In the above mentioned Italian study, catheter obstruction constituted 13%, dislocation 
9%, and leakage 6% of the complications when peritonitis was excluded (Macchini 
et al. 2006). In the NAPRTCS report of 2007, malfunction comprised 48% and leak 
5% of complications also when peritonitis was not included (NAPRTCS 2007 Annual 
Report 2008). In the report of Aksu et al. (2007), dislocation yielded 9%, leakage 
and rotation both 5% of the complications, again when peritonitis was excluded. 
Omentectomy has been shown to reduce obstruction rate and lengthen the survival 
time of the catheter (Macchini et al. 2006, Reissman et al. 1998, Rinaldi et al. 2004). 
The surgical technique and an experienced team for catheter placement are the most 
critical factors for catheter survival (Macchini et al. 2006, Aksu et al. 2007).
Exit-site and tunnel infections
Exit-site infection diagnosis should be made if there is a purulent drainage from the 
exit-site, or notable pericatheter edema, redness, or/and tenderness locally. A positive 
bacterial culture is not required for the diagnosis of exit-site infections (Table 2, 
Schaefer et al. 1999b, Warady et al. 2000).
In a recent Italian study, exit-site infections (ESI) and tunnel infections (TI) were 
shown to be responsible for 59% of catheter-related complications when peritonitis was 
excluded (Macchini et al. 2006), whilst in the NAPRTCS report of 1995, ESI or TI 
was seen in 36% of children between 0 and 5 years (Neu et al. 1995). In contrast, the 
NAPRTCS report of 2007 demonstrated that ESI and TI comprised 18% of catheter-
related complications when peritonitis was excluded (NAPRTCS 2007 Annual Report 
2008). In the report of Aksu et al. (2007), ESI and TI proved to be the most common 
catheter complications (81% when peritonitis was not included), and these were more 
frequent in younger patients. On the other hand, Furth et al. (2000) had stated earlier that 
catheter characteristics, patient age, or race, had no influence on the risk of ESI or TI. 
table 2. Exit-site infection scoring system. A score of ≥4 means infection. Purulent 
drainage, even alone, is an evidence of infection. Adapted from Schaefer et al. (1999b) 
and Piraino et al. (2005).
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2.2.2.2.2 Peritonitis
In children, fever and abdominal pain are considered too nonspecific as symptoms 
for the diagnosis of peritonitis. The diagnosis should be made if the dialysis effluent 
is cloudy, the white blood cell count is more than 100 per μL in the effluent, and at 
least 50% of the leucocytes are polymorphonuclear (Warady et al. 2000).
Peritonitis is a very potent cause of morbidity and the most important cause of 
PD failure despite reduced incidence of infections over the years (Chadha et al. 2010, 
Schaefer et al. 2007). Many reports demonstrate a higher incidence of peritonitis in 
younger children (Neu et al. 2002, NAPRTCS 2007 Annual Report 2008, Hölttä et al. 
2000b, Honda et al. 1996, Hoshii et al. 2006). The NAPRTCS report of 2007 shows an 
annualized peritonitis rate of 0.79 (number of peritonitis per year) between 1992 and 
1996 and a rate of 0.57 between 1997 and 2006. In children less than two years of age 
the rate during the whole follow-up period was 0.86 compared to 0.61 in children over 
twelve years (NAPRTCS 2007 Annual Report 2008). A recent report from Germany 
showed a peritonitis incidence of 0.85 episodes per patient-year in infants starting PD 
during the first year of life (Wedekin et al. 2010). Other risk factors for peritonitis are 
existing ESI or TI of the catheter, a higher degree of connections and spiking of the 
dialysate bags, and not using prophylactic antibiotics at the time of catheter placement 
(Chadha et al. 2010, Szeto et al. 2001, Gadallah et al. 2000).
Peritonitis is most commonly caused by bacteria, in particular gram-positive 
bacteria, that caused approximately 50―70% of the episodes in the early days of 
PD. With improved treatment protocols, the incidence of Gram positive peritonitis 
has been distinctly reduced, whilst the overall incidence of peritonitis has decreased. 
Better connection technology on PD, prophylactic medication for nasal carriage of 
Staphylococcus aureus, good exit-site care, improved skills of the medical team, 
and training of the family are partly responsible for the decreased peritonitis rate 
(Macchini et al. 2006, Chadha et al. 2010, Piraino et al. 2003). The causative organisms 
of peritonitis, according to recent studies, are shown in Table 3. 
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table 3. Causative organisms of peritonitis in children on PD.
2.2.2.2.3 Hernias
Hernias are frequent in PD patients, especially in small children, although the existing 
data is scarce concerning infants. Earlier studies report hernias in 23 to 40% of 
children of all ages, mostly inguinal and ventral ones (Hölttä et al. 1997, von Lilien 
et al. 1987, Khoury et al. 1991, Verrina et al. 1992). One later study reports hernias 
in 11.5% of children with a mean age of nine years at PD onset (Donmez et al. 2003). 
Very few recent studies of children on PD report a prevalence of hernias.
Intraperitoneal pressure
Aranda et al. showed that intraperitoneal pressure (IPP) influences the frequency of 
hernias, and that IPP is lower in children compared to adults (Aranda et al. 2000). 
Elevated IPP can cause discomfort, pain, gastrointestinal reflux, hernias, and also 
loss of ultrafiltration. IPP measurement is an important tool in prescribing dialysis 
treatment concerning tolerance and adequacy (Fischbach et al. 2003). Durand et al. 
first presented the IPP measurement technique in adults (Durand et al. 1992) and 
Fischbach later applied it in children (Fischbach et al. 1994, Fischbach et al. 1996, 
Fischbach et al. 1996). The measurement itself is simple: the child rests in a supine 
position, the zero level is set in the patient’s mid-axillary line and the mean value of 
inspiration and expiration is used (see Fig.6) (Durand et al. 1992). Fischbach et al. 
recommend a normal value for IPP of less than 18 cm of water, although between 5 
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and 15 cm of water is acceptable, depending on the fill volume. The patient’s age, 
sex, and body mass index should also be taken into account (Fischbach et al. 2003). 
figure 6 IPP measurement. Adapted from Durand et al. (1992).
2.2.2.2.4 Intravascular volume status
Hypertension
Hypertension is a common problem seen in as many as 52 to 63% of children on PD 
(Tkaczyk et al. 2006, Hölttä et al. 2001, Donmez et al. 2003, Acar et al. 2008, Mitsnefes 
et al. 2003, Mitsnefes, Stablein 2005). According to NAPRTCS, 77% of the patients 
(both PD and HD) suffered from hypertension, of which 57% was uncontrolled and 
20% controlled at the beginning of dialysis. Risk factors for hypertension included high 
blood pressure (BP) at baseline, young age, and acquired kidney disease as a cause for 
ESRF, and HD as dialysis mode. BP remained high in most patients during the first year 
on dialysis and medication did not correct the situation. However, the first months on 
dialysis seemed to be crucial for getting BP under control (Mitsnefes, Stablein 2005).
Hypovolemia
Hypotension and hypovolemia during dialysis may cause permanent brain or nervous 
system damage. Early cases in Finland reported severe hypovolemia during dialysis 
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in small PD patients (Qvist et al. 2002, Valanne et al. 2004). One of these patients, 
with NPHS1, that experienced longer hypotensive periods, acquired permanent, severe 
visual impairment. There have been three reports on small children aged 1 to 5 years 
with anterior ischemic optic neuropathy as a consequence of hypovolemia or a period 
of low blood pressure values during PD. A permanent visual handicap was reported 
for all, although their hypovolemia and blood pressure levels were corrected (Bates 
et al. 1999, Chutorian et al. 2002, Lapeyraque et al. 2003). Two patients also had 
changes in their brain magnetic resonance imaging (MRI): one displayed periventricular 
white matter abnormalities and the other encephalomalasia and gliosis in the occipital 
cortex bilaterally. These changes suggest chronic hypoperfusion (Bates et al. 1999, 
Lapeyraque et al. 2003).
Heart ultrasound measures
Cardiovascular diseases are a significant reason for deaths and accounted for 32% of 
the deaths in children and young adults with ESRF in a single center study (Offner et 
al. 1999). Left ventricular hypertrophy (LVH) is often detected (45 to 75%) in pediatric 
PD and HD patients (Hölttä et al. 2001, Civilibal et al. 2009, Mitsnefes et al. 2000). 
Left ventricular mass index (LVMI = left ventricular mass divided by body height2.7) 
was also higher in children on dialysis compared to a control population in a couple of 
studies, reflecting a more frequent prevalence of LVH in dialysis patients (Robinson 
et al. 2005, Ten Harkel et al. 2009). Hölttä et al. found that children under 5 years of 
age displayed more frequent LVH when compared to older children (60% versus 30%) 
(Hölttä et al. 2001). In many studies on children with ESRF, the association between 
LVH (or high LVMI) and elevated blood pressure has been established (Hölttä et al. 
2001, Ten Harkel et al. 2009, Mitsnefes et al. 2003, Mitsnefes et al. 2001). There are 
studies indicating that volume overload and long-lasting hypertension further the 
development of LVH (Groothoff et al. 2005, Mitsnefes et al. 2003). In some studies 
the hemoglobin levels were lower in the patients with LVH compared to either patients 
without LVH or controls (Civilibal et al. 2009, Mitsnefes et al. 2000). Quantification 
of the left ventricular mass (LVM) is always an estimation which is based on formulas 
that fit ventricular shape to geometric figures (Vuille, Weyman 1994). Adjustment 
of LVM to body size can also be carried out in many ways such as by comparing 
LVM to height, BSA, or weight (Levy et al. 1987, Foppa et al. 2005). Additionally, 
defining the cut-off point between normal LVM compared to body size and LVH 
is a controversial matter and different methods yield diverse results regarding the 
prevalence of patients with LVH (Foppa et al. 2005).
Bioelectrical impedance analysis
Bioelectrical impedance analysis (BIA) is a non-invasive method to examine body 
composition and is based on different electrical properties of tissues (see Fig.7). First 
utilized in body fat evaluations, BIA is typically used to measure lean mass and body 
fluid volumes such as total body water (TBW). The quantities measured with BIA 
are reactance (Xc) that reflects body cell mass and resistance (R) that is inversely 
proportional to body water volume. The measurement can be done with a specific 
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electric current frequency or with several frequencies. At 50 kHz the current flows 
through both extra and intracellular fluid and BIA value correlates to TBW, but the 
value is in reality representing a weighted sum of extra-cellular water (ECW) and 
intra-cellular water (ICW) volume resistivities (Kyle et al. 2004, Ellis et al. 1999). 
Low frequencies do not pass the cell membrane as well as higher frequencies and 
thus better reflect the ECW (Deurenberg et al. 1995). To distinguish TBW, ECW and 
ICW, a multi-frequency device must be used (Kyle et al. 2004). An increased ECW 
or ECW/TBW ratio may be due to edema or malnutrition in a patient. Basile et al. 
(2007) have studied and developed dry weight prediction equations for adults on HD, 
whilst Edefonti et al. (2001) have used BIA in the evaluation of the nutritional status of 
children on PD. Accordingly, Wühl et al. (1996) have defined equations for calculating 
TBW in children on PD or HD at 50 kHz. The median age of these patients was 11.9 
years (range 4.1―20.3). Later, Brooks et al. (2008) studied the correlation between 
BIA and TBW as well as BIA and blood pressure in older children on HD, although 
ECW evaluations or equations were not performed in these studies. The reference 
values of TBW and ECW for small children, especially for infants, do not yet exist 
which has restricted the use of BIA in small dialysis patients.
figure 7 A) BIA measurement, wrist and ankle placement of electrodes. Adapted from 
Chamney et al. (2002). B) Theoretical BIA current flow. Modeled after Chamney et al. 
(2002).
2.2.2.3 Mortality in children on peritoneal dialysis
The mortality of children on PD is typically 5 to 20% (Shroff et al. 2006, Hölttä 
et al. 1997, NAPRTCS 2007 Annual Report 2008, Hölttä et al. 2000b, Rees 2002). 
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The youngest patients have the lowest survival rate (Verrina et al. 2004, NAPRTCS 
2007 Annual Report 2008). According to the NAPRTCS report from 2007, the most 
frequent causes of death were cardiopulmonary problems and different types of 
infection (NAPRTCS 2007 Annual Report 2008). Co-morbidities such as cardiac, 
gastrointestinal, and metabolic disorders were associated with 76% of the deaths 
in dialysis children in the study by Shroff et al. The most common causes of death 
were brain insults and various infections. The youngest patients were in greater risk 
for death; the mortality rate was almost threefold in children under five years of age 
compared to older ones (Shroff et al. 2006).
2.2.2.4 Growth in children on peritoneal dialysis
Growth in children with ESRF has been a significant concern since dialysis and 
transplantation in children began (Stefanidis et al. 1983). Between detection of renal 
disease and initiation of dialysis, growth deterioration has been demonstrated in 
most children in a study of Lewis et al. (2007). At the beginning of dialysis, 54% 
of the patients were under the fifth percentile in height Z scores (Lewis et al. 2007). 
In the NAPRTCS report of 2007, the mean height standard deviation score (hSDS) 
in children initiating dialysis was -2.55 in children less than two years of age, and 
-1.94 in children between 2 and 5 years. PD patients are smaller than HD patients and 
boys are proportionally smaller than girls at PD initiation (NAPRTCS 2007 Annual 
Report 2008). Several other studies confirm these results: in the report by Shroff et 
al. (2006), the mean hSDS at dialysis start was -2.8 in 98 children between birth and 
16 years of age, whilst children under five had a mean hSDS of only -3.6 at initiation 
of dialysis. In the study by Cansick et al. (2007), a mean hSDS of -2.1 was seen in 
prepubertal children starting PD at a mean age of 2.8 years. Therefore, these children 
are already short statured when entering dialysis programs. Accordingly, the growth 
is poorest in young children.
Healthy children grow fast during the first two years, thus growth impairment in 
infancy has much consequence. Growth during dialysis has not improved as much 
as could have been expected with adequate nutrition and careful management of 
renal bone disease (Stefanidis, Klaus 2007). In a European multi-center study, over 
18 months, the mean hSDS did not change notably during treatment (Schaefer et al. 
1999a). The NAPRTCS reports changes of -0.11 and -0.15 in the mean height Z-scores 
one and two years after the initiation of dialysis for all children on dialysis. Only a 
minimal change of -0.07 in height Z-score was seen in PD patients one year after 
baseline and no change between one and two years was seen. In HD patients, changes 
of -0.18 and -0.31 one and two years after PD onset were detected (NAPRTCS 2007 
Annual Report 2008). In the study of Cansick et al., catch-up growth was found 
in some patients less than 2 years of age during the first year of dialysis (Cansick 
et al. 2007). In a Finnish study, catch-up growth was observed in 62% of children 
less than 5 years of age during a 9-month period (Hölttä et al. 2000b). Adequate 
nutrition, mostly with dietary energy and protein supplementation via nasogastric 
tube or gastrostomy and strict management of phosphorus control are essential in 
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reaching good growth in children on dialysis (Cansick et al. 2007, Kari et al. 2000).
Recombinant human growth hormone (rhGH) is rarely used in children on PD, in 
only 16%, according to the European Dialysis and Transplantation Association (ERA-
EDTA) Registry. Its use has not increased during the last years (Lewis et al. 2007). 
The NAPRTCS reported that 25% of PD patients and 14% of HD patients received 
rhGH during dialysis (Neu et al. 2002). Especially in infants, sufficient nutrition 
is the major factor in assuring growth. The management of hyperphosphatemia, 
hyperparathyroidism, and acidosis are crucial, as well. If the child with ESRF is small 
(hSDS <-1.88) or growth lags behind (height velocity <-2 SDS) despite optimal nutrition 
and medication, rhGH therapy should be started. An early administration of rhGH has 
been recommended but infants were not discussed separately (Stefanidis, Klaus 2007, 
Mahan et al. 2006).
It has been demonstrated that children with residual renal function (RRF) experience 
better growth on PD. Catch-up growth was seen in 58% of RRF patients compared to 
17% of anuric patients in the study of Chadha et al.: about one third of their patients 
had rhGH treatment in both groups (RRF and anuric pt.) (Chadha et al. 2001). Poor 
growth has been associated with increased morbidity and mortality, where patients 
with growth failure display about a threefold risk of death compared to those with 
normal growth (Furth et al. 2002). 
Target height (parent specific mean hSDS) takes the mean height of the local 
population and the height of the parents into account. It gives an estimate of the 
predicted height of the child and deviations of more than ±2 SDS point to some disease 
or disturbance (Sorva et al. 1989).
2.2.2.5 Hemodialysis
Hemodialysis is less used in small children compared to older ones. Only 7% of 
ESRF patients under two years of age were treated on HD compared to 32% in all 
children with ESRF in North America between 1992 and 2007 (2006 Annual Report 
of NAPRTCS 2007). In Finland between 1990 and 2008, only 1% of children under 
two and 21% of all children with ESRF were treated with HD as first treatment mode 
(Finnish Registry for Kidney Diseases 2009). 
In the USA, the vascular access of HD has been an external central catheter in 
69─84% of pediatric patients since the 1990s (NAPRTCS 2007 Annual Report 2008). In 
Finland, HD access in children is typically a dual-lumen venous catheter in the jugular 
or subclavian vein. Arteriovenous (AV) fistulas have been the most common way of 
vascular access in Europe. However, especially in infants, the construction of an AV 
fistula is challenging (Fischbach et al. 2005). The blood is cleansed of waste products 
with extracorporeal perfusion by a HD machine. At the same time, excess water is 
removed by ultrafiltration. HD treatment is normally done at least thrice per week in 
infants (Fischbach et al. 2005). Between treatment days anuric and oliguric patients 
are restricted regarding their intake of liquids to avoid hypervolemia because only a 
limited amount of ultrafiltration can be achieved during each HD session. Intensified 
daily HD has been used and studied in children as well. Fischbach et al. suggested 
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in 2006 that daily HD could improve growth in children (Fischbach et al. 2006), and 
they later demonstrated that daily online hemodiafiltration dialysis, which includes 
both daily dialysis and convective flow added to HD, improves growth in children 
(Fischbach et al. 2010).
2.3 Neurological development and complications in children 
with end-stage renal failure
2.3.1 Neuromotor function evaluations
There are at least 15 distinct instruments with which neuromotor function can be 
evaluated in infants (Heineman, Hadders-Algra 2008). In Table 4, four different 
methods of assessment are presented, two of each kind. The age range of children 
that may be evaluated with these instruments varies from birth to four months and 
between 0 to 3.5 years. All these methods of assessment are aimed at distinguishing 
those infants developing within the normal range from the ones with a deviating 
neuromotor condition. These instruments differ not only in approach but also in validity 
and reliability. Three different validity characteristics, 1) constructive validity, that is 
the ability of a test to identify the measure that it proposes to identify, 2) concurrent 
validity, the degree to which a result from one test agree with a result from a different 
test, and 3) predictive validity, the ability to predict neurological outcome of the 
patient, are presented in Table 4. Intra and inter-observer reliability properties of these 
instruments are also shown in the table. The purpose of the assessment may be, 1) 
discriminative, to distinguish normal development from abnormal, 2) evaluative, to 
notice changes in the development or 3) predictive, to predict neurological outcome. 
Specifying the goal that the assessment must achieve is important for choosing the 
right method of assessment for each patient group and survey (Heineman, Hadders-
Algra 2008).
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table 4. Different instruments for evaluation of neuromotor function in infants. 
Modified after Heineman and Hadders-Algra (2008).
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2.3.2 Neuropsychological and cognitive performance tests
In older children, at least five years of age, different neuropsychological tests can be 
used to evaluate neurodevelopment and cognition. Fennell et al. and Crocker et al. 
used, among others, the Wide Range Achievement Test, Beery-Butenica Development 
Test of Visual Motor Integration to evaluate the neuropsychology of children with 
chronic renal failure (Fennell et al. 1990, Crocker et al. 2002). A Developmental 
Neuropsychological Assessment (NEPSY) and its extension NEPSY-II have been 
used for children with renal transplantation in Finland (Qvist et al. 2002, Haavisto 
et al. submitted). NEPSY can be used for children between 3 and 12 years. This 
instrument describes the patient’s attention and executive functions such as self-
regulation and flexibility in thinking, language and communication skills, sensor 
motor and visuospatial processing as well as memory functions and learning abilities 
(Korkman 1988). NEPSY-II is an extended version of NEPSY, can be used up to age 
16 and also tests social perception (Korkman et al. 2007). 
Intelligence tests have also been used for Finnish pediatric renal and heart 
transplantation patients (Qvist et al. 2002, Haavisto et al. submitted, Haavisto et al. 
2010). These study groups used the revised Wechsler Intelligence Scale for Children 
(WISC-R), which is suitable for children aged seven or more and is a modern IQ test 
(Wechsler 1974). The Wechsler Preschool and Primary Scale of Intelligence, Editions 
I-III (WPPSI─I-III), has been developed after WISC and can be used in children 
between two and a half and seven years (Wechsler 2003). The same IQ tests were used 
by Fennel et al., Crocker et al., and Madden et al. in childhood chronic renal failure 
(Fennell et al. 1990, Crocker et al. 2002, Madden et al. 2003). However, these wider 
neuropsychological and IQ tests can not be used in infants.
Hellbrügge et al. have developed a Munich Functional Developmental Diagnostic 
test (MFED) to evaluate functional development in children between one to three 
years (Hellbrügge et al. 1978). MFED has been used to define early cognitive 
development in Finnish children exposed to alcohol during the fetal period (Autti-
Rämö, Granström 1991a).
2.3.3 Neurological development
There are very few studies into the neurological development of infants on peritoneal 
dialysis. An early literature review by Polinsky et al. in 1987 showed developmental 
delay in 84% of children dialyzed in infancy. After successful renal transplantation, delay 
was seen in 31%. Aluminum load from prior phosphate binders, hyperparathyroidism, 
malnutrition, and psychosocial problems were suspected to influence development 
(Polinsky et al. 1987). Later, Honda et al. reported low developmental quotients at 
the end of PD in 69% of Japanese patients less than two years of age at PD initiation 
(Honda et al. 1995). Geary and Haka-Ikse showed better results in infants with ESRF, 
41% of whom had developmental delay (Geary, Haka-Ikse 1989). Warady et al. reported 
neurodevelopmental delay at the age of one year in only 21% of children on PD. 
However in their study, patients with extra renal or neurological disease, as well as 
two sepsis patients who died before one year of age (18%), were not included in the 
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neurological evaluations. The neurological evaluations were made either with the 
Modified Developmental Assessment Test (MDAT) or the Bayley Scales of Infant 
Development (BSID) at one year. Less than 10%, two of the 28 evaluated patients, had 
significant extrarenal co-morbidity. Approximately two thirds of these patients were 
evaluated with the Stanford Binet Intelligence Scale or the Wechsler Intelligence Scale 
for Children (WISC) later, at least at 4 years of age, most of them having received 
renal transplants. In 79% of the patients, the intelligence was in the average range. 
Nineteen per cent of school aged children attended special education, one of these 
children was deaf (Warady et al. 1999).
Some studies have evaluated children dialyzed during the first years of life at a 
later age. Madden et al. stated that the intelligence quotient (IQ) (mean 87) was within 
the average range in 67% of children dialyzed in infancy and tested at the age of 1 to 
12 years. Eighty-seven per cent of the patients were within two standard deviations 
of the norms (Madden et al. 2003). Qvist et al. showed a mean IQ of 87.5 in children 
transplanted before five years of age and dialyzed prior to renal transplantation, 42% 
being normal average. Moreover, another 42% of patients were classified as borderline 
to low average. Between 6 and 24% had a disorder according to neuropsychological tests 
(Qvist et al. 2002). Young ages at the onset of kidney disease, severity of the disease, 
and longer duration of the disease have been detected as risks for neurocognitive 
development in a study by Slickers et al.: these children with CKD, both dialysis and 
nondialysis patients, were studied after their seventh birthday but 59% of them had their 
kidney disease since birth (Slickers et al. 2007). Elzouki et al. found a clear correlation 
between malnutrition during the first two years of life and microcephaly in children 
with chronic renal failure. In their study, all developmentally delayed children, three 
out of fifteen, had microcephaly (Elzouki et al. 1994). Crocker et al. reported that 
children with congenital ESRF had worse results in long-term memory and fine motor 
coordination tests compared to children with acquired ESRF (Crocker et al. 2002). 
The child with a kidney disease and later ESRF may have co-morbidities such as a 
syndrome or neurological impairment such as hemiparesis. These co-morbid conditions 
naturally have an effect on the neurological outcome of the child (Offner et al. 1999).
Cerebral palsy (CP) is a descriptive term for a group of nonprogressive disorders of 
movement and posture caused by brain damage originating from pre or perinatal period 
or the first years of a child’s life. CP includes changes in muscle tone (mainly rigidity 
or spasticity), muscle weakness, ataxia, unintentional movements or a composition of 
the above mentioned abnormalities. The extent of motor function deficit/abnormality 
may not be revealed before the age of 3 or 4 years (Swaiman, Wu 2006). Children with 
CP often also have other neurological problems such as mental retardation and speech 
and language disorders (Ashwal et al. 2004, Swaiman, Wu 2006). The prevalence of 
CP is typically between 1.2 and 2.5 cases per 1000 live births. Premature birth clearly 
raises the risk for CP; prevalence in very-low-birth-weight pre-term infants being 8 to 
19% compared to that of 1.0 to 1.5‰ in full-term infants (Hagberg et al. 2001, Wu et 
al. 2003, Tommiska et al. 2003, Swaiman, Wu 2006). 
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2.3.4 Brain imaging
There are only few reports about brain imaging studies on dialysis and renal 
transplantation patients. In babies, the brain can be imaged with ultrasound (US), 
however, fontanels must be open for visibility. US is useful in discovering widened 
ventricles, hemorrhages, cystic changes and brain anomalies. However, US is not very 
sensitive in detecting hypoxic-ischemic brain damage (Rikalainen 2005). Computerized 
tomography (CT) is an ever less used method for studying the brain in children, 
except in acute trauma. The disadvantages of CT are poor tissue contrast and radiation 
stress. Nowadays, magnetic resonance imaging (MRI) is the principal method in 
studying the brain of a child. Hypoxic-ischemic lesions are easily detected with 
MRI although it may take a few days after the damage before changes are clearly 
visible. The alterations caused by ischemia in preterm and term infants and their 
development over time are well known. In small preterm infants, the fragile area for 
ischemia is the white matter around the brain ventricles. Over weeks and months, 
this damage converts into periventricular leukomalasia (PVL), in which the matter 
around ventricles becomes scarce and the ventricles become more angulated. The 
clinical condition of these children with PVL is typically spastic diplegia or tetraplegia. 
In full-term infants the susceptible areas to hypoxic damage are basal ganglia, the 
thalamus region and cerebral cortex. Longer and milder ischemia leads to watershed 
area infarcts (Valanne 2005). 
Steinberg et al. performed brain CT in older children with either chronic renal 
failure, or PD treatment or renal transplantation (aged 2 to 18 years, n=22). None of those 
children had a co-morbidity affecting the central nervous system (CNS) and none had 
a clear CNS disorder at the moment imaging was done. Brain atrophy was present in 
59% of the patients. A couple of patients had cortical infarcts and one had hypodensity 
in basal ganglia. Hemodialysis was found to be a risk factor for CT changes, but neither 
the type of renal disease, patient age, duration of renal failure, nor hypotension were 
related to brain atrophy (Steinberg et al. 1985). Elzouki et al. reported brain atrophy by 
CT in 23% of children with chronic renal disease from infancy (mean age 50 months 
at the end of the study, n=13) (Elzouki et al. 1994). Also Schnaper et al. observed brain 
atrophy by CT in 53% of children (n=15) with ESRF; they could not find clear risk 
factors but the HD treatment time of patients with brain atrophy was twice the time 
of patients without atrophy (Schnaper et al. 1983). Agildere et al. analyzed 432 adult 
patients that had received a renal transplant and 132 both child and adult patients that 
had received a liver transplant retrospectively with brain MRI. One third of the patients 
with renal Tx, and 72% of patients with liver Tx, displayed findings in their MRI after 
transplantation. The diagnoses were various, such as white matter changes, posterior 
reversible encephalopathy syndrome (PRES) owing to hypertensive encephalopathy or 
toxicity of immunosuppressive medication and intracranial hemorrhage. The findings 
were either related to transplantation or to chronic kidney or liver disease. Some findings 
seemed not to be secondary to the preceding conditions, but were considered to be 
incidental. The time on dialysis was not analyzed or discussed in the paper (Agildere et 
al. 2006). Another study by Valanne et al. defined neuroradiological findings in children 
with renal transplantation under five years of age (n= 33, born between 1984 and 1991). 
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MRI studies were done at a mean of six years after Tx, and most of these patients were 
on dialysis before Tx. Border-zone infarcts were recorded in 54% of patients; 11% of 
them severe, 33% moderate, and 56% mild lesions. Before transplantation, border zone 
infarcts were seen in 23% of the 26 patients imaged by CT (Valanne et al. 2004). These 
border zones are, for anatomical reasons, the most vulnerable areas to ischemia induced 
by hypoperfusion due to systemic hypotension (Adams et al. 1966) or serious stenosis 
of the internal carotid artery (Weiller et al. 1991). Hemodynamic crises, older age at 
transplantation, and longer duration of dialysis correlated well with border zone infarcts. 
Brain atrophy was seen in 15% of these children, cerebellar infarcts in 18%, and large 
vessel infarcts in 6%, after transplantation; however, 40% presented a normal brain 
MRI and 23% of them had had a clinical hemodynamic crisis (Valanne et al. 2004).
2.3.5 Hearing
In an early report by Bergström and Thompson, hearing loss was found in 47% of 
children with chronic renal failure. Ototoxic, congenital and genetic hearing defects 
were more common in children compared to older patients. The etiology of hearing 
loss was unknown in only 5% of the children (Bergström, Thompson 1983). Later 
reports showed hearing loss in 18 to 47% of children with chronic or end-stage renal 
disease (Qvist et al. 2002, Nikolopoulos et al. 1997, Mancini et al. 1996, Warady 
et al. 1993). Nikolopoulos et al. reported sensorineural hearing loss (SNHL) for an 
unknown cause in 30% of 46 children with chronic renal failure, whereas one patient 
(2%) had treatment with ototoxic antibiotics. None of the PD group (n=9) carried a 
hearing defect (Nikolopoulos et al. 1997). Aminoglycosides and furosemide often 
used in children with kidney diseases are responsible for ototoxicity (Matz 1990). In 
the study of Warady et al. (1993), four out of 14 pediatric patients (28%) on long-term 
PD, had hearing loss and three of them had received intra-venous aminoglycoside 
treatment. Mancini et al. found a significant correlation between aminoglycoside and 
furosemide treatments and SNHL in children with CKD (Mancini et al. 1996). The 
possible accumulation of drugs and diminished excretion of them due to renal failure 
in patients on PD must be taken into account during treatment.
2.4 Congenital nephrotic syndrome and neurological impairment
Nephrotic syndrome (NS) may be congenital, or it may develop later in life. It typically 
has many etiologies. In both types of NS, there are some conditions that have been 
associated with neurological problems (Goldenberg et al. 2005, Jalanko 2009).
Congenital NS, such as NPHS1, comprises a group of uncommon kidney defects 
in which severe proteinuria is present already from the first months of life. The cause 
of congenital NS may be genetic such as a mutation in NPHS1, or more frequently in 
NPHS2, causing nonfunctional protein podocin which is, like nephrin, a part of the slit 
diaphragm complex (Jalanko 2009). There are also other gene mutations such as WT1 
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in the Denys-Drash syndrome (Coppes et al. 1993), and LamB2 in Pierson syndrome 
(Zenker et al. 2004b, Zenker et al. 2004a), causing proteinuria in the glomerulus. 
In Galloway-Mowat syndrome (GMS), in addition to NS, patients also present CNS 
anomalies including hypotonia, microcephaly, brain anomalies, and psychomotor 
retardation (Cooperstone et al. 1993, Kozlowski et al. 1989, Lin et al. 2001). It is an 
autosomal recessive disease, in which the genetic defect is unknown. In addition to 
NS and CNS impairment, these patients may display other extrarenal disorders such 
as short stature, facial anomalies and hiatus hernia (Jalanko 2009, Cooperstone et al. 
1993, Kozlowski et al. 1989). Jalanko speculates that since podocytes and neuronal 
cells resemble each other and have common proteins in their structure there may be 
genetic disorders that affect both kidney and CNS (Jalanko 2009).
In late-onset NS, genetic defects of oxidative phosphorylation, that is defects in 
respiratory chain (RC); have been reported since the 1980s. These patients also have 
different neurological diseases, and some of them have hearing deficiencies. Their 
genetic defects have been detected in mitochondrial (mt) DNA (Tanaka et al. 1986, 
Hameed et al. 2001, Niaudet, Rotig 1996). Goldenberg et al. reported congenital NS 
with respiratory chain enzyme deficiency in a few patients in 2005. One of the three 
patients experienced seizures and a coma in the acute phase, but otherwise his neurology 
was normal. Two other patients died very young but their neurological abnormality 
was not described (Goldenberg et al. 2005).
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3 aims of the study
Infants and young children with ESRF have a poorer outcome, higher mortality, and 
suboptimal growth compared to older children. Due to NPHS1 defects, more young 
children in Finland require treatment for ESRF, including PD, compared to other 
countries. Thus, we have an obligation to develop treatment modalities for this age 
group. PD is the most commonly used RRT modality in this age group wherein HD 
is more difficult to perform, especially if one wants the child to spend as much time 
at home as possible to improve development and quality of life for the child and his/
her family.
In this study, we have focused on the youngest children, those needing PD before 
the age of two years. We have prospectively followed these children in detail using 
a standardized treatment and follow-up protocol based on our earlier studies and the 
literature, and compared the results with our previous experiences. We have also closely 
monitored the neurological outcome of these children.
The specific aims were:
1. To prospectively follow all children under 2 years of age at onset of peritoneal 
dialysis, using a standardized protocol, and evaluate their metabolic control, 
intravascular volume status, and growth.
2. To compare the results of prospectively followed patients with those reached during 
previous years. 
3. To document neurological development and possible brain imaging pathology in 
these very young, still developing children.
4. To characterize a group of NPHS1 children with similar neurological findings 
since birth, including muscular dystonia and athetosis.
5. To make improvements and new recommendations for our RRT therapy and follow-
up based on the findings of these studies.
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4 Patients and methods 
4.1 Patients and controls
The studies included all children less than two years of age treated with chronic 
PD between 1995 and 2005 in Finland (studies I-III), and six NPHS1 patients with 
a neurological athetotic syndrome and their NPHS1 control group (study IV; see in 
detail Table 5).
table 5. Demographic data of patients included in studies I to IV. In study IV the data 
of control patients is shown in parenthesis.
Study I included 23 small children who were treated consecutively with chronic PD 
between 1995 and 2000 in Finland. The inclusion criterion, in addition to PD treatment, 
was the child’s age under two years at PD onset. Three patients also belonged to study 
IV. This retrospective data was analyzed in order to obtain a control group for our 
prospectively followed PD patients. 
The prospective studies II and III included all small children born between 2001 
and 2005 who were treated with a preplanned strict PD protocol. The inclusion criterion 
was also that the patient was aged less than two years at the commencement of PD.
Study IV comprised NPHS1 patients with an unknown, congruent neurological 
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syndrome. Six children out of altogether 70 (8.6%) NPHS1 patients born between 
1984 and 2003 had severe muscular hypotonia, dystonia, and athetoid movements. We 
call this movement disorder muscular dystonia and athetosis (MDA). Three of these 
patients were also included in study I.
As controls for NPHS1 patients with MDA, we enrolled 29 consecutive 
NPHS1 patients born between 1984 and 1991 who had undergone neurological and 
neuroradiological examinations for former studies at our institution (Qvist et al. 2002, 
Valanne et al. 2004).
4.2 Methods
4.2.1 Study design and data collection
In 2001, we made a prospective study protocol concerning PD treatment, nutrition, 
medication, and examinations in children under two years of age at the onset of PD. 
This study design is demonstrated below.
figure 8 Study design of the prospective part of this study in children with PD onset 
under two years of age (II, III). Ward visits are noted at baseline, one and three months 
and every third month thereafter.
The data from our retrospectively studied PD patient group (I) which included patient 
characteristics, information about the PD period and complications, medication, 
laboratory values, and growth data was collected from patient records and analyzed 
until the end of PD. 
Methods of the study of NPHS1 with MDA patients (IV) are introduced later in 
this section (4.2.10).
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4.2.2 Nutrition
Here and in the following chapters, we describe the methods used in our prospectively 
studied PD patient group unless otherwise stated.
Nutrition was planned by the same dietician and evaluated at least once per month, 
sometimes even weekly in patients with PD initiation between 2001 and 2005 (II). 
The energy amount of the diet was planned to be 80-90 kcal/kg per day, and protein 
provided 2.0-2.5 g/kg per day depending on the growth of the patient. The diet was 
mainly composed of infant milk and cereal products, and energy supplements. One 
patient required a gastrostomy and sixteen patients a permanent nasogastric tube to 
guarantee sufficient energy intake. Food intake was analyzed from two-day food records 
in 14 children. The Aivo2000-Diet32 program version 1.4.4.1. (AIVO Finland Oy, 
Turku, Finland) was used to count energy, protein, and nutrient amounts in the diet. 
We estimated that the children received additional energy from the dialysis solution 
glucose of approximately 10 kcal/kg per day. This amount was not included in the 
nutrition calculations.
4.2.3 Medication
Regular medication for ESRF was programmed for all patients (II). Calcium carbonate 
was used as a calcium substitute and phosphate binder. Alphacalcidol was given daily 
as vitamin D substitution, contrary to our earlier pulse therapy thrice a week used in 
the retrospectively analyzed patients. In case of a high, rapidly rising intact parathyroid 
hormone (iPTH) level of grater than 400 ng/L and high calcium-phosphate product 
(see below) the alphacalcidol dosage was switched to pulse therapy (Ala-Houhala et 
al. 1995).
All patients received subcutaneous human erythropoietin with an initial dose of 150 
IU/kg per week and oral iron supplementation of 2-3 mg/kg per day to reach normal 
blood hemoglobin values. Medication is reported at baseline, and at three and six 
months. Comparison of the medication with the retrospectively analyzed PD patient 
group is done at six months. Antihypertensive medication was given to patients with 
hypertension when hypervolemia was excluded. Mainly β-blockers or calcium channel 
blockers were used. No one received growth hormone therapy during PD.
4.2.4 Dialysis
PD treatment initiation and family training took place in the Children’s Hospital 
in Helsinki. For three patients, dialysis had been introduced already at their local 
hospital and chronic PD prescription and family training was performed at our clinic.
The dialysis catheter, mostly a Tenckhoff curled 1-cuff, in studies I and II, was 
inserted by the same two urologists at our center, the Children’s Hospital in Helsinki, 
two weeks before PD initiation. Three children in the prospectively followed group 
(II) and seven children in the retrospective group (I) got their catheters only a few days 
before PD start, due to a prompt need of dialysis at their local hospital. 
In the prospectively followed PD patient group (II), we used a nightly fill volume of 
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800 mL/m2 of body surface area (BSA) per dialysis exchange in children under one year 
of age and 1000 mL/m2 of BSA in older children. CCPD was the first choice of modality. 
Nightly PD treatment lasted approximately ten to eleven hours encompassing 12-14 
exchanges. In nephrectomized patients, we performed two manual daytime dialysis 
solution exchanges (duration about one hour per exchange) to avoid hypervolemia. 
The last fill in the morning, as well as the daytime exchanges, were carried out with 
approximately 50% of the nightly dwell volume. TPD was chosen for patients with 
outflow pain, or ultrafiltration problems, or if better clearance was needed. TDP 
treatment time was the same as in CCPD but 22-26 exchanges with 50% dialysate 
exchange per cycle were performed during the night. In the middle of the TPD program 
one full outflow was performed to avoid overfill of the peritoneal cavity. In patients 
with PD initiation between 1995 and 2000 (I), the dialysis principle was similar to the 
one demonstrated above.
We used Baxter Home Choice cycler PD machines (Baxter Healthcare Corp., 
Deerfield, IL, USA) for all of our prospectively followed patients. Dialysates were pH-
neutral bicarbonate-lactate-buffered dextrose solutions (Physioneal, Baxter Healthcare 
Corp.) and all dextrose concentrations were used. Weight limits were applied for the 
determination of glucose concentrations needed for exchanges. Nighttime PD was 
usually performed with low (glucose 13.6 mg/mL) and medium glucose concentration 
(22.7 mg/mL) mixtures but daytime exchanges were mostly carried out with high (38.6 
mg/mL) or medium glucose concentration solutions to get better ultrafiltration with 
smaller daytime dwells. In a couple of patients that were growing poorly or with low 
plasma albumin values, we transiently used amino acid dialysate (Nutrineal, Baxter 
Healthcare Corp.) to improve their nutritional status. In one patient with ultrafiltration 
problems, we tried icodextrin dialysate without any notable help (Extraneal, Baxter 
Healthcare Corp.) before switching to HD. In retrospectively analyzed PD patients (I), 
other PD machines that are suitable for young children were also used.
4.2.5 Uremia control
All prospectively followed PD patients (II) visited our pediatric nephrology ward 
both one and three months after PD start, and every third month thereafter. Follow-up 
at their local hospital took place every one to three weeks. Growth measurements, 
laboratory tests, 24-hour dialysate and urine collections, IPP measurements, blood 
pressure, BIA, and heart ultrasound for the study were performed during these visits.
4.2.5.1 Laboratory assessments
Regularly followed routine laboratory tests are shown in Table 6.
Blood urea nitrogen (BUN) was targeted to remain below 40 mmol/L. Our target for 
blood hemoglobin was the lower limit of normal for age, at a minimum. Serum ferritin 
was aimed to be over 100 µg/L and saturated transferrin more than 20%. IPTH was 
aimed at high normal up to two-fold the upper limit of normal. Because the laboratory 
methods of iPTH varied during the study period, the upper limit of normal or multiples 
of it was used in reporting the values (the upper limit during the prospective study was 
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73 ng/L). Ionized-calcium phosphate product (ion-Ca x Pi) was targeted to be lower 
than 2.5 mol2/L2 (Tertti, Klaus 2006). 
table 6. Laboratory assessments which were regularly examined in our prospectively 
followed patients during PD. Tests written in bold characters are reported in this thesis 
and/or in study II.
4.2.5.2 Adequacy of peritoneal dialysis
An adequacy of dialysis was examined one and three months after dialysis initiation 
and thereafter every third month, coincident with the patient’s normal PD prescription 
(II). We used 24-hour dialysate (and urine if not anuric) collection and analyzed it 
with the PD Adequest 2.0 computer program (Baxter Healthcare Corp.). Weekly urea 
Kt/V was targeted to be over 3.0. These children received more protein than adult 
patients and thus the urea purification was aimed higher than is recommended for 
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adults to guarantee that BUN values did not rise too high. Creatinine clearance (Crcl) 
was aimed to be more than 65 L/week per 1.73 m2. Crcl is related to BSA, which is 
relatively high in infants in comparison to older children and adults. The other method 
for reporting creatinine purification is weekly creatinine Kt/V, introduced by Ishikura 
et al. (2003), and it correlates the clearance of creatinine with total body water, not 
relative to BSA. We also calculated the weekly creatinine Kt/V in our prospective 
PD patients. According to Ishikura et al., in adult patients (male; 170 cm, 65 kg), 
a Crcl level of 60 L/week per 1.73 m2 corresponds to a weekly creatinine Kt/V of 
1.52 (Ishikura et al. 2003), which was used as cut-off point for acceptable creatinine 
purification in our patients too.
A 4-hour peritoneal equilibration test (PET) was performed directly after the 24-
hour dialysate and urine collection with high glucose concentration dialysis solution 
and a fill volume of 800 mL/m2 in children under one year of age and 1000 mL/m2 in 
older children. The fill volume during PET was relatively low compared to the latest 
recommendations. However, in order to avoid high intraperitoneal pressure (IPP), we 
used high glucose concentration (38.6 mg/mL) solution in PET, which gives relatively 
high ultrafiltration (UF) and thus raises IPP during the test. The PET findings, the 
individual peritoneal transport capacities, are not reported here; however, PET results 
were used in the PD Adequest 2.0 program in planning an individual PD program for 
every patient and when checking it during ward visits. 
A modified 24-hour dialysate and urine collection was used in the retrospectively 
analyzed PD patients (I) and it was available in only 15 patients (Hölttä et al. 2000b). 
It differs from the collection used in the prospective study. Thus, the comparison of 
purifications is not valid between these two patient groups.
4.2.6 Complications of peritoneal dialysis
4.2.6.1 Catheter and hernias
Data about catheter-related complications, and hernias were collected from patient 
records.
4.2.6.2 Intraperitoneal pressure measurement
IPP was measured once or twice when introducing PD between 2001 and 2005, and 
then at least during every protocol ward visit (II). The dwell volume at measurement 
was the above mentioned 800 or 1000 mL/m2 of BSA. To avoid discomfort, vomiting, 
and hernias and to be sure that the volume could be increased with growth in the 
near future, we targeted an IPP lower than 10 cm of H2O in children under two years 
of age, and lower than 16 cm of H2O in older children. If the IPP was clearly higher 
than targeted, we used dwell volumes smaller than the test volume on PD.
If clearances were poor (see below), and the IPP of an acceptable level, we increased 
the dialysis dosage by adding dialysis time, dwell volumes, or number of exchanges 
depending of the type of peritoneum.
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4.2.6.3 Peritonitis
Peritonitis was considered possible when the patient had cloudy peritoneal fluid or 
clinical findings (fever, abdominal pain, diarrhea), and when the peritoneal fluid 
contained more than 100 leucocytes/μL, 50% or more of which were polymorphonuclear 
cells. A positive peritoneal fluid Gram stain amplified the diagnosis, and consequently, 
a positive peritoneal fluid or blood culture confirmed it (Thompson et al. 2005, Warady 
et al. 2000) (I, II).
4.2.6.4 Intravascular volume status
Blood pressure measurements were performed at ward visits. We used the mean 
value of oscillometric measurements taken every two hours over 24 hours. Weighing 
of the patient, plasma N-terminal atrial natriuretic peptide (ANP-N), BIA, and 
echocardiography were performed on the same day for intravascular volume status 
estimation (II).
Hypertension
Our definition of hypertension was based on the Second Task Force reference values 
for diastolic and systolic daytime blood pressure. If the mean diastolic or systolic blood 
pressure exceeded the 95th percentile for age and gender, hypertension was established 
(National High Blood Pressure Education Program Working Group 1996). Patients 
with hypertension, signs of clinical overload, and ANP-N over 3 nmol/L, based on a 
previous study at our center (Hölttä et al. 2001), were regarded as hypervolemic (II).
In both patient groups, blood pressures were measured regularly, even daily, but 
accurate BP data was lacking in the retrospective patient group. Thus, we report 
hypertension frequency only in the prospectively followed PD patients (II) and 
comparison of the prevalence of hypertension between the two groups could not be 
made. See the medication issued for hypertension in chapter 4.2.4 (Medication).
Heart ultrasound measures 
All echocardiography examinations in the prospectively studied patients were 
performed by he same cardiologist (II). The data collected included, left ventricular 
end-diastolic dimension (LVEDD), left ventricular end-systolic dimension (LVESD), 
interventricular septal dimension at end-diastole (SeptD), left ventricular posterior 
wall thickness at end-diastole (LVPWD), and ejection fraction (EF). The reference 
values for LVEDD, LVESP, SeptD, and LVPWD were computed according Lester et 
al. (Lester et al. 1987). For these reference values, age, gender, height, weight, and 
heart rate (HR) were also taken into account. Left ventricular mass was defined using 
M-mode echocardiography and Devereux formula (Devereux et al. 1986). LVM was 
related to body height2.7, according to Simone et al., to establish a linear relationship 
(de Simone et al. 1992). This is cited here as the left ventricular mass index (LVMI). 
LVH was diagnosed if the LVMI exceeded the 95th percentile of gender and age (de 
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Simone et al. 1992). The LVM data were also analyzed according to Foster et al. with 
a new method in which LVM is related to body size to give an LV mass-for-height 
Z-score, which is appropriate for small children. LVH was also stated if the Z-score 
exceeded the 95th percentile. The Z-scores of LV mass-for-height and heart dimensions 
were taken to correlation analyses (II).
Bioimpedance analysis
BIA measurements were performed with a Nutriguard-M multi-frequency analyzer 
(Data Input GmbH, Darmstadt, Germany) providing resistance (R) and reactance 
(Xc) (II). The patient was in supine position, with electrodes placed on hand and foot 
(Kyle et al. 2004). The electrodes were halved due to the small size of our patients. A 
frequency of 50 kHz was used in the measurements, which were technically demanding 
due to patient age. The resistance index RI = height2/R (Houtkooper et al. 1989, 
Schaefer et al. 2000) was used for correlation analyses.
4.2.7 Mortality and hospitalization
Mortality is reported as deaths per follow-up years. Hospitalization is reported as 
the total number of days in hospital divided by the total number of patient-years on 
PD (I, II).
4.2.8 Growth in children on peritoneal dialysis
Height, weight, and head circumference were documented during ward visits (I, II). 
If accessible, these measures are reported also at birth, as well as at six and three 
months before PD onset. Height, head circumference, and birth weight values are 
expressed as mean height standard deviation scores (hSDS), that is, standard deviations 
of normal Finnish children (Kantero, Tiisala 1971, Sorva et al. 1984). Weight after 
birth was compared to height and registered as percentiles of Finnish mean values 
(Sorva et al. 1984). Growth was judged as good, if growth velocity was normal for 
age and gender, which was defined as either no change or a positive change in hSDS 
during the study period (I, II, III). Parental target height, also called midparental 
height, was assessed according to Sorva et al. (Sorva et al. 1989) (II).
Two of the retrospectively analyzed PD patients were excluded from growth analysis, 
one due to a very short PD period (0.2 years) and the other because of notably deviant 
growth due to severe congenital heart disease (I).
4.2.9 Neurological development and complications
4.2.9.1 Risk factors for development
In our neurological analysis on PD patients with dialysis initiation between 2001 and 
2005, risk factors for brain damage and neurological development were determined 
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as follows: 1) a clear disturbance during the intrauterine period, 2) an Apgar score 
less than 4 at one minute (ICD-10) or lower than 5 at five minutes (van Schie et al. 
2007), 3) intensive care and respirator treatment perinatally or later during infancy 
before PD initiation, and 4) co-morbidities such as syndromes and brain insults before 
PD start that are known to affect the child’s motor or psychomotor development. 
Intubation needed for transfer to another hospital was not considered a risk factor 
for development (III).
4.2.9.2 Neurological examinations and tests
The same pediatric neurologist examined prospectively all children with PD initiation 
between 2001 and 2005 when PD was started, every third month until the child 
turned one year, and every six months thereafter (III). After Tx, the children with 
neurological abnormalities visited a neurologist at least every year. We collected 
data about neurological evaluations performed at local hospitals. Children and their 
development were evaluated also with other methods as follows.
Motor development was investigated with the Alberta Infant Motor scale (AIMS) 
(Piper et al. 1992) by a physiotherapist (III). AIMS tests were done in all patients at 
PD start and during ward visits until Tx but not at over 20 months of age. There were 
two to seven evaluations per patient. AIMS was selected because it is a suitable test 
battery for infants and small children up until 18 to 20 months of age. Moreover, it 
was already in use at our center and the physiotherapists were experienced with it.
An occupational therapist conducted a Munich Functional Developmental 
Diagnostic test (MFED, Münchener funktionelle Entwikclungsdiagnostik test) to assess 
functional development (Hellbrügge et al. 1978). The test was carried out in 15 children 
every six months after the age of one until the age of two or at most until Tx (one to 
four experiments per patient, range 13-20 months). Six patients were transplanted 
early before any MFED evaluations had been done. Four developmental areas were 
tested; 1) fine motor skills, 2) perception, 3) social skills, and 4) autonomous activity. 
Three categories were used in evaluating development; 1) abilities lower than the 
actual age (<5th percentile), 2) normal abilities (between 5th and 50th percentiles), and 
3) good abilities (>50th percentile). MFED was chosen because it evaluates functional 
development in this young age group. MFED was already standardized for Finnish 
children by Dr. S. Ruoho in 1983 and it was used in the study of Autti-Rämö et al. 
(Autti-Rämö 1993, Autti-Rämö, Granström 1991b).
Neuropsychological tests were conducted on 16 out of 21 patients (76%) at about 
five years of age. Other patients were too young for these evaluations. The tests were 
the Wechsler Preschool and Primary Scale of Intelligence (WPPSI) and parts of the 
Developmental Neuropsychological Assessment (NEPSY). In some patients, also the 
Developmental Test of Visual-Motor Integration (VMI) and the Direct Memory Access 
(DMA) were used. Moreover, we collected data about therapies needed, which were 
speech or occupational therapy.
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4.2.9.3 Brain imaging
To exclude obvious CNS malformations and hemorrhage, brain US was performed in 
patients under one year of age one month after PD start in patients between 2001 and 
2005. In 15 patients, US was done already before PD introduction on clinical grounds. 
Routine brain MRI (or CT) was performed before renal transplantation (preTx) (N=19 
/MRI and N=1 /CT) and two years after transplantation (Tx) (N=12, all MRI). Two 
more patients were imaged soon after Tx (1 MRI and 1 CT) for clinical reasons. In 
addition, brain MRI was performed on three newborn children for clinical reasons (III).
4.2.9.4 Hearing tests
Prospectively followed PD patients which were younger than seven months were 
tested with transient evoked otoacoustic emission (TEOAE) (N=6). A pass criterion 
of signal-to-noise ratio (SNR) at least 6 dB, at the minimum of three of the five half 
octave bands was used, with concurrent reproducibility of at least 50%. The same 
criteria were in use at our neonatal intensive care unit for the auditory screening test. 
Behavioral observation audiometry (BOA) was done in children at least 7 months of 
age, every six months during dialysis ((N=19, 1 to 4 studies per patient). The normal 
audition threshold was 30 dB for 0.5―2 kHz. Most of the children who reached the 
age of 3 years were checked with conditioned play audiometry although they had 
already been transplanted (N=12). The normal hearing threshold for 0.5―4 kHz 
was set at 20 dB. Furthermore, one patient was examined with a brainstem evoked 
response auditory (BERA) test at his local hospital. One patient died during PD before 
any hearing test was done.
4.2.9.5 Neurodevelopmental outcome
The neurodevelopmental outcome of prospectively followed PD patients was divided 
into three groups: 1) normal, 2) minor impairment, and 3) major impairment. The 
grouping criteria are presented below, see Table 7. Grading of CP was done according 
to Riegel et al. (Riegel et al. 1995, Hagberg et al. 1975). This classification has earlier 
been used in a Finnish pediatric neurological study by Lano (Lano 2002). On grade 
1, the functional disability is minimal or not notable. On grade 2, the functional 
limitation is clear but independent walking is possible. On grades 3 and 4, independent 
walking or movement is not possible.
table 7. Grading criteria for neurological impairment in our PD patients, adapted for 
the patient material from Lano (2002).
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4.2.10 NPHS1 with muscular dystonia and athetosis
In the retrospective study of six patients with NPHS1 and MDA (IV), the analysis 
included prenatal and perinatal risk factors, bilirubin and albumin values as a newborn, 
severe infections during the first six months, acute hemodynamic and neurological 
insults, and growth data. Neurological data were recorded to define neurological 
symptoms. Neuroradiology was evaluated. In controls, risk factors, as well as 
neurological and neuroradiological substance were already collected to a large degree 
for earlier studies at our center (Qvist et al. 2002, Valanne et al. 2004). Consequently, 
we collected additional data such as growth, bilirubin, and albumin parameters. In 
addition, for those six patients with NPHS1+MDA, their NPHS1 mutation, basic 
laboratory data, as well as urine organic acids, blood lactate, and viral antibodies, and 
blood and urine amino acids were documented. Typical renal biopsy findings (classical 
dilatation of renal tubules) were certified. Their brain imaging was re-evaluated by a 
pediatric neuroradiologist and a pediatric neurologist. Their EEG reports and auditory 
examinations were gathered. Neuropsychological test evaluations were collected. For 
two patients, WPPSI-revised and/or two various visual perception tests had been 
performed at preschool age and WISC-III or NEPSY at school age.
4.2.10.1 Analysis of mitochondrial DNA
In three patients with MDA, isolation of total DNA from the kidney (2 patients) 
was done with phenol and chloroform and from the blood (1 patient) with a QI-
Aamp Blood Kit (Qiagen, Hilden, Germany). Analysis of the patients’ mtDNA was 
performed with conformation-sensitive gel electrophoresis followed by sequencing, 
to find mutations and polymorphism. In the other three patients, kidney or blood 
samples were not accessible.
A novel mtDNA mutation was verified with restriction fragment analysis. A second 
novel mutation was verified with allele-specific amplification (IV).
4.2.11 Ethical considerations
The study protocol was approved by the Ethics Committee for Pediatrics, Adolescent 
medicine and Psychiatry at the University of Helsinki, Finland. A written informed 
consent was obtained from the parents after the purpose and design of this study was 
thoroughly explained to them.
4.2.12 Statistics
In measures such as growth and test evaluations, patients’ ages were corrected 
according to the expected date of delivery. All statistical analyses were performed 
with SPSS versions 10.0-17.0 for Windows (SPSS Inc., Chicago, IL, USA). The values 
are reported as mean ± 1 standard deviation (SD) or as median and range. Pearson’s 
correlation coefficient was used in simple correlations and Spearman’s correlation 
in non-normally distributed data. Comparisons between values such as growth and 
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laboratory parameters in normally distributed data were done with the analysis of 
variance (ANOVA) and Student’s T test. The Friedman test was used with Dunn’s 
test for non-normally distributed data when comparing values over time. Associations 
in non-normally distributed data were analyzed with non-parametric Mann-Whitney 
U test (non-related samples) and Wilcoxon signed ranks test (related samples). Chi 
square test with Yates’ correction for continuity and Fisher’s exact test were used when 
comparing categorical variables between two groups. Incidences between patient groups 




In the retrospectively analyzed PD patient group, almost 100% of the diet was given by 
a nasogastric tube (I). In the prospective group, 16 patients (76%) needed a permanent 
nasogastric tube and one patient a gastrostomy to assure adequate energy intake. 
Nutritional intake of energy, protein, and some minerals, and vitamins, according to 
the food records from the prospective group, are presented in Table 8 (II). Energy intake 
was about 100% of the recommended. Our prospectively studied PD patients received 
more protein than the safe level for normal growth and development suggests, whereas 
iron and calcium intakes without supplementation were lower than recommended in the 
Nordic Nutrition Recommendation (NNR) (Nordic council of Ministers 2004). Phosphate 
intake was low as planned, as a part of the normal diet in ESRF patients. The intake of 
selenium, zinc and magnesium was also low compared to NNR (II, unpublished data).
table 8. Nutritional mean intake of energy, protein, minerals, and vitamins in 14 
patients, PD initiation between 2001 and 2005 (II [energy and protein intake] and 
unpublished data [minerals and vitamins]). 
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5.2 Medication for uremia
There were no statistical differences in EPO, oral iron, calcium, and alphacalcidol 
doses between retrospectively analyzed and prospectively studied patients after six 
months on PD. EPO dose was lower and peroral calcium dose higher in our patients 
between 2001 and 2005 compared to the retrospective group treated between 1995 and 
2000, but the differences were not statistically significant. The retrospectively analyzed 
patients received significantly more sodium chloride perorally as supplementation; 
see Table 9 (I, II).
At baseline, in patients with PD onset between 2001 and 2005, alphacalcidol was 
given daily to 20 patients (95%), while one patient had pulse therapy. At three months, 
12 patients (57%) still received daily dosage, seven (33%) had pulse therapy, and for 
two (10%) the medication was paused due to low iPTH values. At six, nine and twelve 
months the dosage modes were 13 daily/6 pulse/2 pause, 11 daily/4 pulse/0 pause and 
4 daily/5 pulse/0 pause (II). See the iPTH values in these patients in the next chapter.
table 9. Medication information in prospective PD patients at baseline, at 3 and 6 
months and in retrospectively analyzed patients at 6 months.
5.3 Dialysis
Our patients and some outcome measures are presented in Table 10. There was 
no statistical difference between age, PD duration, number of NPHS1 patients or 
nephrectomized patients, or in gender distribution between our two patient groups: 
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1) PD initiation between 1995 and 2000, here referred to as retrospectively analyzed 
PD patients (I), and 2) PD initiation between 2001 and 2005, here referred to as the 
prospective group or prospectively followed patients (II). Peritonitis frequency was 
lower in this prospective group but the difference was not statistically significant.
The retrospectively analyzed PD patient group altogether constituted of 377 dialysis 
months and the prospective group 284 months. CCPD was the most common dialysis 
modality when considering treatment time with 66% in the retrospectively analyzed PD 
patients and 61% in the prospective patients. TPD proportions of dialysis time were 22% 
and 38% in these groups. Only the retrospectively analyzed PD patients were treated 
with CAPD (12% of the dialysis time). Five of the retrospectively analyzed PD patients 
and two of the prospectively followed patients needed HD for some time between PD 
periods. In the prospective PD patient group, it constituted altogether 3 months (1% 
of dialysis time). From both groups, three patients were transferred permanently to 
HD because of difficult peritonitis, ultrafiltration failure, or dialysate leakage (I, II, 
unpublished data).
table 10. Patient comparison in children under 2 years of age with PD onset between 
1995 and 2000 (I) and between 2001 and 2005 (II).
5.4 Uremia control
5.4.1 Laboratory assays
Essential laboratory values are presented in Table 11. There were no statistical 
differences in creatinine, hemoglobin, calcium or phosphate, PTH, or cholesterol and 
triglyceride values between retrospectively analyzed and prospectively followed PD 
patients. PTH and triglyceride values seemed however to be lower in the prospective 
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group. BUN values were statistically lower in the prospective group (I, II).
Intact PTH levels were difficult to control in our prospective group. IPTH values in the 
retrospectively analyzed and in the prospectively followed PD patient groups are shown 
in Figure 9. In both groups, a clear tendency towards an increase in iPTH during PD 
can be seen. Differences between these patient groups were not statistically significant.
table 11. Laboratory values at 6 months on PD in children less than two years of age 
at PD onset between 1995 and 2000 (Study I) and between 2001 and 2005 (Study II).
figure 9 Percentage of patients with a plasma intact parathyroid hormone level 
below or over twice and thrice the upper limit of normal (ULN) during dialysis in 
retrospectively analyzed (I) and prospective PD patients (II). Numbers of patients above 
the columns.
5.4.2 Adequacy of PD
In retrospectively analyzed patients with a modified 24-hour dialysate collection, the 
adequacy parameters were mean urea Kt/V 3.2 ± 1.0 and mean Crcl 67 ± 23 L/week 
per 1.73 m2 at about nine months on PD (n=15) (I). However, the dialysate collection 
method was different to our prospectively studied patients (see Methods in chapter 
4.2.5.2). In the prospective group, these values were mean urea Kt/V 3.3 ± 0.8 and 
Results    63
mean Crcl 49 ± 19 L/week per 1.73 m2 at three months (n=21), 3.5 ± 0.6 and 49 ± 18 
L/week per 1.73 m2 at six months (n=18), and 3.5 ± 0.8 and 49 ± 30 L/week/1.73 m2 
at nine months (n=9), respectively. Patients with RRF showed no significantly higher 
urea purification compared with anuric patients. The Crcl levels were significantly 
better in patients with RRF between 2001 and 2005: 66 ± 27 L/week per 1.73 m2 
compared to 44 ± 13 L/wk per 1.73 m2 in anuric patients (p<0.001) (II). 
The Crcl levels in our prospectively followed PD patients were lower than targeted, 
in particular in anuric patients. Still, these patients grew well during PD. When our 
material was analyzed with the method of Ishikura et al. (2003), described in the 
methods section, the mean weekly creatinine Kt/V was 2.2 ± 0.9 in all patients. In 
anuric patients it was 1.9 ± 0.6 and 3.0 ± 1.2 in children with RRF. The determined 
cut-off point; a weekly creatinine Kt/V of 1.52 which corresponded to a Crcl of 60 L/
week per 1.73 m2 in male adults, was in our patient material equal to a Crcl level of 35 
L/week per 1.73 m2, see Figure 10. Thus, if the child is growing and developing well, 
as low Crcl as 35 L/week per 1.73 m2 or over seems to be enough. 
figure 10 Creatinine clearances in 21 prospective PD patients less than 2 years of age 
at onset of PD. Patients with residual renal function are marked with empty circles and 
anuric patients with filled circles. Fit line represents all measurements. Vertical dashed 
line shows weekly creatinine Kt/V of 1.52 and horizontal line corresponds to a creatinine 
clearance value of 35 L/week 1.73 m2 (unpublished data).
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5.5 Complications of PD
5.5.1 Catheter–related complications and hernias
The need for surgical intervention for PD catheters, catheter-related infections, 
peritonitis. and hernias before PD onset and during PD in retrospectively analyzed 
and prospectively followed PD patients are presented in Figure 11. There were no 
significant differences in the number of patients having catheter problems or hernias 
between the groups. There were less catheter exchanges in the prospective PD patient 
group but the difference was not statistically significant (I, II).
figure 11 Catheter repositions and exchanges, tunnel and exit-site infections, peritonitis, 
and hernia in patients under age 2 at PD initiation (n=23, study I; n=21, study II, 
unpublished data).
5.5.2 Peritonitis
Peritonitis frequency is shown in Tables 10 and 12 (I, II). Peritonitis incidence and 
causative organisms are presented in Table 12. Prospectively followed PD patients 
had less peritonitis, but the difference in peritonitis incidence was not statistically 
significant. However, more prospectively followed PD patients were peritonitis free 
during the whole PD period compared to retrospectively analyzed patients (p=0.036) 
(I, II and unpublished data). Staphylococcus aureus was a frequent organism in the 
prospective group and 86% of these infections were detected in two patients, whom 
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both experienced three bouts of peritonitis. In the families of these patients, nasal 
carriers of S. aureus were found (unpublished data). 
table 12. Causative organisms of peritonitis in patients under two years of age on PD 
between 1995 and 2000 (I), and between 2001 and 2005 (II and unpublished data 
[causative organisms])
5.5.3 Intravascular volume status
Blood pressures, plasma ANP-N and BIA values, linear heart dimensions, and LV 
mass-for-height Z-scores of our prospective PD patients are presented in Table 13. 
At a stable stage on PD, at 3 months after PD initiation, high plasma ANP-N (n=19) 
correlated well with both systolic and diastolic hypertension (r=0.59, p=0.007 and 
r=0.57, p=0.011). LVH (Z-scores, n=19) also correlated well with both systolic and 
diastolic hypertension (r=0.67, p=0.002 and r=0.54, p=0.017) at three months on 
PD but not with plasma ANP-N. LVEDD and systolic hypertension (n=15) showed 
a good correlation at 3 months (r=0.62, p=0.013). All these preceding correlations 
of about the same magnitude were also seen at baseline and at 6 months on PD (II). 
BIA RI correlated only in the beginning of PD with LVEDD (n=12, r=0.59, p=0.045) 
(unpublished data). LVEDD diminished significantly between baseline and 3 months 
(p=0.002), as well as between baseline and 6 months (p=0.024). The proportion of 
patients with LVH (counted with Z-scores) decreased during PD. The improvement 
was statistically significant (p=0.016; PD start vs. 3 months and p=0.035; PD start 
vs. 6 months) (II).
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Antihypertensive medication was needed in 70% of the retrospectively studied PD 
patients at some point during PD, while the percentage was only 33% in our prospective 
group (I, II).
Prospectively followed patients had no clear periods with clinical hypovolemia. 
Nor did we find data about clinically significant periods of hypovolemia in the patient 
records of the retrospectively analyzed PD patients (I, II).
In conclusion, LVH decreased in the prospectively followed patients with time 
during PD. However, many patients still had high blood pressures during PD.
table 13. Blood pressures and patients exceeding the 95th percentile, plasma ANP-N 
and patients exceeding the value 3 nmol/L, and BIA resistance, resistance index, and 
reactance. Under the linear heart dimensions and LV mass-for height Z-scores and 




Between 1995 and 2000 two patients (9%) died during PD (in 31.4 patient- years). 
One died due to a subarachnoidal hemorrhage, and the second died of congenital 
heart disease with severe heart insufficiency (I). Between 2001 and 2006, one patient 
(5%) with NPHS1 and normal neurology died during PD (in 23.7 patient-years) due 
to pneumonia after an anesthesia complication. None of these prospectively followed 
patients died after PD during the neurological follow-up (II). See Table 10.
Hospitalization is shown in Table 10. Hospitalization time was significantly shorter 
in patients with PD onset between 2001 and 2005 (I, II). 
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5.7 Growth
There were no significant differences in hSDSs in the beginning of PD, at three or six 
months on PD in the retrospectively analyzed PD patients or in those prospectively 
followed, nor between these two groups. Our prospective PD patients were significantly 
taller at the end of dialysis compared to the PD onset (p=0.036); the mean hSDS at 
baseline was -1.3 ± 1.2 and -0.9 ± 1.0 at the end of PD. Catch-up growth was detected 
in 64% and 57% of the patients in these groups (I, II).
In the prospectively followed patients, their height was also compared with their 
parental target height. Although these children grew well, they were significantly 
shorter during dialysis and at the end of PD at a mean age of 1.71 years compared with 
their parental target height predictions (P < 0.01 at baseline, 6 months on PD, and at 
the end of PD) (II).
The mean head circumference (hcf) SDS (n=14) in our prospective PD patient group 
was -1.0 ± 1.1 at the beginning of PD and -1.2 ± 1.1 at nine months. The difference 
was not statistically significant. Three patients (14%) had microcephaly (hcfSDS lower 
than -2.0) at baseline and at the end of PD, two of them at both time points. In all, 
microcephaly was seen in five patients at some point during PD. One of them had 
NPHS1, one had multicystic kidneys, and the others had some co-morbidity (III).
figure 12 Growth in patients less than two years of age at dialysis onset treated on PD 
for at least 6 months between 1995 and 2000 (study I), and 2001 and 2005 (study II, 
III). Mean height SDS at baseline, and at three and six months on PD.
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5.8 neurological development (iii)
5.8.1 Risk factors for development and birth
Altogether eleven patients (52%) in our prospectively followed group were found to 
have one or more risk factors for their neurodevelopment, detected before PD onset. 
Six children had perinatal asphyxia (29%) and others had neonatal risk factors. Six 
children (29%) had co-morbidities. See Table 14.
More than half of our patients (57%) were born prematurely. Their mean hSDS at 
birth was -0.7 ± 1.5, mean birth weight was 2549 ± 596g, and five (24%) were small for 
gestational age (SGA). Head circumference SDS was less than -2.0 in three of fifteen 
measured patients (20%). Two of them also had short stature, so they were small but 
balanced. Prematurity, SGA, or small head circumference were not considered as risk 
factors for their neurological development but they were added in statistical analyses when 
examining explanatory factors for neurological abnormalities. See details in Table 14.
table 14. Demographics and risk factors for neurological development in prospectively 
followed PD patients less than two years of age at PD initiation. At the end of this 
study, patients no. 1-6 had normal neurodevelopment; patients no. 7-15 had minor 
impairment; and patients no. 16-21 major impairment (III).
5.8.2 Brain imaging
In three patients with perinatal asphyxia, brain infarcts were detected soon after 
birth by MRI. One of them also had a thrombosis of sinus sagittalis. In the patient 
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with insulinoma and severe hypotension at two weeks, MRI showed an occipital 
infarct on the right after this episode. In three other patients, US showed some other 
abnormality as newborn: germinal matrix cysts, lenticulostriatal vasculopathy, and 
ventriculomegaly in one patient each. These minor abnormalities were later normalized 
in the first two patients. The patient with ventriculomegaly and fibromuscular dysplasia 
is discussed below.
In the brain MRIs/CTs (n=19/1), examined during PD as a part of pretransplantation 
studies, in addition to those four already earlier detected infarcts, one patient with 
NPHS1 had periventricular leukomalasia (PVL). Also the patient with Townes-Brocks 
syndrome had developed ventriculomegaly and needed a ventriculo-peritoneal shunt 
after renal Tx. Four NPHS1 patients had widened cerebrospinal fluid (CSF) spaces in 
their brain MRI during PD but the findings were normalized after Tx. These temporary 
changes of CSF spaces have also earlier been documented in NPHS1 patients during 
PD (Valanne et al. 2004).
After the kidney Tx, eight of fourteen patients with either MRI or CT evaluations (57%) 
had normal findings. The patient with fibromuscular dysplasia and ventriculomegaly, 
detected as a newborn, suffered from transient right hemiparesis after transplantation 
due to a stenotic middle cerebral artery. This finding was later confirmed with brain 
angiography. Yet another NPHS1 patient with previously normal findings was found 
to have mild periventricular ischemia after Tx. (Table 2 in Study III, Laakkonen et 
al. in press).
In summary, four patients (19%) had brain infarcts, detected before PD initiation, 
and three more patients (14%) had PVL or other ischemic lesions. PVL was due to 
perinatal asphyxia. New findings were seen after Tx in only two patients. In the first 
one, born preterm, no clear reason was found, but the ischemia was periventricular 
referring to a perinatal etiology. In the second one, fibromuscular dysplasia caused the 
ischemic lesions. Children with risk factors for their neurological development had 
abnormal brain images more often at some time point during the study (p=0.002). The 
number of abnormal brain images at any time-point of this study, is shown in Table 15.
5.8.3 Hearing
Two children with NPHS1 had sensorineural hearing loss. One was diagnosed in the 
beginning of PD and the other after renal Tx. The patient with Townes-Brocks syndrome 
had a combined hearing loss (sensorineural and conductive defect) discovered after 
Tx. Townes-Brocks syndrome has been shown to cause hearing loss in about 62% 
of the patients (range 11 to 100%) (Powell, Michaelis 1999). All these three patients 
needed a hearing aid. In three other patients, normal hearing could not be proven 
because no hearing test had yet been done after Tx. In 14 of 20 examined patients 
(70%) the hearing was normal. See Table 15.
5.8.4 neurological follow-up
The results of the neurological evaluations during PD are shown in Table 15. All 
patients in our prospective group, examined with AIMS tests, were below or near 
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the mean for the normal population in their neuromotor development during PD 
in infancy. The normal level was reached over time faster in patients with no risk 
factors for development. At one year of age, almost all patients without risk factors 
for development reached the normal level while almost all patient with risk factors 
developed slowly and stayed below the normal level of neuromotor development 
according to AIMS tests (Figures 1 a and b in study III, Laakkonen et al. in press). 
Seventeen children (81%) received physiotherapy during PD. In children over one year 
of age on PD functional development was good according to MFED tests performed 
by the occupational therapist. For only one of the patients of 15 studied, the functional 
developmental age was abnormal during PD; this child had a co-morbidity (pat. no. 
21, see Table 14).
Three patients (14%) developed CP. All three were premature, had perinatal 
asphyxia, and brain infarcts or PVL explaining their handicap. Two of these patients 
had also cognitive disability, in one of them only a mild one. Twelve other patients (57%) 
had some other neurodevelopmental abnormalities. Two patients with co-morbidity 
belonged to this group. These disabilities and their frequencies are shown in Table 15. 
Neurological abnormalities in these patients could not explain the preterm birth, low 
birth weight (SGA), birth head circumference less than -2 SD, low Apgar scores, need 
for special care as newborn, co-morbidity or nephrectomy. 
5.8.5 Neurodevelopmental outcome
At the end of this study, six of 21 (29%) prospectively followed patients were evaluated 
to have normal neurodevelopment. Neurodevelopmental impairment, including all 
neurological abnormalities and hearing defects at the end of our study, was detected 
altogether in 15 patients. Six patients (29%) had a major impairment and nine (43%) 
a minor impairment (Table 15). The three different groups of neurological outcomes 
(normal development/minor impairment/major impairment) are shown in Table 14. 
The neurological problems in these patients did not worsen during PD and all children 
tolerated PD well. The patients with risk factors for development had more often 
major impairment compared to other patients (p=0.004).
Every one of the school aged children (n=15) attended full-time school. Two of 
them (13%) needed part-time and five (33%), all with major impairment, needed full-
time special education.
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table 15. The proportion of children with abnormal findings in neurological 
evaluations (AIMS, MFED, and neuropsychological tests), brain imaging, hearing and 
neurodevelopmental outcome in prospectively followed PD patients under two years 
of age at PD onset (III). AIMS, Alberta Infant Motor Scale. MFED, Munich Functional 
Developmental Diagnostic test.
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5.9 NPHS1 with muscular dystonia and athetosis (IV)
NPHS1 with muscular dystonia and athetosis (MDA) is a new syndrome not described 
earlier in the literature. All these six patients had a typical renal histology of CNF, 
severe early proteinuria with hypoalbuminemia and normal glomerular filtration 
rate (GFR). Four patients were Fin-major homozygotes and one was Fin-major and 
Fin-minor heterozygote. In one patient, the NPHS1 mutation analysis was not done. 
The patients’ neurological syndrome MDA onset took place between the neonatal 
period and 8 months of age. It was diagnosed before 11 months of age in all patients 
and worsened during stress situations like infections. EEG did not reveal epileptic 
discharges in any of these patients. 
These patients were significantly shorter than the controls. At the age of nine months 
their mean hSDS was -3.1 ± 1.1 compared to -1.4 ± 1.4 in the controls (p=0.01).
Brain MRI (n=4) showed increased signal activity in the globus pallidus area 
in all imaged NPHS1+MDA patients (Figure 13). In MRI and CT, watershed area 
infarcts were seen in three patients. In the number 
of patients with a brain infarction, the difference 
between NPHS1+MDA patients and controls was not 
significant. Widened cerebrospinal fluid (CSF) spaces 
were seen in four patients with NPHS1+MDA (67%).
A hearing defect was present in four of the five 
tested patients; three of which had severe SNHL and 
one mild SNHL. In the two remaining patients, the 
hearing could not be proven totally normal because 
of an early death. There were statistical differences 
in the frequency of hearing deficit between 
NPHS1+MDA patients and controls (p=0.017).
figure 13 Brain MRI in a 21 months old patient 
with NPHS1 with MDA (axial T2-weighted image), 
indicating increased signal activity in the globus 
pallidus area. Small vertical arrows show these areas. 
Mild widening of the CSF space is seen in Sylvian 
fissures, horizontal arrow showing the right side.
5.9.1 Explaining factors for the neurological syndrome
External factors like neonatal events and complications, prevalence of brain infarcts, or 
septic infections during the first six months did not explain the neurological abnormality 
of the NPHS1+MDA patients, who needed more frequent special care as a newborn 
compared to the controls.
An emphasis was given to the detection of neonatal bilirubin values and bilirubin-
albumin ratio because both brain MRI/CT findings (increased signal intensity in 
globus pallidus area) and the neurological syndrome strongly resembled bilirubin 
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encephalopathy. Eighty per cent of the NPHS1+MDA patients and 59% of the controls 
had a serum bilirubin-albumin molar ratio higher than 0.63, which has been thought 
to be a cut-off point of inducing a hearing defect. The limit for neurotoxicity in serum 
bilirubin-albumin molar ratio is 0.8 and 50% of NPHS1+MDA patients and 15% of 
controls exceeded it. However, the controls with molar ratios as high as in NPHS1+MDA 
patients, did not even have a hearing defect. Thus, this condition could not be explained 
by plain chronic bilirubin encephalopathy although the low serum albumin level in 
newborn NPHS1 patients could be a risk factor.
Brain infarcts were equally common in both patients groups, in 50% of NPHS1+MDA 
patients and in 59% of controls. Control patients had more severe infarctions compared 
to NPHS1+MDA patients. Therefore, MDA can not be explained by brain infarcts.
Plasma and urine aminoacids, urinary organic acids, blood and liquor lactate, 
blood pyruvate and ammonium levels, as well as serum creatinine kinase measured 
in some NPHS1+MDA patients did not reveal any metabolic disease that could 
have explained the MDA symptoms. The EEGs, taken because of convulsion-like 
seizures, showed no epileptic activity in any of these patients. For one patient’s muscle 
biopsy, electron microscopy and mitochondrial enzyme tests were normal. Also an 
electroneuromyography (ENMG) study in one patient was normal.
MtDNA was analyzed in three patients. No known mitochondrial mutation that 
could explain MDA was found in these patients. Together 24 nucleotide position 
aberrations were found. Twenty-two of them were common polymorphisms or found 
in databases. Two different, new mutations were found and their implication could 
not be explained.
5.9.2 outcome of patients with muscular dystonia and athetosis
Four of the NPHS1 patients with MDA (67%) died early. Two of them died during 
dialysis between 1 and 2 years, one due to peritonitis and another with myocardial 
hypertrophy and its’ consequences. Two patients died after renal Tx, one with pneumonia 
at the age of two years and another because of multiorgan failure following Tx at 
the age of three years. Among the other NPHS1 patients born during the same time 
period as these NPHS1+MDA patients, only six (9%) had died.
Two NPHS1 patients which survived had functioning renal grafts, severe dystonia, 




Nowadays even the youngest patients, infants, are treated actively with peritoneal 
dialysis. Therefore, we wanted to evaluate the adequacy of dialysis, metabolic and fluid 
balance, complications, growth, and neurological development in this patient group, and 
on that basis construct suitable medication, nutrition, peritoneal dialysis prescription, 
and adequate, but not too exhausting, follow-up programs for these patients. We first 
evaluated the preceding facts in a retrospective PD population, treated in our center 
between 1995 and 2000 and started a prospective study of PD patients of similar age 
in 2001, treating 21 patients with this protocol. Neurological follow-up was one part 
of this prospective study. We also described a small NPHS1 patient population with a 
severe neurological syndrome in order to establish an explanation for their symptoms.
6.1 Supportive treatment
6.1.1 Nutrition (II)
Nutrition provided enough energy for the age group in our prospectively followed 
patients. The mean amount of energy was 100% of the RDA in healthy children of 
this age. Comparatively, the amount of energy in the study by Hölttä et al. (2000b) 
in children under five years of age (between 1995 and 2000) was 109% of the RDA 
at baseline, which is almost the same as in our patients treated between 2001 and 
2005. Catch-up growth was observed in most patients in both of these studies. Our 
patients’ protein intake was higher than recommended in the newest Kidney Disease 
Outcomes Quality Initiative (KDOQI) guidelines, with a mean intake of 2.3 ± 0.6 
g/kg per day. In contrast, the recent recommendations are 1.5–1.8 g/kg per day for 
children under one year and 1.3 g/kg per day for children between one and three 
years (KDOQI Work Group 2009). The same amount of proteins has been provided 
to children less than five years of age in the above mentioned study by Hölttä et al. 
(Hölttä et al. 2000b). High protein intake increases the need of phosphate binders 
which are mainly calcium-based. When we counted together dietary calcium, which 
was fairly low, and calcium from phosphate binders at three months on PD, it still 
remained under the upper limit of the KDOQI recommendation of 1000 mg/day for 
children between one and three years. However, the KDOQI guide for children between 
six and twelve months is not more than 540 mg/day, which we exceeded (KDOQI 
Work Group 2009). In fact, 40% of our patients had an ion-Ca x Pi higher than 
recommended. A high calcium phosphorus product is a risk for vascular calcification 
and should be avoided (Klaus et al. 2006). Phosphate binders that contain a high 
amount of calcium increase the calcium load of patients. New calcium free phosphate 
binders are, however, not yet officially registered for small children. Most of our infants 
with ESRF have protein malnutrition before PD due to severe protein losses through 
their kidneys before nephrectomy as they are nephrotic. Although these infants need 
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higher protein substitution at the commencement of PD, their protein intake should 
probably be reduced after a few months on PD, and at the age of one year, to reduce 
the risks for vascular calcification. 
6.1.2 Medication (II)
Daily dosing of vitamin D was used between 2001 and 2005. Our aim was to provide a 
more physiological calcium-phosphate-PTH balance for bone mineralization compared 
to pulse therapy. Pulse therapy of vitamin D has been claimed to reduce bone formation 
and reduce linear growth in children with secondary hyperparathyroidism. PTH levels 
were lower in children with adynamic bone disease during intermittent calcitriol 
therapy compared to children without adynamic bone disease (Goodman et al. 1994, 
Kuizon et al. 1998). The European Paediatric Dialysis Working Group recommended 
PTH values of two to three times the upper limit of normal during PD (Klaus et al. 
2006). We aimed to reach normal or two-fold the upper normal limit concerning iPTH. 
These levels were difficult to control in our prospective patient group and alphacalcidol 
doses had to be readjusted repeatedly in order to keep iPTH at target levels. Moreover, 
about 50% of our patients had to be switched to pulse therapy. In Finland, it has been 
shown in children with CKD and secondary parathyroidism (mean age 5.6 years) 
by Ala-Houhala et al. (Ala-Houhala et al. 1995) that alphacalcidol pulses normalize 
and stabilize PTH levels well in the predialysis period. During follow-up, vitamin D 
metabolite concentrations were normal, growth was low normal, and bone mineral 
density did not decrease. This knowledge formed the basis for our procedure when 
changing our patients to the pulse therapy when PTH rose rapidly or was very high. 
A more recent study in Finland also showed, in a small group of infant patients, that 
growth was better with pulse therapy compared to daily dosing of vitamin D (Saarinen 
et al. 2007). Vitamin D analogs or calcimimetics were not used in our patients due to 
scarce experience in this age group. Serum FGF23 levels have been studied by Kazama 
et al. (Kazama et al. 2005) and Nakanishi et al. (Nakanishi et al. 2005) in adult HD 
patients, whose iPTH levels were greater than 300 ng/L. They all concluded that serum 
FGF23 level was a good indicator in prognosticating the response to vitamin D therapy 
and a valuable factor in predicting the course of secondary hyperparathyroidism in 
patients with chronic dialysis (Kazama et al. 2005, Nakanishi et al. 2005). In the 
future, follow-up of the circulating concentration of FGF23 blood level may provide 
a good tool for the evaluation of calcium-phosphorus-vitamin D balance in secondary 
hyperparathyroidism in pediatric PD patients, especially together with iPTH assays.
Mean dietary iron was only around 50% of the daily recommendation in our 
prospectively followed PD patients. Moreover, uremia and calcium containing phosphate 
binders worsen absorption of iron from the diet. Thus, our patients received iron and 
EPO supplementation to attain normal red cell formation and normal blood hemoglobin, 
which were reached. 
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6.2 Peritoneal dialysis
6.2.1 Uremia control (I, II)
Metabolic control was good in our patients between 1995 and 2005. There were 
no differences in hemoglobin, creatinine, calcium, phosphate, iPTH, cholesterol, or 
triglyceride values between patients treated during 1995–2000 and 2001–2005. BUN 
values were statistically lower in patients treated in 2001–2005. Low BUN values, 
despite high protein intake, were probably due to high levels of urea purification 
reached in our patients; see below. The difficulty in controlling iPTH values, even 
in prospectively studied patients, is discussed above. Favorable metabolic control is 
also seen in other studies in older children on PD (Schaefer et al. 1999a, Chadha et 
al. 2001).
The weekly Kt/V levels for urea, describing the clearance of small-sized molecules, 
were good during dialysis between 2001 and 2005 (mean at six months 3.5 ± 0.6), as 
well as in the retrospectively studied patients between 1995 and 2000 (mean at nine 
months 3.2 ± 1.0). Our target of 3.0 in the prospective patients was well reached. 
Differences in Kt/V for urea were not significant between anuric and RRF patients. 
In studies on children of all ages, a mean Kt/V urea of 2.0 to 3.45 has been reported 
(Schaefer et al. 1999a, Chadha et al. 2001, van der Voort et al. 2000): our results in 
infants are comparable to them. Acceptable clearance of mid-sized molecules was 
harder to achieve in our prospectively studied PD patients. In the retrospective patient 
group, the dialysate collection was modified and the Crcl values raised by 15% (Hölttä 
et al. 2000b). Thus, the mean Crcl of 67 ± 23 L/week per 1.73 m2 at nine months on PD 
is not comparable to the Crcl of 49 ± 18 L/week per 1.73 m2 in prospectively studied 
patients. Especially in nephrectomized children, the Crcl values between 2001 and 
2005 remained far behind our target of 65 L/week per 1.73 m2 (44 ± 13 L/wk per 1.73 
m2 in anuric patients vs. 66 ± 27 L/week per 1.73 m2 in children with RRF). Patients 
with RRF had significantly better Crcl. Schaefer et al. reported a mean Crcl of 53 ± 
24 L/week per 1.73 m2 in 51 infants on PD (Schaefer et al. 1999a), whilst Chadha et 
al. (2001) observed a mean Crcl of 70 ± 18 L/week per 1.73 m2 in 24 children (50% 
anuric). They also noted that anuric children had a notably lower mean Crcl (59 L/
week per 1.73 m2) compared to children with RRF (81 L/week per 1.73 m2) (Chadha 
et al. 2001). However, Crcl is related to BSA that is proportionally large in infants 
compared to older children and adults. This fact may partly explain lower Crcl values, 
particularly in infants. Another method to evaluate creatinine purification is weekly 
Kt/V for creatinine which correlates the clearance with total body water, not with BSA 
(Ishikura et al. 2003). In our patients, the mean Crcl was 49 ± 20 L/week per 1.73 m2 
and the mean creatinine Kt/V 2.19 ± 0.91, which being higher than 1.52 correspond 
to Crcl of 60 in an adult male. A weekly Kt/V for creatinine of 1.52 is equivalent to a 
Crcl of 35 L/week per 1.73 m2. Thus, we recommend Crcl values of over 40 L/week per 
1.73 m2 as acceptable in infants if their growth is good. However, the use of creatinine 
Kt/V needs to be tested in a larger population of children in the future.
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6.3 Complications of peritoneal dialysis
6.3.1 Catheter-related problems, peritonitis and hernias (I, II)
Catheter-related technical problems were common. Repositions of catheters were 
equally common during 1995–2000 as during 2001–2005, being necessary in roughly 
30% of the patients. Catheter exchanges were less common in the prospectively followed 
patients, in only 19% versus 43% in the retrospective study but this difference was not 
statistically significant. Rees reported catheter exchanges in 60% of their infants on 
PD, three times as frequently as in the patients treated in our clinic during 2001-2005 
(Rees 2002). Other studies report catheter exchanges in about 20% of children and 
adolescents (NAPRTCS 2007 Annual Report 2008, Macchini et al. 2006, Neu et al. 
1995, Aksu et al. 2007), similar to our results in infants between 1995 and 2000. It is 
probable that there will be less malposition problems with the new Flex-Neck® infant 
catheter, which has a shorter intraperitoneal part. So far, there are no publications 
about these newer catheters in children. 
The annualized peritonitis rate in our patients was 0.83 between 1995 and 2000 
and 0.67 between 2001 and 2005. Earlier reports on Finnish patients indicate that the 
peritonitis rate in children under five years of age had been 1.64 between 1986 and 
1994 and 1.28 between 1995 and 1997 (Hölttä et al. 1997, Hölttä et al. 2000b). The 
NAPRTCS report of 2007 showed a rate of 0.86 in children under two years of age 
(NAPRTCS 2007 Annual Report 2008) and a recent report of Wedekin et al. (2010) 
showed a peritonitis rate of 0.85 in infants. Most reports show a higher peritonitis rate 
in younger children compared to the older ones (Neu et al. 2002, NAPRTCS 2007 
Annual Report 2008, Hölttä et al. 2000b, Honda et al. 1996, Hoshii et al. 2006). For 
example, Boehm et al. (Boehm et al. 2005) reported in 2005 a peritonitis rate of 1.22 
in children under two and 0.52 in older children. They also compared the peritonitis 
rate between anuric children (1.41) and children with RRF (0.61) and stated that anuria 
is a risk factor for peritonitis. Anuric patients also have day-time exchanges, and thus 
have more connections, which increase the possibility of infections. However, in our 
study between 1995 and 2000, the anuric patients had a peritonitis rate of 0.81, and the 
children with RRF a higher rate of 0.85, so there was no significant difference. Our 
results have steadily and significantly improved with time, with the peritonitis rate 
in infants treated between 2001 and 2005 being comparable to that in older children. 
Careful training of the families, good hygiene, and developed PD connectors probably 
form an important part of this development. Anuria did not increase the peritonitis rate.
Hernias, mostly inguinal, were common in our patients: 57% of our retrospectively 
analyzed PD patients needed a hernia operation during PD, similar to the 48% seen 
for the prospectively followed patients. Hernias were operated prior to PD initiation 
in 15% and 38% of the patients, respectively. These differences were not statistically 
significant. Hernias were reported previously in 29% of children under five years of age 
in Finland (Hölttä et al. 1997). Thus, we comparatively saw more hernias in the youngest 
patients. The ESRF patients, and especially the NPHS1 patients, have hypoproteinemia 
prior to PD, and their tissues might be more vulnerable to hernias. Despite this fact, 
hernias were not seen more frequently in NPHS1 patients in our patient populations. 
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Furthermore, hernias were frequently seen also elsewhere in PD patients, especially 
in small children. Hernias were observed in 23 to 40% of children during PD in some 
earlier studies and also in a more recent one (von Lilien et al. 1987, Khoury et al. 1991, 
Verrina et al. 1992, Jander et al. 2006). It seems that infants are more prone to hernias 
and thus the need for a preemptive hernia operation at catheter insertion should be 
considered in the youngest patients.
IPP should be monitored during PD to detect excessive IPP values in order to avoid 
hernias and leakages.
6.3.2 Intravascular volume status (II)
Hypertension was detected in 57% of our prospectively followed patients at some point 
during PD, all of which were anuric. In our retrospective patient group, the frequency 
of high BP could not be defined, however a previous study in our center reported high 
BP in 73% of patients less than five years of age on PD (Hölttä et al. 2001). Although 
hypertension was less common between 2001 and 2005, it still remained a problem 
during PD. Antihypertensive medication was used in 70% of patients at some point 
during PD between 1995 and 2000, but in only 33% of our prospective PD patients. 
Plasma ANP-N correlated moderately with hypertension, indicating hypervolemia in 
patients with high BP. Due to the lack of normal values for BIA measures for infants 
and small children, BIA was not very helpful in estimating intravascular volume status. 
Nor did it correlate with high blood pressure. It is possible that BIA RI was not the 
right measure for the correlation analyses, but we found no better measure from the 
literature. Nevertheless, strict intervention for high blood pressure is important in 
anuric children. If the child is hypervolemic, ultrafiltration should be increased. If 
no hypervolemia is present, antihypertensive medication should be started. On the 
other hand, severe hypovolemia is a risk during PD, especially if the child has an 
infection or is vomiting, and hypovolemia may cause brain damage (Lapeyraque et 
al. 2003). Thus, it is probably safer to permit mild hypervolemia in infants on PD. 
At the commencement of PD, a total of 86% of the prospectively studied PD patients 
had LVH when using LVMI and the 95th percentile as a cut-off point for LVH, compared 
with 60% in patients less than five years of age treated between 1995 and 1999 at our 
center (Hölttä et al. 2001). Surprisingly, according to one of the newest studies on 
young PD and renal TX patients, in 57% of the healthy, school-aged control children, 
the LVMI exceeded the 95th percentile (Ten Harkel et al. 2009). This raises a question 
about the reliability of LVMI in determining LVH. Quantification of left ventricular 
mass (LVM) and determining the limit for LVH are controversial (Foppa et al. 2005). 
Small children are a particular challenge in the use of LVMI, which is proportioned to 
height, thus increasing more rapidly in short children. Thus, one may ask if the often 
used LVMI represents the complex relationship between LVM and body size during the 
whole childhood while body proportions change substantially, especially during infancy 
(Foster et al. 2008). Foster et al. (2008) have focused on LVH definition problems. They 
developed LV mass-for-height reference centile curves and compared them with the 
LVMI method in evaluating the proportion of patients with LVH in children with ESRF. 
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They concluded that their new method normalizes LVM for body size, and thereby 
especially in small children, less than 140 cm tall, gives a more precise estimate of 
LVH. Thus, we used Foster’s et al. LV mass-for-height and the 95th percentile as a cut-
off point for LVH, and LVH was seen in only 33% of our patients treated between 2001 
and 2005 at baseline. The difference between frequencies of LVH calculated with the 
two different methods; 86% and 33% of the patients, is noteworthy. The proportion of 
patients with LVH, calculated with LV mass-for-height, decreased with time during 
PD, which also indicates successful management of intravascular volume status.
6.4 Mortality and hospitalization (I, II)
Mortality was low in our patients, 9% between 1995 and 2000, and 5% between 2001 
and 2005. Rees reported four deaths in 20 infants (20%) during PD (Rees 2002) and 
a 10% mortality was observed in the study by Shroff et al. Relative risk for death 
was 2.7 times higher in children under five at the start of dialysis compared to older 
children (Shroff et al. 2006). Co-morbidity has been shown to be a significant risk 
factor for higher mortality in children during ESRF and PD (Shroff et al. 2006, Kari 
et al. 2000).
Hospitalization times have decreased steadily during the last years in small PD 
patients in Finland. In the early 1990’s, the patients under five years of age stayed at 
hospital for 150 days per patient-year. Later in the 1990’s, the number was 95 days 
per patient-year (Hölttä et al. 2000b). Training of the families developed in the 1990’s 
and thus many children could be treated with PD at home. In our retrospectively 
analyzed patients, the hospitalization time was again higher; 124 days per patient-
year. However, there were three children who had to spend their whole dialysis period 
in hospital; one due to a severe heart disease, the other two for social reasons. When 
we excluded these three patients, the hospitalization time is reduced to 93 days per 
patient-year, which is comparable to the report by Hölttä et al. from about the same time 
period. Hospitalization time in our prospectively followed PD patients was significantly 
lower, only 65 days per patient-year. Most of these hospital days consisted of routine 
PD controls, with complications being the second largest group. The reduction of 
complications, effective training of the families and short, one to three days long 
routine ward visits have reduced the time spent in hospital. While this improves the 
quality of life for both the child and his or her family, one may question whether the 
ward visits are too stressful for the patient with all the examinations, including pre-
transplantation studies, spanning only a few days. In an earlier report by Becker et al., 
the hospitalization times were only 0 to 30 days per year (mean 14.5 days) in children 
under five years of age on PD. The inpatient controls were included (Becker et al. 1997). 
According to a recent NAPRTCS analysis by Carey et al., the hospitalization times were 
longer in neonates compared to children between one month and two years at dialysis 
initiation (54 vs. 39 days, p<0.001). Moreover, some children were not hospitalized 
at all, which raises the question of whether the children had only outpatient controls 
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or if the ward controls were excluded from the data. Most of the patients were on PD 
(<10% on HD) (Carey et al. 2007). Besides, the authors do not report whether the 
days are total per dialysis time or per patient-year, and thus comparison to our data 
is not possible. There are some reports about hospitalization in children on HD, in 
children with CKD or ESRF but the exact hospitalization days or the PD patients are 
not separately reported. The number of hospitalization days in our study seems to be 
higher compared to other reports. We, however, include the training of the family, 
controls, and pretransplantation studies, in addition to the treatment of complications, 
to the hospitalization days, which probably raises the total number significantly. Our 
protocol controls occurred at one and three months after PD onset and every third 
month thereafter. This was to ensure proper nutrition, metabolic control, PD adequacy 
evaluations, and good growth to our patients. Almost all of our patients come from 
far away to our center and thus, outpatient controls are not useful in time-consuming 
studies such as adequacy measurements.
6.5 Growth in children on peritoneal dialysis (I, II)
Most of our patients grew well during PD. Catch-up growth was seen in 64% of patients 
between 1995 and 2000 and in 57% during 2001─2005. In the retrospectively analyzed 
patients, the mean hSDS at the beginning of PD was -1.5 and at the end of PD -1.2. 
The overall mean hSDS at the beginning of PD was -1.3 and at the end of PD -0.9 in 
both groups, when the patient with severe congenital heart disease was excluded from 
the retrospective group. In the prospectively studied group, the difference in hSDSs 
between PD end and start was statistically significant. When compared to other studies, 
these children were not small. Cansick et al. (Cansick et al. 2007) reported a mean 
hSDS of -2.06 in children with a mean age of 2.8 years at PD onset. In children under 
two years of age, they noticed a mean change of +0.31 in the hSDS during the first 
year on dialysis. They found no correlation between hSDS change and alphacalcidol 
or phosphate binder doses, mean hemoglobin, sodium, phosphate, albumin, or PTH 
levels, as was also the case in our patients. In the study by Cansick et al., the median 
PTH was 1.5 times the upper limit of normal (ULN), while in our patients it was about 
twice the ULN after three months and about thrice the ULN after six months on PD. 
However, Cansick et al. do not reveal the time point of their PTH measurements, or 
the dosage of alphacalcidol, and thus a direct comparison to our data is impossible. We 
tried to improve growth with daily administration of alphacalcidol. However, control 
of iPTH was difficult, and pulse therapy was needed for many patients. Furthermore, 
Saarinen et al. (2007) showed, in a small PD patient population, that growth was 
better with pulse therapy of vitamin D. Schroff et al. (2006) reported a mean hSDS 
of -3.6 at the beginning of dialysis (PD or HD) and a final hSDS of -2.6 in children 
under five years of age. Those children were clearly smaller than our patients, with 
the youngest patients having the greatest growth deficit, however, the change in hSDS 
was not statistically significant. In the NAPRTCS report of 2007, the mean hSDS in 
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children commencing dialysis was -2.55 in children under two years of age, with PD 
patients being smaller than HD patients (NAPRTCS 2007 Annual Report 2008). The 
mean waiting time for a kidney transplant at our institution is only 9 months and as a 
consequence, our follow-up time for growth is relatively short. However, our patients 
clearly achieve normal growth during PD, with catch-up growth in 50% of patients, 
when appropriate medication and adequate nutrition are provided. 
None of the earlier reports on children on PD have compared height with their 
midparental height. Our prospectively studied PD patients had a normal mean hSDS at 
birth (-0.69). Most of them grew normally for age during PD but they clearly lagged their 
midparental height at around 18 to 24 months of age. This is because they lost relative 
height prior to PD. In a very recent report by Tainio et al. (Tainio et al. in press), the 
authors report the final adult heights for 105 patients with renal Tx at a median age of 
4.5 years. In males the mean final hSDS was -1.2 (168.7 cm) and in females -1.7 (153.7 
cm). Their growth duration was prolonged and final heights were reached at a mean 
age of 18.1 in males and 16.0 years in females. Both genders with kidney Tx before 
the age of five years reached puberty earlier compared to older transplant patients, 
the mean difference being around one year. Thirteen per cent of the patients received 
rhGH therapy before and 30% after the renal Tx, while 56% did not get rhGH therapy 
at any time (Tainio et al. in press). The mean hSDS in boys is comparable to our growth 
measures in small children at PD end. However, the mean final hSDS in girls is clearly 
lower than in our prospective group at the end of PD. The patients in the Tainio et al. 
study were treated earlier than our patients and young patients on PD or with a kidney 
Tx might grow better today. After Tx there are also other confusing factors affecting 
growth such as corticosteroids as a part of immunosuppressive medication, and a direct 
comparison of these patient groups is not possible.
We did not have GH in our study protocol and thus we refrained from GH treatment 
in this age group. In our opinion, nutrition and proper management of ESRF (dialysis, 
medication) must first be instituted, and thereafter GH treatment can be considered if 
the child still is growing poorly.
6.6 Neurological development in patients treated with PD (III)
In 48% of the prospectively followed PD patients, no risk factors were detected for 
impaired neurological development before PD initiation; 30% of the patients had normal 
neurodevelopment. Only minor impairments such as specific language impairment or 
attention deficit disorders were seen, altogether in 70% of these patients. However, 
more than half of the patients in the prospective group (11 of 21, 52%) had some 
predialysis risk factor for their development. The risk factors included pre-, peri- 
and neonatal risk factors and co-morbidities. Three of the patients with risk factors 
(27%), had normal neurodevelopment. Eight of the eleven risk factor patients (73%), 
had neurological impairment at the end of this study. Six of those eight (75%), had 
a major impairment. On the other hand, six of all these twenty-one prospectively 
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followed PD patients had some co-morbidity or syndrome in addition to their renal 
disease. The one with severe hypoglycemia as a newborn, and severe hypotension 
at two weeks, had normal neurodevelopment. All other patients with co-morbidity 
(five of six, altogether 83%) developed a neurological impairment during the study 
period and for most of them it was a major one. The prevalence of any neurological 
impairment was similar in both groups: in patients with or without predialysis risk 
factors, but only the patients with risk factors had major impairments. The proportion 
of patients with a neurological abnormality was higher than we expected. Yet, we 
report very mild impairments, such as dyspraxia and other problems, which may 
disappear within time, and presumably these minor problems do not cause permanent 
impairment. Very few studies report a neurological outcome in young PD patients. 
Warady et al. (1999) reported a small group of patients (n=28) treated with PD in 
infancy. They excluded all children with co-morbidities and neurological diseases 
from their study. Thus, the comparison between their study and ours is impossible. 
At the age of one year, they saw a neurological delay in 21% of the patients. Half 
of their patients were, however, hypotonic at one year. A considerable proportion of 
patients were also tested with an assessment of global intelligence from the age of 4 
years and in 79% of the patients the performance was in an average range One patient 
was deaf, but the authors did not report his/her performance separately. Honda et al. 
(1995) reported abnormal development in 69% of 15 patients at the end of CAPD. 
Their PD treatment had been started before 2 years of age. Our aim was to analyze 
the neurological development of all children dialyzed in infancy or before two years 
of age. Thus, we also included patients with co-morbid conditions and clear neonatal 
risk factors in our study.
Prospectively followed patients underwent no notable periods of additional diseases 
or severe hypo- or hypertensive crises during PD. The patient with NPHS1 and 
intrauterine alcohol exposure had one longer period with hypertension during PD. He 
developed attention deficit disorder and visuomotor disability, which are not typical 
consequences of hypertension problems. PD did not worsen the neurological status of 
the prospectively studied patients who were followed with examinations by a pediatric 
neurologist and AIMS tests.
CP was diagnosed in 14% of the prospectively followed PD patients, all of them 
displaying explanatory findings in the brain MRI. The prevalence of CP in our patients 
is similar to that seen in extremely-low-birth-weight infants (11%) in Finland (Tommiska 
et al. 2003), and clearly higher than in the whole population (2 to 3 newborns in 1,000) 
(The Finnish CP Association 2010). All our patients with CP had premature birth but 
none of them had extremely low birth weight.
Even after the neurological follow-up study on the prospective PD patients, it 
is difficult to define the etiology of neurological abnormalities in every case. Most 
patients had a clear reason for the impairment, such as brain infarct or co-morbidity. 
With the methods of assessments used here, we saw no worsening of the neurological 
condition during PD. There were seven patients without predialysis risk factors who 
developed a minor impairment. These impairments were not detected during PD but 
later with neuropsychological tests, at approximately five years of age. Only one of 
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them had changes in her brain MRI, detected during PD in pretransplantation studies. 
The etiology of this finding remains unclear. In six other patients with no risk factors, 
but with a minor impairment, we failed to find any sure explanation for their condition. 
We did not ask or analyze the existence of learning difficulties or other neurological 
aberrations in the parents. We were not able to analyze all minor predialysis factors 
such as degree and duration of acidosis or hypertension, adequacy of nutrition, or 
psychosocial factors in these children. On the grounds of our study, it is possible to say 
that the children with major impairment as well as two patients with minor impairment 
had clear reasons for their disability, but the etiology of their abnormality remained 
unsolved in most children with minor impairment.
6.7 NPHS1 with muscular dystonia and athetosis (IV)
Most of the NPHS1 patients with muscular dystonia and athetosis (MDA) died at an 
early age. Those who survived are severely handicapped and need outside support to 
manage their everyday life. The reason for this newly described neurological condition 
in NPHS1 patients could not be clarified. If the reason lies in the chromosomes or in 
the mtDNA, we should see new patients with MDA. After our report on NPHS1 with 
MDA, one NPHS1 patient with neurological symptoms which might be MDA has 
been born but her diagnosis is not yet certain. All NPHS1 patients have significantly 
low plasma albumin values, especially before diagnosis and subsequent daily albumin 
infusions. Almost all of them are also preterm and thus prone to bilirubin toxicity. 
Hypoalbuminemia predisposes NPHS1 patients to bilirubin toxicity and chronic bilirubin 
encephalopathy, kernicterus, while albumin is an important bilirubin binding protein in 
the blood. Free unconjugated bilirubin affects the central nervous system and may cause 
bilateral lesions in the globus pallidus and subthalamus regions, seen in the brain MRI. 
It may also cause a hearing defect and abnormal brainstem auditory evoked potentials 
(Shapiro 2003). Kernicterus is still seen, but it is a very rare condition with an incidence 
of 1 per 40,000 to 150,000 in live births in the Western world. The children with 
bilirubin encephalopathy first have a tendency to opistotonus, then probably seizures 
and apnea. Within time they usually develop an athetoid cerebral palsy, hearing loss, 
dental dysplasia, paralysis of upward gaze, and other handicaps (Maisels 2009). Many of 
these symptoms were also seen in our NPHS1+MDA patients. They also had increased 
signal intensity in the globus pallidus area in the brain MRI. Thus, there are plenty of 
facts supporting the possibility of kernicterus as a cause for the neurological syndrome 
in our patients. However, a statistical difference in the bilirubin levels as a newborn 
was not seen between the NPHS1+MDA patients compared to the controls.
In the future, it is important to document an exceptionally heavy placenta and 
edema and exclude NPHS1. In NPHS1 patients, intravenous albumin infusions should 
be started soon after detection of a low plasma albumin level and they should probably 
always be treated with phototherapy even in case of relatively low bilirubin levels to 
avoid possible neurological sequelae.
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6.8 Limitations of the study
The mean duration of PD was only 1.1 ± 0.6 years in our prospectively studied patients 
and 1.4 ± 0.8 years in our retrospective patient group. In two thirds of the patients 
(n from 15 to 16) the dialysis period was at least nine months. This relatively short 
PD duration allows only a short follow-up time for growth. There are also many 
confounding factors affecting growth such as co-morbidities, nutrition, and infections. 
Bone biopsies were not taken to aid evaluation of Ca-Pi metabolism, growth and 
bone health. Thus, we could not say anything about bone health itself but tried to 
follow-up and describe factors having an effect on bone growth, such as iPTH and 
Ca-Pi balance. Vitamin D levels were not measured in blood, which would have been 
interesting for evaluating bone metabolism and vitamin D substitution. Nevertheless, 
adynamic bone disease can be excluded as growth was normal. Alkaline phosphatase 
(AFOS) levels were also normal.
Problems were encountered regarding BIA measurements, due to the lack of a 
healthy control group. Thereby the BIA values gave very little information about the 
intravascular volume status of our patients.
Neuropsychological tests were not included in our study plan but they are a part of 
follow-up in all transplanted children. Study time points and investigators thus vary 
slightly. Also, the methods used vary between hospitals. Thus, the information from 
our neuropsychological tests is not totally uniform. They offer important information 
but do not provide critical information about these patients.
6.9 Future considerations
Evaluation of cognition is not yet possible, however in the future it would be interesting 
as well as important to arrange a follow-up study and evaluate these children at school 
age with congruent study assessments.
It would be interesting to further analyze the possibility of chronic bilirubin 
encephalopathy in some NPHS1 patients. No difference in bilirubin concentrations 
between MDA patients and normal CNF controls were observed in this study. It would 
be important to know possible factors affecting a bilirubin induced injury of the central 
nervous system, whilst all NPHS1 patients have low plasma albumin levels, why do 
only a small proportion of patients with high plasma bilirubin present neurological 
symptoms? Are some patients more vulnerable to injury or do some patients have 
protecting factors? Or is this neurological lesion caused by some other factor?
The decision to start or to refuse dialysis treatment in a small child, that is to start 
active treatment targeting at renal Tx, must include the discussion of the child’s possible 
co-morbidity. If the co-morbidity is fatal, active treatment should not be initiated. In 
our center, every infant with ESRF has been actively treated if they have survived until 
PD is started. In children with a co-morbidity or neurological injury, the decision about 
active treatment is a difficult ethical problem. However, when we look back now, at 
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these children with neurological impairments, we would not have refused any of them 
active treatment.
It is important to evaluate the growth in these patients after renal Tx, to see if catch-
up growth continues or starts later. The final height of these patients is of great interest. 
To be able to assure good growth in the future in these small children with ESRF, an 
early diagnosis of CKD as well as careful planning of the treatment and nutrition are 
important already before PD. Whether the predicted height could be achieved in that 
case, remains to be seen later.
PD treatment that is carried out at home, usually for many months, requires a lot 
of contribution from the family. In the future, it is important to evaluate the quality of 
life of the families, their resources, and how they cope with this exceptional situation. 
The parents have to be nurses in addition to parents. Furthermore, we are evaluating 
the parent-child relationship in families with a child with ESRF and peritoneal dialysis.
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7 conclusions
The studies I-IV evaluate dialysis outcome, growth, and neurological development 
in children less than two years of age at the onset of PD and in a group of NPHS1 
patients with a neurological syndrome.
The main conclusions are the following:
1) Metabolic control was good in infants treated between 1995 and 2005. Reaching 
a balance in calcium-phosphorus metabolism was demanding and iPTH levels were 
difficult to control. Daily administration of vitamin D did not control the patients’ 
secondary hyperparathyroidism and many patients were switched to pulse therapy to 
reach optimal iPTH levels. The reduction of dietary protein should be implemented 
after the first months of PD to reduce calcium based phosphate binders. Thus, the 
risk for vascular calcification can be diminished. 
2) Hypertension was a common problem. Evaluation of intravascular volume status 
with existing tools is demanding. However, less antihypertensive medication was used 
between 2001 and 2005 than earlier. Fifty-seven per cent of patients treated between 
2001 and 2005 had long-term hypertension, yet most of them without antihypertensive 
medication.
3) Growth during PD was good in the whole study population and catch-up growth 
was seen in most patients. Careful planning and implementation of nutrition and an 
adequate dialysis dose are important factors in assuring growth. Although the children 
grew well, they were significantly smaller at the end of PD than their predicted 
midparental height, calculated from the heights of their parents.
4) We found neurological impairment in 15 out of 21 prospectively studied patients 
at the end of the follow-up. In 29% of the cases, there was a major impairment and 
in 43% only some minor ones. Impairments were seen especially in patients with 
neonatal, perinatal or co-morbidity-related risk factors but milder ones in patients 
without risk-factors. All patients with major impairment had a predialysis risk factor 
for their development. PD did not worsen the neurological condition. Of these 21 
prospectively studied patients, 19% had a brain infarct and 14% some other ischemic 
lesion or PVL. Hovewer, all school-aged children attended full-time school. Part-time 
special education was needed in 13% and full-time in 33%.
5) NPHS1 with MDA is a new syndrome, not described earlier. We did not find any clear 
explanation for the symptoms of these patients although we analyzed their mitochondrial 
genome and evaluated risk factors for neurological injury. Hyperbilirubinemia together 
with hypoalbuminemia amplifies the toxicity of bilirubin and kernicterus is a possible 
explanation, however, this could not be proven within the scope of this study.
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6) Based on the above findings we have focused more on early diagnosis and aggressive 
RRT from the beginning and have adjusted our follow-up program. More focus is 
given on Ca-Pi balance, blood pressure follow-up and therapy of hypertension. In 
infants and small children, lower Crcl levels; over 40 L/week per 1.73 m2 can be 
allowed even in anuric patients if they grow well. In addition to regular follow-up of 
blood pressure, left ventricular mass and the presence of LVH (with the method of 
Foster et al.) should be evaluated regularly during PD. Children with risk factors for 
developmental impairment are carefully supervised to characterize their problems 
and to minimize their developmental sequelae.
Acknowledgements    89
acknowledgements
This study was carried out at the Children’s Hospital, Helsinki University Central 
Hospital.
My sincere gratitude is due to Docent Jari Petäjä, Director of the Department of 
Gynecology and Pediatrics, Helsinki University Central Hospital, Professor Mikael 
Knip, Chair of the Children’s Hospital, University of Helsinki, and Docent Eero Jokinen, 
Head of the Department of Pediatrics, Helsinki University Central Hospital as well 
as Professors emeritus Christer Holmberg, Erkki Savilahti, and Jaakko Perheentupa 
for providing excellent research facilities. Professor Markku Heikinheimo, Head of 
the Institute of Clinical Medicine, Head of the National Graduate School of Clinical 
Investigation and former Head of the Pediatric Graduate School at the University 
of Helsinki, is appreciated due to his worthy work he has done in bringing young 
investigators together and especially, in ensuring learning and growth of investigators 
during research projects. Docent Jussi Merenmies, present Head of the Pediatric 
Graduate School, for continuing valuable work with us researchers.
I wish to give special thanks to the following persons:
My outstanding supervisors, Professor Christer Holmberg and Kai Rönnholm, for 
their enthusiasm in medicine and pediatric nephrology, for providing me with such 
an interesting research project, and for teaching me both clinical skills and scientific 
method. Christer, your love of medicine and small patients made this research project 
true and gave life to it. I felt like coming home when planning and starting this study 
with you. You have taught me so much about medicine, scientific thinking and writing. 
Astonishingly, you have always found time for my study in spite of your numerous 
duties in Finland and abroad. Your positive attitude and ability always to find a 
solution in hard situations are worth admiration. Your laugh is always remembered. 
Kai, your teaching of clinical skills in pediatric nephrology and dialysis to me has 
been a prerequisite for this clinical study in children with a severe disease and strict 
treatment. Your experienced guidance has always been assured through these years. 
I have found something new and very important: the fascinating world of science 
with help of you Christer and Kai. I appreciate you deeply. 
Docent Agneta Ekstrand and Docent Kai Eriksson for their authentic interest and 
skilful, thorough review and constructive criticism of this thesis.
Docents Olli Koskimies and Matti Nuutinen, members of my thesis committee, for 
advice and important support throughout the study.
All of my collaborators. MD Juha-Matti Happonen is thanked for all heart examinations 
and for teaching cardiological facts during this study. Docent Tuula Lönnqvist for 
90
neurological examinations and for being the expert and teacher of pediatric neurology 
during all these years. Docent Leena Valanne for analyzing brain images and for 
teaching neuroradiology during this study. Docent Eino Marttinen for analyzing 
bone age images and for radiological advice. Professor Hannu Jalanko for important 
advice, ideas and work with this study and for being such an excellent example of 
a researcher. MD Jukka Karikoski for otological examinations and teaching. MD 
Johanna Uusimaa for mitochondrial DNA analyses and for writing her own research 
section of my article. Tuula Hölttä for teaching me, sharing data and for helping me 
with my material. Erik Qvist for sharing important data and for positive attitude, 
support and encouragement. Docent Marja Ala-Houhala, Docent Matti Nuutinen, 
MD Pekka Arikoski, MD Seppo Juuti, MD Janne Kataja, MD Anja Nuuja, and MD 
Tuija Kautto for co-operation concerning patients and patient data during this study. 
All Pediatric Nephrologists at the Children’s Hospital for your valuable co-operation. 
Patrik Finne for providing me the data from the Finnish Registry for Kidney Diseases.
Renal nurses Ulla Sandholm and Lisbeth Björkstam for their precise and dedicated work 
during this study and for friendship. Personnel at the Ward of Pediatric Nephrology 
and Transplantation for positive attitude and valuable work during the study. Dietician 
Aila Paganus for her valuable work with patients and for her important advices and 
teaching about science of nutrition.
Research fellows in Lastenlinnantie and in Biomedicum Helsinki 2. MD Helena 
Valta for her primary advice during this study and for friendship. Anne Sarajuuri 
for discussions about methods of assessments, different analyses and variety of life 
and for “regular” sport activity. Marianne Sidoroff for being a little sister to me. 
Mirjami Siltanen, Sanna Wickman, Matti Hero, Paula Seikku, Elisa Ylinen, Helena 
Olkinuora, Sonja Strang-Karlsson, Pirjo Tynjälä, Maarit Tarkiainen, Tuija Fontell, 
Anu Usvasalo, Karoliina Wehkalampi, Hanne Rintamäki, Sari Honkanen, and Anne 
Nikkonen among others for sharing the community of pediatric research.
 
Patients and the parents for participating this study. This thesis is dedicated to you 
and all families with a child with a chronic kidney disease.
Jennifer Rowland for linguistic editing of this thesis.
My dear friends. First of all, Annamari Autiosuo for special friendship and for sharing 
joy and sorrow whenever needed. Riikka Halme-Berneking for important friendship 
despite long distances. Handbell ensemble Sonus, especially SonusKvartetti (Sanna 
and Hanna Helasterä, Laura Arjamaa) for sharing the joy of music during many, many 
years. Special thanks to Sinikka Honkanen for introducing the world of handbells 
to us. Jaana Lamberg for her friendship and linguistic help with this thesis. Liisa 
Sunila, Anni Mäkinen, Sari Manni, Satu Reinikainen and many other friends for 
the valuable gift of friendship.
Acknowledgements    91
My dear parents, Sinikka and Erkki Vilén, for letting me be just me. Thank you for 
giving me a safe and loving home as a child. Thank you for many trips to nature 
where I could see the miracle of life in its’ different forms. My brothers Jouni and 
Jarno for sharing these days of our lives. My late grandmothers and especially my 
late grandfather, Pappa, who was always interested in me, my studies and thoughts.
My children Mikael, Markus, Kristian, Karoliina, and Sarlotta for bringing so much 
love, joy, activity, music, sport, new friends, challenges, and new sights into my life. 
Mikael is thanked for image processing for this thesis. You are totally invaluable and 
a great joy of my life.
My dear husband Timo for sharing this life with me. For your love, kindness, patience, 
and flexibility during this study. For many travels and interests together. You have 
always been encouraging and have believed in my capability as a doctor and researcher. 
Without your help and support this thesis would not be true today.
This study was financially supported by the Foundation for Paediatric Research, 
the Sigrid Juselius Foundation, the Finnish Kidney Foundation, Finnish Society of 
Nephrology, the Research Funds of Helsinki University Hospital, and the University 






Acar B, Yalcinkaya F, Cakar N, Yuksel S, Ozcakar ZB, Uncu N, Kara N, Elhan AH, 
Ekim M. The outcome for pediatric patients on peritoneal dialysis. J Nephrol 
21, 3:394-399, 2008. 
Adams JH, Brierley JB, Connor RC, Treip CS. The effects of systemic hypotension 
upon the human brain. Clinical and neuropathological observations in 11 cases. 
Brain 89, 2:235-268, 1966. 
Agildere AM, Basaran C, Cakir B, Ozgul E, Kural F, Haberal M. Evaluation of 
neurologic complications by brain MRI in kidney and liver transplant recipients. 
Transplant Proc 38, 2:611-618, 2006. 
Aksu N, Yavascan O, Anil M, Kara OD, Erdogan H, Bal A. A ten-year single-
center experience in children on chronic peritoneal dialysis--significance of 
percutaneous placement of peritoneal dialysis catheters. Nephrol Dial Transplant 
22, 7:2045-2051, 2007. 
Ala-Houhala M, Holmberg C, Rönnholm K, Paganus A, Laine J, Koskimies O. 
Alphacalcidol oral pulses normalize uremic hyperparathyroidism prior to 
dialysis. Pediatr Nephrol 9, 6:737-741, 1995. 
Alexander SR and Honda M. Continuous peritoneal dialysis for children: a decade 
of worldwide growth and development. Kidney Int Suppl. 40, S65-74, 1993. 
Aranda RA, Romao Junior JE, Kakehashi E, Domingos W, Sabbaga E, Marcondes 
M, Abensur H. Intraperitoneal pressure and hernias in children on peritoneal 
dialysis. Pediatr Nephrol 14, 1:22-24, 2000.
Ashwal S, Russman PS, Blasco PA, Miller G, Sandler A, Shevell M, Stevenson R. 
Practice parameter: Diagnostic assessment of the child with cerebral palsy: 
Report of the Quality Standards Subcommittee of the American Academy of 
Neurology and Practice Committee of the Child Neurology Society. Neurology 
62, 6:851-863, 2004.
Autti-Rämö I. The outcome of children exposed to alcohol in utero. A Prospective 
follow-up study during the first three years. University of Helsinki, 1993. 
Autti-Rämö I and Granström ML. The effect of intrauterine alcohol exposition in 
various durations on early cognitive development. Neuropediatrics 22, 4:203-
210, 1991a. 
Autti-Rämö I and Granström ML. The psychomotor development during the first 
year of life of infants exposed to intrauterine alcohol of various duration. 
Fetal alcohol exposure and development. Neuropediatrics 22, 2:59-64, 1991b. 
Bargman JM. Rethinking the peritoneal dialysis prescription: results of recent studies. 
Nephrology (Carlton) 11, 2:85-89, 2006. 
Basile C, Vernaglione L, Di Iorio B, Bellizzi V, Chimienti D, Lomonte C, Rubino A, 
D’Ambrosio N. Development and validation of bioimpedance analysis prediction 
equations for dry weight in hemodialysis patients. Clin J Am Soc Nephrol 2, 
4:675-680, 2007. 
94
Bates CM, Baum M, Hunchik M, Quan A. Acute vision loss in children with autosomal 
recessive polycystic kidney disease. Am J Kidney Dis 34, 6:1125-1128, 1999. 
Becker N, Brandt JR, Sutherland TA, Avner ED, Watkins SL. Improved outcome of 
young children on nightly automated peritoneal dialysis. Pediatr Nephrol 11, 
6:676-679, 1997. 
Bergström L and Thompson P. Hearing loss in pediatric renal patients. Int J Pediatr 
Otorhinolaryngol 5, 3:227-234, 1983. 
Blumberg A, Hanck A, Sander G. Vitamin nutrition in patients on continuous 
ambulatory peritoneal dialysis (CAPD). Clin Nephrol 20, 5:244-250, 1983. 
Boehm M, Riesenhuber A, Winkelmayer WC, Arbeiter K, Mueller T, Aufricht C. 
Early erythropoietin therapy is associated with improved growth in children 
with chronic kidney disease. Pediatr Nephrol 22, 8:1189-1193, 2007. 
Boehm M, Vecsei A, Aufricht C, Mueller T, Csaicsich D, Arbeiter K. Risk factors 
for peritonitis in pediatric peritoneal dialysis: a single-center study. Pediatr 
Nephrol 20, 10:1478-1483, 2005. 
Brooks ER, Fatallah-Shaykh SA, Langman CB, Wolf KM, Price HE. Bioelectric 
impedance predicts total body water, blood pressure, and heart rate during 
hemodialysis in children and adolescents. J Ren Nutr 18, 3:304-311, 2008. 
Bunchman TE. Chronic dialysis in the infant less than 1 year of age. Pediatr Nephrol 
9 Suppl, S18-22, 1995. 
Cansick J, Waller S, Ridout D, Rees L. Growth and PTH in prepubertal children on 
long-term dialysis. Pediatr Nephrol 22, 9:1349-1354, 2007. 
Carey WA, Talley LI, Sehring SA, Jaskula JM, Mathias RS. Outcomes of dialysis 
initiated during the neonatal period for treatment of end-stage renal disease: 
a North American Pediatric Renal Trials and Collaborative Studies special 
analysis. Pediatrics 119, 2:e468-73, 2007. 
Chadha V, Blowey DL, Warady BA. Is growth a valid outcome measure of dialysis 
clearance in children undergoing peritoneal dialysis? Perit Dial Int 21 Suppl 
3, S179-84, 2001. 
Chadha V, Schaefer FS, Warady BA. Dialysis-associated peritonitis in children. Pediatr 
Nephrol 25, 3:425-440, 2010.
Chamney PW, Kramer M, Rode C, Kleinekofort W, Wizemann V. A new technique for 
establishing dry weight in hemodialysis patients via whole body bioimpedance. 
Kidney Int 61, 6:2250-2258, 2002. 
Chantler C. Renal failure in childhood. In: Black D and Jones NF, eds. Renal disease. 
Blackwell Scientific Publications, Oxford, 1979, 825-869.
Chutorian AM, Winterkorn JM, Geffner M. Anterior ischemic optic neuropathy in 
children: case reports and review of the literature. Pediatr Neurol 26, 5:358-
364, 2002. 
Civilibal M, Caliskan S, Oflaz H, Sever L, Candan C, Canpolat N, Kasapcopur O, 
Arisoy N. Left ventricular function by ‘conventional’ and ‘tissue Doppler’ 
echocardiography in paediatric dialysis patients. Nephrology (Carlton) 14, 
7:636-642, 2009. 
Comty CM, Cohen SL, Shapiro FL. Pericarditis in chronic uremia and its sequels. 
Ann Intern Med 75, 2:173-183, 1971. 
References    95
Cooperstone BG, Friedman A, Kaplan BS. Galloway-Mowat syndrome of abnormal 
gyral patterns and glomerulopathy. Am J Med Genet 47, 2:250-254, 1993. 
Coppes MJ, Huff V, Pelletier J. Denys-Drash syndrome: relating a clinical disorder 
to genetic alterations in the tumor suppressor gene WT1. J Pediatr 123, 5:673-
678, 1993. 
Crocker JF, Acott PD, Carter JE, Lirenman DS, MacDonald GW, McAllister M, 
McDonnell MC, Shea S, Bawden HN. Neuropsychological outcome in children 
with acquired or congenital renal disease. Pediatr Nephrol 17, 11:908-912, 2002. 
de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, 
Alderman MH. Left ventricular mass and body size in normotensive children 
and adults: assessment of allometric relations and impact of overweight. J Am 
Coll Cardiol 20, 5:1251-1260, 1992. 
Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential 
for anticancer therapeutics. Nat Rev Cancer 7, 9:684-700, 2007. 
Deurenberg P, Tagliabue A, Schouten FJ. Multi-frequency impedance for the prediction 
of extracellular water and total body water. Br J Nutr 73, 3:349-358, 1995. 
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. 
Echocardiographic assessment of left ventricular hypertrophy: comparison to 
necropsy findings. Am J Cardiol 57, 6:450-458, 1986. 
Donmez O, Aladag S, Cigerdelen N, Kocak S. Outcome in children on chronic 
peritoneal dialysis. Adv Perit Dial 19, 269-272, 2003. 
Durand PY, Chanliau J, Gamberoni J, Hestin D, Kessler M. Routine measurement of 
hydrostatic intraperitoneal pressure. Adv Perit Dial 8, 108-112, 1992. 
Edefonti A, Picca M, Damiani B, Garavaglia R, Loi S, Ardissino G, Marra G, 
Ghio L. Prevalence of malnutrition assessed by bioimpedance analysis and 
anthropometry in children on peritoneal dialysis. Perit Dial Int 21, 2:172-179, 
2001. 
Ellis KJ, Bell SJ, Chertow GM, Chumlea WC, Knox TA, Kotler DP, Lukaski HC, 
Schoeller DA. Bioelectrical impedance methods in clinical research: a follow-up 
to the NIH Technology Assessment Conference. Nutrition 15, 11-12:874-880, 
1999. 
Elzouki A, Carroll J, Butinar D, Moosa A. Improved neurological outcome in children 
with chronic renal disease from infancy. Pediatr Nephrol 8, 2:205-210, 1994. 
Feld LG and Waz WR. Treatment of Hypertension. In: Barrat TM, Avner E, Harmon 
W, eds. Pediatric Nephrology, 4th Edition, Lippincott Williams & Wilkins, 
Maryland, USA, 1031-1049, 1999.
Fennell RS, Fennell EB, Carter RL, Mings EL, Klausner AB, Hurst JR. Association 
between renal function and cognition in childhood chronic renal failure. Pediatr 
Nephrol 4, 1:16-20, 1990. 
Finnish Registry for Kidney Diseases (FRKD) 1967 - 2008. Finne Patrik, personal 
communication, December 16, 2009.
Fischbach M, Desprez P, Donnars F, Geisert J. Hydrostatic intraperitoneal pressure 
in children on peritoneal dialysis: practical implications. An 18-month clinical 
experience. Adv Perit Dial 10, 294-296, 1994. 
96
Fischbach M, Desprez P, Terzic J, Lahlou A, Mengus L, Geisert J. Use of intraperitoneal 
pressure, ultrafiltration and purification dwell times for individual peritoneal 
dialysis prescription in children. Clin Nephrol 46, 1:14-16, 1996. 
Fischbach M, Edefonti A, Schroder C, Watson A. European Paediatric Dialysis Working 
Group. Hemodialysis in children: general practical guidelines. Pediatr Nephrol 
20, 8:1054-1066, 2005. 
Fischbach M, Terzic J, Becmeur F, Lahlou A, Desprez P, Battouche D, Geisert J. 
Relationship between intraperitoneal hydrostatic pressure and dialysate volume 
in children on PD. Adv Perit Dial 12, 330-334, 1996. 
Fischbach M, Terzic J, Laugel V, Escande B, Dangelser C, Helmstetter A. Measurement 
of hydrostatic intraperitoneal pressure: a useful tool for the improvement of 
dialysis dose prescription. Pediatr Nephrol 18, 10:976-980, 2003. 
Fischbach M, Terzic J, Menouer S, Dheu C, Seuge L, Zalosczic A. Daily on line 
haemodiafiltration promotes catch-up growth in children on chronic dialysis. 
Nephrol Dial Transplant 25, 3:867-873, 2010. 
Fischbach M, Terzic J, Menouer S, Dheu C, Soskin S, Helmstetter A, Burger MC. 
Intensified and daily hemodialysis in children might improve statural growth. 
Pediatr Nephrol 21, 11:1746-1752, 2006. 
Fischbach M and Warady BA. Peritoneal dialysis prescription in children: bedside 
principles for optimal practice. Pediatr Nephrol 24, 9:1633-42; quiz 1640, 1642, 
2009. 
Flanigan MJ, Doyle C, Miller L. Tidal peritoneal dialysis: a pediatric experience. 
Adv Perit Dial 7, 275-278, 1991. 
Flatmark A. Scandiatransplant 20 years. Tissue Antigens 34, 1:30-34, 1989. 
Food and Agriculture Organization of the WHO. Human energy requirements. Report 
of a joint FAO/WHO/UNU expert consultation. FAO, Rome, 2001. 
Foppa M, Duncan BB, Rohde LE. Echocardiography-based left ventricular mass 
estimation. How should we define hypertrophy? Cardiovasc Ultrasound 3, 
17, 2005. 
Foster BJ, Mackie AS, Mitsnefes M, Ali H, Mamber S, Colan SD. A novel method of 
expressing left ventricular mass relative to body size in children. Circulation 
117, 21:2769-2775, 2008. 
Furth SL, Donaldson LA, Sullivan EK, Watkins SL. North American Pediatric 
Renal Transplant Cooperative Study, Peritoneal dialysis catheter infections 
and peritonitis in children: a report of the North American Pediatric Renal 
Transplant Cooperative Study. Pediatr Nephrol 15, 3-4:179-182, 2000. 
Furth SL, Hwang W, Yang C, Neu AM, Fivush BA, Powe NR. Growth failure, risk 
of hospitalization and death for children with end-stage renal disease. Pediatr 
Nephrol 17, 6:450-455, 2002. 
Gadallah MF, Ramdeen G, Mignone J, Patel D, Mitchell L, Tatro S. Role of preoperative 
antibiotic prophylaxis in preventing postoperative peritonitis in newly placed 
peritoneal dialysis catheters. Am J Kidney Dis 36, 5:1014-1019, 2000. 
Gao D, Kraus MA, Ronco C, and Clark WR. The biology of dialysis. In: Warady B, 
Schaefer F, Fine RN, Alexander SR, eds. Pediatric dialysis. Kluwer Academic 
Publishers, Dordrecht/Boston/London, 13-34, 2000.
References    97
Geary DF and Haka-Ikse K. Neurodevelopmental progress of young children with 
chronic renal disease. Pediatrics 84, 1:68-72, 1989. 
Goldenberg A, Ngoc LH, Thouret MC, Cormier-Daire V, Gagnadoux MF, Chretien D, 
Lefrancois C, Geromel V, Rotig A, Rustin P, Munnich A, Paquis V, Antignac 
C, Gubler MC, Niaudet P, de Lonlay P, Berard E. Respiratory chain deficiency 
presenting as congenital nephrotic syndrome. Pediatr Nephrol 20, 4:465-469, 
2005. 
Gonzalez E, Schomberg J, Amin N, Salusky IB, Zaritsky J. Sevelamer carbonate 
increases serum bicarbonate in pediatric dialysis patients. Pediatr Nephrol 
25, 2:373-375, 2010.
Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB. 
Development of adynamic bone in patients with secondary hyperparathyroidism 
after intermittent calcitriol therapy. Kidney Int 46, 4:1160-1166, 1994. 
Groothoff JW, Lilien MR, van de Kar NC, Wolff ED, Davin JC. Cardiovascular 
disease as a late complication of end-stage renal disease in children. Pediatr 
Nephrol 20, 3:374-379, 2005. 
Haavisto A, Korkman M, Jalanko H, Holmberg C, Qvist E. Neurocognitive function of 
pediatric heart transplant recipients. J Heart Lung Transplant 29, 7:764-770, 2010.
Haavisto A, Korkman M, Qvist E. Neurodevelopmental outcome of pediatric kidney 
transplant recipients. Submitted.
Hagberg B, Hagberg G, and Olow I. The changing panorama of cerebral palsy in 
Sweden 1954-1970. I. Analysis of the general changes. Acta Paediatr Scand 
64, 2:187-192, 1975.
Hagberg B, Hagberg G, Beckung E, Uvebrant P. Changing panorama of cerebral palsy 
in Sweden. VIII. Prevalence and origin in the birth year period 1991-94. Acta 
Paediatr 90, 3:271-277, 2001.
Hameed R, Raafat F, Ramani P, Gray G, Roper HP, Milford DV. Mitochondrial cytopathy 
presenting with focal segmental glomerulosclerosis, hypoparathyroidism, 
sensorineural deafness, and progressive neurological disease. Postgrad Med 
J 77, 910:523-526, 2001.
Harmon WE. Overview of Chronic Renal Failure. In: Barrat TM, Avner E, Harmon 
W, eds. Pediatric Nephrology. 4th Edition, Lippincott Williams & Wilkins, 
Maryland, USA, 1151-1154, 1999.
Haycock GB. Homeostasis, Sodium and Body Fluids. In: Barrat TM, Avner E, Harmon 
W, eds. Pediatric Nephrology, 4th Edition, Lippincott Wlliams & Wilkins, 
Maryland, USA, 133-153, 1999.
Heineman KR and Hadders-Algra M. Evaluation of neuromotor function in infancy 
- A systematic review of available methods. J Dev Behav Pediatr 29, 4:315-
323, 2008. 
Hellbrügge T, Köhler G, and Egelkraut H. Münchener funktionelle Entwiklungsdiagnostik 
für das zweite und dritte Lebensjahr. Germany, 1978.
Holmberg C, Antikainen M, Rönnholm K, Ala Houhala M, Jalanko H. Management 
of Congenital nephrotic syndrome of the Finnish type. Pediatr Nephrol 9, 
1:87-93, 1995. 
98
Holmberg C, Tryggvason K, Kestilä M, and Jalanko H. Congenital nephrotic syndrome. 
In: Avner E, Harmon W, Niaudet P, eds. Pediatric Nephrology. 5th Edition , 
Lippincott Williams & Wilkins, Philadelphia, 523-532, 2004.
Honda M, Iitaka K, Kawaguchi H, Hoshii S, Akashi S, Kohsaka T, Tuzuki K, Yamaoka 
K, Yoshikawa N, Karashima S, Itoh Y, Hatae K. The Japanese National Registry 
data on pediatric CAPD patients: a ten-year experience. A report of the Study 
Group of Pediatric PD Conference. Perit Dial Int 16, 3:269-275, 1996. 
Honda M, Kamiyama Y, Kawamura K, Kawahara K, Shishido S, Nakai H, Kawamura 
T, Ito H. Growth, development and nutritional status in Japanese children 
under 2 years on continuous ambulatory peritoneal dialysis. Pediatr Nephrol 
9, 5:543-548, 1995. 
Hoshii S, Wada N, Honda M. Japanese Study Group of Pediatric Peritoneal Dialysis, A 
survey of peritonitis and exit-site and/or tunnel infections in Japanese children 
on PD. Pediatr Nephrol 21, 6:828-834, 2006.
Houtkooper LB, Lohman TG, Going SB, Hall MC. Validity of bioelectric impedance 
for body composition assessment in children. J Appl Physiol 66, 2:814-821, 1989.
Huttunen N. Congenital nephrotic syndrome of Finnish type: study of 75 patients. 
Arch Dis Child 51, 344-348, 1976. 
Hölttä T. Improvement in peritoneal dialysis treatment in childhood, with emphasis 
on small children, University of Helsinki, Helsinki, Finland, 2000c.
Hölttä T, Happonen JM, Rönnholm K, Fyhrquist F, Holmberg C. Hypertension, cardiac 
state, and the role of volume overload during peritoneal dialysis. Pediatr Nephrol 
16, 4:324-331, 2001. 
Hölttä T, Rönnholm K, Holmberg C. Adequacy of dialysis with tidal and continuous 
cycling peritoneal dialysis in children. Nephrol Dial Transplant 15, 9:1438-
1442, 2000a. 
Hölttä T, Rönnholm K, Jalanko H, Holmberg C. Clinical outcome of pediatric patients 
on peritoneal dialysis under adequacy control. Pediatr Nephrol 14, 10-11:889-
897, 2000b. 
Hölttä TM, Rönnholm KA, Jalanko H, Ala-Houhala M, Antikainen M, Holmberg C. 
Peritoneal dialysis in children under 5 years of age. Perit Dial Int 17, 6:573-
580, 1997. 
Isakova T and Wolf MS. FGF23 or PTH: which comes first in CKD? Kidney Int 78, 
10:947-949, 2010. 
Ishikura K, Hataya H, Ikeda M, Honda M. Suitable dialytic indicators for pediatric 
peritoneal dialysis patients: the alternative to creatinine clearance. Perit Dial 
Int 23, 3:270-275, 2003. 
Jalanko H. Congenital nephrotic syndrome. Pediatr Nephrol 24, 11:2121-2128, 2009. 
Jander A, Nowicki M, Tkaczyk M, Makulska I, Zwolinska D, Latoszynska J, 
Boguszewska-Baczkowska A, Grenda R, Balasz-Chmielewska I, Zagozdzon 
I, Zaluska-Lesniewska I, Zurowska A, Stefaniak E, Zachwieja J, Leszczynska B, 
Roszkowska-Blaim M, Zachwieja K, Pietrzyk JA, Wiercinski R, Zoch-Zwierz 
W, Stankiewicz R. Chronic peritoneal dialysis in infants - preliminary results 
of the multicenter survey. Przegl Lek 63 Suppl 3, 72-74, 2006. 
References    99
Jüppner H. Phosphate and FGF-23. Kidney Int Suppl 121:S24-7, 2011. 
Kantero R and Tiisala R. Growth of head circumference from birth to 10 years. A 
mixed longitudinal study. Acta Paediatr Scand Suppl 220:27-32, 1971. 
Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L. Outcome and growth of infants 
with severe chronic renal failure. Kidney Int 57, 4:1681-1687, 2000. 
Kazama JJ, Sato F, Omori K, Hama H, Yamamoto S, Maruyama H, Narita I. Gejyo 
F, Yamashita T, Fukumoto S, Fukagawa M. Pretreatment serum FGF-23 levels 
predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 67, 
3:1120-1125, 2005. 
KDOQI Work Group. KDOQI Clinical Practice Guideline for Nutrition in Children 
with CKD: 2008 update. Executive summary. Am J Kidney Dis 53, 3 Suppl 
2:S11-104, 2009. 
KDOQI and National Kidney Foundation, III. Clinical practice recommendations for 
anemia in chronic kidney disease in children. Am J Kidney Dis 47, 5 Suppl 
3:S86-108, 2006. 
Kestilä M, Lenkkeri U, Männikkö M, Lamerdin J, McCready P, Putaala H, Ruotsalainen 
V, Morita T, Nissinen M, Herva R, Kashtan CE, Peltonen L, Holmberg C, Olsen 
A, Tryggvason K. Positionally cloned gene for a novel glomerular protein--
nephrin--is mutated in congenital nephrotic syndrome. Mol Cell 1, 4:575-582, 
1998. 
Khoury AE, Charendoff J, Balfe JW, McLorie GA, Churchill BM. Hernias associated 
with CAPD in children. Adv Perit Dial 7, 279-282, 1991. 
Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova 
E, Stefanidis CJ, Strazdins V, Vande Walle J, Schroder C, Zurowska A, Ekim 
M. European Pediatric Dialysis Working Group (EPDWG). Prevention and 
treatment of renal osteodystrophy in children on chronic renal failure: European 
guidelines. Pediatr Nephrol 21, 2:151-159, 2006. 
Kopple JD, Mercurio K, Blumenkrantz MJ, Jones MR, Tallos J, Roberts C, Card B, 
Saltzman R, Casciato DA, Swendseid ME. Daily requirement for pyridoxine 
supplements in chronic renal failure. Kidney Int 19, 5:694-704, 1981. 
Korkman M. NEPSY. A proposed neuropsychological test battery for young 
developmentally disabled children. University of Helsinki, Helsinki, Finland, 
1988.
Korkman M, Kirk U, and Kemp S. NEPSY - Second Edition (NEPSY-II). San Antonio, 
Texas: Harcourt Assessment, 2007.
Kozlowski PB, Sher JH, Nicastri AD, Rudelli RD. Brain morphology in the Galloway 
syndrome. Clin Neuropathol 8, 2:85-91, 1989. 
Kriley M and Warady BA. Vitamin status of pediatric patients receiving long-term 
peritoneal dialysis. Am J Clin Nutr 53, 6:1476-1479, 1991. 
Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB. 
Diminished linear growth during intermittent calcitriol therapy in children 
undergoing CCPD. Kidney Int 53, 1:205-211, 1998. 
100
Kyle UG, Bosaeus I, De Lorenzo AD, Deurenberg P, Elia M, Gomez JM, Heitmann 
BL, Kent-Smith L, Melchior JC, Pirlich M, Scharfetter H, Schols AM, Pichard 
C. Composition of the ESPEN Working Group, Bioelectrical impedance analysis 
- part I: review of principles and methods. Clin Nutr 23, 5:1226-1243, 2004. 
Lano A. The Value of Neonatal Neurological Assessment in Predicting 
Neurodevelopmental Problems at Preschool Age. Medical Faculty of the 
University of Helsinki, Helsinki, Finland, 2002. 
Lapeyraque AL, Haddad E, Andre JL, Bremond-Gignac D, Taylor CM, Rianthavorn 
P, Salusky IB, Loirat C. Sudden blindness caused by anterior ischemic optic 
neuropathy in 5 children on continuous peritoneal dialysis. Am J Kidney Dis 
42, 5:E3-9, 2003. 
Lester LA, Sodt PC, Hutcheon N, Arcilla RA. M-mode echocardiography in normal 
children and adolescents: some new perspectives. Pediatr Cardiol 8, 1:27-33, 
1987. 
Levy D, Savage DD, Garrison RJ, Anderson KM, Kannel WB, Castelli WP. 
Echocardiographic criteria for left ventricular hypertrophy: the Framingham 
Heart Study. Am J Cardiol 59, 9:956-960, 1987. 
Lewis M, Shaw J, Reid C, Evans J, Webb N, Verrier-Jones K. Growth in children 
with established renal failure - a Registry analysis (chapter 14). Nephrol Dial 
Transplant 22 Suppl 7, vii176-80, 2007. 
Lin CC, Tsai JD, Lin SP, Tzen CY, Shen EY, Shih CS. Galloway-Mowat syndrome: a 
glomerular basement membrane disorder? Pediatr Nephrol 16, 8:653-657, 2001. 
Macchini F, Valade A, Ardissino G, Testa S, Edefonti A, Torricelli M, Luzzani S. 
Chronic peritoneal dialysis in children: catheter related complications. A single 
center experience. Pediatr Surg Int 22, 6:524-528, 2006. 
Madden SJ, Ledermann SE, Guerrero-Blanco M, Bruce M, Trompeter RS. Cognitive 
and psychosocial outcome of infants dialysed in infancy. Child Care Health 
Dev 29, 1:55-61, 2003. 
Mahan JD, Warady BA. Consensus Committee, Assessment and treatment of short 
stature in pediatric patients with chronic kidney disease: a consensus statement. 
Pediatr Nephrol 21, 7:917-930, 2006. 
Maisels MJ. Neonatal hyperbilirubinemia and kernicterus - not gone but sometimes 
forgotten. Early Hum Dev 85, 11:727-732, 2009. 
Mancini ML, Dello Strologo L, Bianchi PM, Tieri L, Rizzoni G. Sensorineural hearing 
loss in patients reaching chronic renal failure in childhood. Pediatr Nephrol 
10, 1:38-40, 1996. 
Matz GJ. Clinical perspectives on ototoxic drugs. Ann Otol Rhinol Laryngol Suppl 
148, 39-41, 1990. 
McGonigle RJ, Boineau FG, Beckman B, Ohene-Frempong K, Lewy JE, Shadduck 
RK, Fisher JW. Erythropoietin and inhibitors of in vitro erythropoiesis in the 
development of anemia in children with renal disease. J Lab Clin Med 105, 
4:449-458, 1985. 
McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and 
inhibition of erythropoiesis in renal insufficiency. Kidney Int 25, 2:437-444, 
1984. 
References    101
Merril JP, Murray JE, Harrison JH, Guild WR. Succesful homotransplantation of the 
human kidney between identical twins. J Am Med Assoc 160, 277-282, 1956. 
Mitch WE. Metabolic and clinical consequences of metabolic acidosis. J Nephrol 19 
Suppl 9, S70-5, 2006. 
Mitsnefes M, Ho PL, McEnery PT. Hypertension and progression of chronic renal 
insufficiency in children: a report of the North American Pediatric Renal 
Transplant Cooperative Study (NAPRTCS). J Am Soc Nephrol 14, 10:2618-
2622, 2003. 
Mitsnefes M and Stablein D. Hypertension in pediatric patients on long-term dialysis: 
a report of the North American Pediatric Renal Transplant Cooperative Study 
(NAPRTCS). Am J Kidney Dis 45, 2:309-315, 2005. 
Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF. Severe 
left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. 
Pediatr Nephrol 14, 10-11:898-902, 2000. 
Mitsnefes MM, Kimball TR, Witt SA, Glascock BJ, Khoury PR, Daniels SR. Left 
ventricular mass and systolic performance in pediatric patients with chronic 
renal failure. Circulation 107, 6:864-868, 2003. 
Mitsnefes MM, Schwartz SM, Daniels SR, Kimball TR, Khoury P, Strife CF. 
Changes in left ventricular mass index in children and adolescents after renal 
transplantation. Pediatr Transplant 5, 4:279-284, 2001. 
Mydlik M, Derzsiova K, Valek A, Szabo T, Dandar V, Takac M. Vitamins and continuous 
ambulatory peritoneal dialysis (CAPD). Int Urol Nephrol 17, 3:281-286, 1985. 
Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, 
Shigematsu T, Fukagawa M. Serum fibroblast growth factor-23 levels predict 
the future refractory hyperparathyroidism in dialysis patients. Kidney Int 67, 
3:1171-1178, 2005. 
National High Blood Pressure Education Program Working Group on Hypertension 
Control in Children and Adolescents. Update on the 1987 Task Force Report 
on High Blood Pressure in Children and Adolescents: a working group report 
from the National High Blood Pressure Education Program. Pediatrics 98:649-
658, 1996.
National Kidney Foundation (KDOQI). KDOQI clinical practice guidelines for bone 
metabolism and disease in children with chronic kidney disease. American 
Journal of Kidney Diseases : The Official Journal of the National Kidney 
Foundation 46 (Suppl 1), S1-S122, 2005. 
Neu AM, Ho PL, McDonald RA, Warady BA. Chronic dialysis in children and 
adolescents. The 2001 NAPRTCS Annual Report. Pediatr Nephrol 17, 8:656-
663, 2002. 
Neu AM, Kohaut EC, Warady BA. Current approach to peritoneal access in North 
American children: a report of the Pediatric Peritoneal Dialysis Study 
Consortium. Adv Perit Dial 11, 289-292, 1995. 
Niaudet P and Rotig A. Renal involvement in mitochondrial cytopathies. Pediatr 
Nephrol 10, 3:368-373, 1996. 
102
Nikolopoulos TP, Kandiloros DC, Segas JV, Nomicos PN, Ferekidis EA, Michelis KE, 
Apostolopoulos NJ, Adamopoulos GK. Auditory function in young patients 
with chronic renal failure. Clin Otolaryngol Allied Sci 22, 3:222-225, 1997.
II. NKF-K/DOQI. Clinical Practice Guidelines for Peritoneal Dialysis Adequacy: 
update 2000. Am J Kidney Dis 37, Suppl 1:S65-S136, 2001.
Nordic council of Ministers. Nordic Nutrition Recommendations NNR 2004 - integrating 
nutrition and physical activity. Report no. 13., Copenhagen, Denmark, 2004.
North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). North 
American Pediatric Renal Transplant Cooperative Study (NAPRTCS). 2004 
Annual Report. 2005. Available online at https://web.emmes.com/study/ped/
annlrept/annlrept2004.pdf
North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). 
Contributions of the Transplant Registry: The 2006 Annual Report of the North 
American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). 2007. 
Available online at https://web.emmes.com/study/ped/annlrept/annlrept.html
North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) 2007 
Annual Report. Renal Transplantation, Dialysis, Chronic Renal Insufficiency. 
2008. Available online at https://web.emmes.com/study/ped/annlrept/annlrept.
html
Offner G, Latta K, Hoyer PF, Baum HJ, Ehrich JH, Pichlmayr R, Brodehl J. Kidney 
transplanted children come of age. Kidney Int 55, 4:1509-1517, 1999. 
Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F. 
Advanced coronary and carotid arteriopathy in young adults with childhood-
onset chronic renal failure. Circulation 106, 1:100-105, 2002. 
Oreopoulos DG, Katirtzoglou A, Arbus G, Cordy P. Dialysis and transplantation in 
young children. Br Med J 1, 6178:1628-1629, 1979. 
Patrakka J, Kestilä M, Wartiovaara J, Ruotsalainen V, Tissari P, Lenkkeri U, Männikkö 
M, Visapää I, Holmberg C, Rapola J, Tryggvason K, Jalanko H. Congenital 
nephrotic syndrome (NPHS1): features resulting from different mutations in 
Finnish patients. Kidney Int 58, 3:972-980, 2000. 
Piper MC, Pinnell LE, Darrah J, Maguire T, Byrne PJ. Construction and validation 
of the Alberta Infant Motor Scale (AIMS). Can J Public Health 83 Suppl 2, 
S46-50, 1992. 
Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li 
PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley 
L. ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections 
recommendations: 2005 update. Perit Dial Int 25, 2:107-131, 2005. 
Piraino B, Bernardini J, Florio T, Fried L. Staphylococcus aureus prophylaxis and 
trends in gram-negative infections in peritoneal dialysis patients. Perit Dial 
Int 23, 5:456-459, 2003.
Polinsky MS, Kaiser BA, Stover JB, Frankenfield M, Baluarte HJ. Neurologic 
development of children with severe chronic renal failure from infancy. Pediatr 
Nephrol 1, 2:157-165, 1987. 
Powell CM and Michaelis RC. Townes-Brocks syndrome. J Med Genet 36, 2:89-93, 
1999. 
References    103
Price CG and Suki WN. Newer modifications of peritoneal dialysis: options in the 
treatment of patients with renal failure. Am J Nephrol 1, 2:97-104, 1981. 
Putaala H, Soininen R, Kilpeläinen P, Wartiovaara J, Tryggvason K. The murine 
nephrin gene is specifically expressed in kidney, brain and pancreas: inactivation 
of the gene leads to massive proteinuria and neonatal death. Hum Mol Genet 
10, 1:1-8, 2001. 
Quan A and Baum M. Protein losses in children on continuous cycler peritoneal 
dialysis. Pediatr Nephrol 10, 6:728-731, 1996. 
Querfeld U. The clinical significance of vascular calcification in young patients with 
end-stage renal disease. Pediatr Nephrol 19, 5:478-484, 2004. 
Qvist E, Pihko H, Fagerudd P, Valanne L, Lamminranta S, Karikoski J, Sainio K, 
Rönnholm K, Jalanko H, Holmberg C. Neurodevelopmental outcome in high-
risk patients after renal transplantation in early childhood. Pediatr Transplant 
6, 1:53-62, 2002. 
Rees L. Management of the infant with end-stage renal failure. Nephrol Dial Transplant 
17, 9:1564-1567, 2002. 
Rees L and Shaw V. Nutrition in children with CRF and on dialysis. Pediatr Nephrol 
22, 10:1689-1702, 2007. 
Rees L and Shroff RC. Phosphate binders in CKD: chalking out the differences. 
Pediatr Nephrol 25, 3:385-394, 2010. 
Reissman P, Lyass S, Shiloni E, Rivkind A, Berlatzky Y. Placement of a peritoneal 
dialysis catheter with routine omentectomy - does it prevent obstruction of the 
catheter? Eur J Surg 164, 9:703-707, 1998. 
Riegel K, Ohrt B, Wolke D, Österlund K. Die Entwicklung gefährdet geborener Kinder 
bis zum fünften Lebensjahr. (The development of at-risk children until the fifth 
year of life. The Arvo Ylppö longitudinal study in South Bavaria and South 
Finland). Ferdinand Enke Verlag, Stuttgart, Germany, 1995.
Rikalainen H, Aivojen ultraäänitutkimus. In: Soimakallio S, Kivisaari L, Manninen 
H, Svedström E, Tervonen O, eds. Radiologia. WSOY, Helsinki, Finland, 579-
583, 2005.
Rinaldi S, Sera F, Verrina E, Edefonti A, Gianoglio B, Perfumo F, Sorino P, Zacchello 
G, Cutaia I, Lavoratti G, Leozappa G, Pecoraro C, Rizzoni G. Italian Registry 
of Pediatric Chronic Peritoneal Dialysis, Chronic peritoneal dialysis catheters in 
children: a fifteen-year experience of the Italian Registry of Pediatric Chronic 
Peritoneal Dialysis. Perit Dial Int 24, 5:481-486, 2004. 
Robinson RF, Nahata MC, Sparks E, Daniels C, Batisky DL, Hayes JR, Mahan JD. 
Abnormal left ventricular mass and aortic distensibility in pediatric dialysis 
patients. Pediatr Nephrol 20, 1:64-68, 2005. 
Rönnholm KA and Holmberg C. Peritoneal dialysis in infants. Pediatr Nephrol 21, 
6:751-756, 2006. 
Ross EA, Shah GM, Reynolds RD, Sabo A, Pichon M. Vitamin B6 requirements of 
patients on chronic peritoneal dialysis. Kidney Int 36, 4:702-706, 1989. 
Saarinen TT, Arikoski P, Holmberg C, Rönnholm K. Intermittent or daily administration 
of 1-alpha calcidol for nephrectomised infants on peritoneal dialysis? Pediatr 
Nephrol 22, 11:1931-1938, 2007. 
104
Sanchez CP, Goodman WG, and Salusky I. Chronic Renal Failure, Osteodystrophy. 
In: Barrat TM, Avner E, Harmon W, eds. Pediatric Nephrology. 4th Edition , 
Lippincott Williams & Wilkins, Maryland, USA, 1231-1250, 1999.
Schaefer F, Feneberg R, Aksu N, Donmez O, Sadikoglu B, Alexander SR, Mir S, Ha 
IS, Fischbach M, Simkova E, Watson AR, Moller K, von Baum H, Warady 
BA. Worldwide variation of dialysis-associated peritonitis in children. Kidney 
Int 72, 11:1374-1379, 2007. 
Schaefer F, Klaus G, Mehls O. Peritoneal transport properties and dialysis dose affect 
growth and nutritional status in children on chronic peritoneal dialysis. Mid-
European Pediatric Peritoneal Dialysis Study Group. J Am Soc Nephrol 10, 
8:1786-1792, 1999a. 
Schaefer F, Klaus G, Muller-Wiefel DE, Mehls O. Intermittent versus continuous 
intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal 
dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis 
Study Group (MEPPS). J Am Soc Nephrol 10, 1:136-145, 1999b. 
Schaefer F, Wühl E, Feneberg R, Mehls O, Schärer K. Assessment of body composition 
in children with chronic renal failure. Pediatr Nephrol 14, 7:673-678, 2000.
Schnaper HW, Cole BR, Hodges FJ, Robson AM. Cerebral cortical atrophy in pediatric 
patients with end-stage renal disease. Am J Kidney Dis 2, 6:645-650, 1983. 
Shapiro SM. Bilirubin toxicity in the developing nervous system. Pediatr Neurol 29, 
5:410-421, 2003. 
Shroff R, Rees L, Trompeter R, Hutchinson C, Ledermann S. Long-term outcome of 
chronic dialysis in children. Pediatr Nephrol 21, 2:257-264, 2006. 
Silver J and Naveh-Many T. FGF23 and the parathyroid glands. Pediatr Nephrol 25, 
11:2241-2245, 2010. 
Slickers J, Duquette P, Hooper S, Gipson D. Clinical predictors of neurocognitive 
deficits in children with chronic kidney disease. Pediatr Nephrol 22, 4:565-
572, 2007. 
Sorva R, Perheentupa J, Tolppanen EM. A novel format for a growth chart. Acta 
Paediatr.Scand. 73, 4:527-529, 1984. 
Sorva R, Tolppanen EM, Lankinen S, Perheentupa J. Growth evaluation: parent and 
child specific height standards. Arch Dis Child 64, 10:1483-1487, 1989. 
Stefanidis CJ, Hewitt IK, Balfe JW. Growth in children receiving continuous ambulatory 
peritoneal dialysis. J Pediatr 102, 5:681-685, 1983. 
Stefanidis CJ and Klaus G. Growth of prepubertal children on dialysis. Pediatr Nephrol 
22, 9:1251-1259, 2007.
Steinberg A, Efrat R, Pomeranz A, Drukker A. Computerized tomography of the brain 
in children with chronic renal failure. Int J Pediatr Nephrol 6, 2:121-126, 1985. 
Swaiman K and Wu Y. Cerebral palsy. In: Swaiman K, Ashwal S, Ferriero D, eds. 
Pediatric Neurology, Volume 1. 4th Edition , Mosby Elsevier, Philadelphia, 
USA, 491-504, 2006.
 Szeto CC, Chow KM, Leung CB, Wong TY, Wu AK, Wang AY, Lui SF, Li PK. Clinical 
course of peritonitis due to Pseudomonas species complicating peritoneal 
dialysis: a review of 104 cases. Kidney Int 59, 6:2309-2315, 2001. 
References    105
Tainio J, Qvist E, Vehmas R, Jahnukainen K, Valta H, Jahnukainen T, Jalanko H. 
Pubertal Development is Normal in Adolescents After Renal Transplantation 
in Childhood. Transplantation (in press).
Tamura T, Vaughn WH, Waldo FB, Kohaut EC. Zinc and copper balance in children on 
continuous ambulatory peritoneal dialysis. Pediatr Nephrol 3, 3:309-313, 1989. 
Tanaka K, Ueno M, Atsumi T, Fukagawa M, Koike Y. A case of mitochondrial 
encephalomyopathy with nephrotic syndrome. Rinsho Shinkeigaku 26, 11:1190-
1196, 1986. 
Ten Harkel AD, Cransberg K, Van Osch-Gevers M, Nauta J. Diastolic dysfunction 
in paediatric patients on peritoneal dialysis and after renal transplantation. 
Nephrol Dial Transplant 24, 6:1987-1991, 2009.
The Finnish CP Association. CP-vamma (cerebral palsy). Available online at:
www.cp-liitto.fi, 2010.
Thompson AE, Marshall JC, Opal SM. Intraabdominal infections in infants and 
children: descriptions and definitions. Pediatr Crit Care Med 6, 3 Suppl:S30-5, 
2005. 
Tkaczyk M, Nowicki M, Balasz-Chmielewska I, Boguszewska-Baczkowska H, Drozdz 
D, Kollataj B, Jarmolinski T, Jobs K, Kilis-Pstrusinska K, Leszczynska B, 
Makulska I, Runowski D, Stankiewicz R, Szczepanska M, Wiercinski R, Grenda 
R, Kanik A, Pietrzyk JA, Roszkowska-Blaim M, Szprynger K, Zachwieja J, 
Zajaczkowska MM, Zoch-Zwierz W, Zwolinska D, Zurowska A. Hypertension 
in dialysed children: the prevalence and therapeutic approach in Poland - a 
nationwide survey. Nephrol Dial Transplant 21, 3:736-742, 2006. 
Tommiska V, Heinonen K, Kero P, Pokela ML, Tammela O, Järvenpää AL, Salokorpi 
T, Virtanen M, Fellman V. A national two year follow up study of extremely 
low birthweight infants born in 1996-1997. Arch Dis Child Fetal Neonatal Ed 
88:F29-35, 2003.
Twardowski ZJ, Nolph K, Khanna R, Prowant BF, Ryan L, Moore H. Peritoneal 
equilibration test. Perit Dial Bull 7, 138-147, 1987. 
Valanne L. Pediatrinen neuroradiologia. In: Soimakallio S, Kivisaari L, Manninen 
H, Svedström E, Tervonen O, eds. Radiologia. WSOY, Helsinki, Finland, 515-
521, 2005.
Valanne L, Qvist E, Jalanko H, Holmberg C, Pihko H. Neuroradiologic findings in 
children with renal transplantation under 5 years of age. Pediatr Transplant 
8, 1:44-51, 2004. 
van der Heijden BJ, van Dijk PC, Verrier-Jones K, Jager KJ, Briggs JD. Renal 
replacement therapy in children: data from 12 registries in Europe. Pediatr 
Nephrol 19, 2:213-221, 2004. 
van der Voort JH, Harvey EA, Braj B, Geary DF. Can the DOQI guidelines be met 
by peritoneal dialysis alone in pediatric patients? Dialysis Outcomes Quality 
Initiative. Pediatr Nephrol 14, 8-9:717-719, 2000. 
van Schie PE, Becher JG, Dallmeijer AJ, Barkhof F, Weissenbruch MM, Vermeulen RJ. 
Motor outcome at the age of one after perinatal hypoxic-ischemic encephalopathy. 
Neuropediatrics 38, 2:71-77, 2007. 
106
Verrina E, Amici G, Perfumo F, Trivelli A, Canepa A, Gusmano R. The use of the 
PD Adequest mathematical model in pediatric patients on chronic peritoneal 
dialysis. Perit Dial Int 18, 3:322-328, 1998. 
Verrina E, Andreetta B, Bassi S, Bonaudo R, Caringella DA, Castellani A, Cavalli P, 
Edefonti A, Lavoratti G, Longo L. Chronic peritoneal dialysis in paediatrics: 
experience of a national registry. Pediatr Nephrol 6, 1:78-81, 1992. 
Verrina E, Edefonti A, Gianoglio B, Rinaldi S, Sorino P, Zacchello G, Lavoratti G, 
Maringhini S, Pecoraro C, Calevo MG, Turrini Dertenois L, Perfumo F. A 
multicenter experience on patient and technique survival in children on chronic 
dialysis. Pediatr Nephrol 19, 1:82-90, 2004. 
von Lilien T, Salusky IB, Yap HK, Fonkalsrud EW, Fine RN. Hernias: a frequent 
complication in children treated with continuous peritoneal dialysis. Am J 
Kidney Dis 10, 5:356-360, 1987. 
Vuille C, Weyman A. Left Ventricle I: General Considerations, assessment of 
chamber size and function. In: Weyman A, ed. Principles and Practice of 
Echocardiography. 2nd edition , Lea & Febinger, Malvern, Pennsylvania, USA, 
576-624, 1994.
Warady BA, Belden B, Kohaut E. Neurodevelopmental outcome of children initiating 
peritoneal dialysis in early infancy. Pediatr Nephrol 13, 9:759-765, 1999. 
Warady BA, Feneberg R, Verrina E, Flynn JT, Müller-Wiefel DE, Besbas N, Zurowska 
A, Aksu N, Fischbach M, Sojo E, Donmez O, Sever L, Sirin A, Alexander SR, 
Schaefer F, for the International Pediatric Peritonitis Registry (IPPR). Peritonitis 
in Children Who Receive Long-Term Peritoneal Dialysis: A Prospective 
Evaluation of Therapeutic Guidelines. J Am Soc Nephrol 18: 2172-2179, 2007.
Warady BA, Hebert D, Sullivan EK, Alexander SR, Tejani A. Renal transplantation, 
chronic dialysis, and chronic renal insufficiency in children and adolescents. 
The 1995 Annual Report of the North American Pediatric Renal Transplant 
Cooperative Study. Pediatr Nephrol 11, 1:49-64, 1997. 
Warady BA, Kriley M, Alon U, Hellerstein S. Vitamin status of infants receiving 
long-term peritoneal dialysis. Pediatr Nephrol 8, 3:354-356, 1994. 
Warady BA, Reed L, Murphy G, Kastetter S, Karlsen E, Alon U, Hellerstein S. 
Aminoglycoside ototoxicity in pediatric patients receiving long-term peritoneal 
dialysis. Pediatr Nephrol 7, 2:178-181, 1993. 
Warady BA, Schaefer F, Holloway M, Alexander S, Kandert M, Piraino ., Salusky 
I, Tranaeus A, Divino J, Honda M, Mujais S, Verrina E, for the International 
Society for Peritoneal dialysis (ISPD) Advisory Committee on Peritonitis 
Management in Pediatric Patients. Consensus guidelines for the treatment of 
peritonitis in pediatric patients receiving peritoneal dialysis. Perit Dial Int 20, 
6:610-624, 2000.
Warady BA, Watkins SL, Fivush BA, Andreoli SP, Salusky I, Kohaut EC, Vonesh EF. 
Validation of PD Adequest 2.0 for pediatric dialysis patients. Pediatr Nephrol 
16, 3:205-211, 2001. 
Wassner S and Baum M. Chronic Renal Failure, Physiology and Management. In: 
Barrat TM, Avner ED, Harmon WE, eds. Pediatric Nephrology. 4th Edition , 
Lippincott Williams & Wilkins, Maryland, USA, 1155-1196, 1999.
References    107
Watson AR, Gartland C. European Paediatric Peritoneal Dialysis Working Group, 
Guidelines by an Ad Hoc European Committee for Elective Chronic Peritoneal 
Dialysis in Pediatric Patients. Perit Dial Int 21, 3:240-244, 2001. 
Wechsler D. WPPSI-III - Wechsler Preschool and Primary Scale of Intelligence - Third 
Edition. NCS Pearson, Inc., USA, 2003.
Wechsler D. Wechsler Intelligence Scale for Children, Revised. The Psychological 
Corporation, New York, USA, 1974.
Wedekin M, Ehrich JH, Offner G, Pape L. Renal Replacement Therapy in Infants 
with Chronic Renal Failure in the First Year of Life. Clin J Am Soc Nephrol 
5, 1:18-23, 2010. 
Weiller C, Ringelstein EB, Reiche W, Buell U. Clinical and hemodynamic aspects of 
low-flow infarcts. Stroke 22, 9:1117-1123, 1991. 
Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone 
disorder in children. Pediatr Nephrol 23, 2:195-207, 2008. 
Wesseling-Perry K. FGF-23 in bone biology. Pediatr Nephrol 25, 4:603-608, 2010. 
World Health organization (WHO). Energy and protein requirements. Report of a 
Joint FAO/WHO/UNU Expert Consultation. WHO Technical Report Series 
724. WHO, Geneva, 1985.
Wu YW, Escobar GJ, Grether JK, Croen LA, Greene JD, Newman TB. Chorioamnionitis 
and cerebral palsy in term and near-term infants. JAMA 290, 20:2677-2684, 
2003. 
Wühl E, Fusch C, Scharer K, Mehls O, Schaefer F. Assessment of total body water 
in paediatric patients on dialysis. Nephrol Dial Transplant 11, 1:75-80, 1996. 
Yu X, Sabbagh Y, Davis SI, Demay MB, White KE. Genetic dissection of phosphate- 
and vitamin D-mediated regulation of circulating Fgf23 concentrations. Bone 
36, 6:971-977, 2005. 
Zachara BA, Gromadzinska J, Wasowicz W, Zbrog Z. Red blood cell and plasma 
glutathione peroxidase activities and selenium concentration in patients with 
chronic kidney disease: a review. Acta Biochim Pol 53, 4:663-677, 2006. 
Zenker M, Aigner T, Wendler O, Tralau T, Muntefering H, Fenski R, Pitz S, Schumacher 
V, Royer-Pokora B, Wühl E, Cochat P, Bouvier R, Kraus C, Mark K, Madlon 
H, Dotsch J, Rascher W, Maruniak-Chudek I, Lennert T, Neumann LM, Reis 
A. Human laminin beta2 deficiency causes congenital nephrosis with mesangial 
sclerosis and distinct eye abnormalities. Hum Mol Genet 13, 21:2625-2632, 
2004a. 
Zenker M, Tralau T, Lennert T, Pitz S, Mark K, Madlon H, Dotsch J, Reis A, 
Muntefering H, Neumann LM. Congenital nephrosis, mesangial sclerosis, and 
distinct eye abnormalities with microcoria: an autosomal recessive syndrome. 
Am J Med Genet A 130A, 2:138-145, 2004b.

